WO2024079351A1 - Novel piperazine-based sulfonamides and their use as neuroprotective and/or neurorestorative agents - Google Patents
Novel piperazine-based sulfonamides and their use as neuroprotective and/or neurorestorative agents Download PDFInfo
- Publication number
- WO2024079351A1 WO2024079351A1 PCT/EP2023/078567 EP2023078567W WO2024079351A1 WO 2024079351 A1 WO2024079351 A1 WO 2024079351A1 EP 2023078567 W EP2023078567 W EP 2023078567W WO 2024079351 A1 WO2024079351 A1 WO 2024079351A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- heterocycloalkyl
- aryl
- cycloalkyl
- heteroaryl
- Prior art date
Links
- 230000000324 neuroprotective effect Effects 0.000 title abstract description 8
- 230000001928 neurorestorative effect Effects 0.000 title abstract description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title description 23
- 229940124530 sulfonamide Drugs 0.000 title description 5
- 150000003456 sulfonamides Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 195
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 23
- 239000012453 solvate Substances 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 17
- -1 CO2R11 Chemical group 0.000 claims description 138
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 108
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 87
- 229910052739 hydrogen Inorganic materials 0.000 claims description 76
- 239000001257 hydrogen Substances 0.000 claims description 73
- 125000003118 aryl group Chemical group 0.000 claims description 69
- 229910052731 fluorine Inorganic materials 0.000 claims description 62
- 229910052801 chlorine Inorganic materials 0.000 claims description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 58
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 56
- 125000001072 heteroaryl group Chemical group 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 36
- 125000003545 alkoxy group Chemical group 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 29
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 27
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 25
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 16
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- 239000003054 catalyst Substances 0.000 claims description 10
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 150000004820 halides Chemical group 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- BKDMXVREWXKZLB-UHFFFAOYSA-N 3-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCCNC1 BKDMXVREWXKZLB-UHFFFAOYSA-N 0.000 claims description 5
- WFTPSTRUUZKFRH-UHFFFAOYSA-N 4-(2-phenylethyl)piperidine Chemical compound C1CNCCC1CCC1=CC=CC=C1 WFTPSTRUUZKFRH-UHFFFAOYSA-N 0.000 claims description 5
- RDRQUUWCJTYHCT-UHFFFAOYSA-N 4-(trifluoromethyl)piperidine Chemical compound FC(F)(F)C1CCNCC1 RDRQUUWCJTYHCT-UHFFFAOYSA-N 0.000 claims description 5
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 claims description 5
- QBLLOOKBLTTXHB-UHFFFAOYSA-N 4-fluoropiperidine Chemical compound FC1CCNCC1 QBLLOOKBLTTXHB-UHFFFAOYSA-N 0.000 claims description 5
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 claims description 5
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 claims description 4
- HFBLCYZEOGXHDP-UHFFFAOYSA-N 3-benzylpyrrolidine Chemical compound C=1C=CC=CC=1CC1CCNC1 HFBLCYZEOGXHDP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- GMIRFHIMHXOTKR-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)ethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1CCN1CCNCC1 GMIRFHIMHXOTKR-UHFFFAOYSA-N 0.000 claims description 3
- LODHVDKKTUZVDK-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)ethyl]piperazine Chemical compound C1=CC(F)=CC=C1CCN1CCNCC1 LODHVDKKTUZVDK-UHFFFAOYSA-N 0.000 claims description 3
- FMZLXODEXODXFD-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)propyl]piperazine Chemical compound C=1C=C(F)C=CC=1C(C)CN1CCNCC1 FMZLXODEXODXFD-UHFFFAOYSA-N 0.000 claims description 3
- PHODFIDDEBEGCS-UHFFFAOYSA-N 2,2-dimethylpyrrolidine Chemical compound CC1(C)CCCN1 PHODFIDDEBEGCS-UHFFFAOYSA-N 0.000 claims description 3
- DJGJQTGPHMCSEI-UHFFFAOYSA-N 2-(3-phenylpropyl)piperazine Chemical compound C=1C=CC=CC=1CCCC1CNCCN1 DJGJQTGPHMCSEI-UHFFFAOYSA-N 0.000 claims description 3
- VOVVHNIABAJHJZ-UHFFFAOYSA-N 3-phenylmethoxypiperidine Chemical compound C=1C=CC=CC=1COC1CCCNC1 VOVVHNIABAJHJZ-UHFFFAOYSA-N 0.000 claims description 3
- CWBMYKUPMLRKQK-UHFFFAOYSA-N 3-phenylmethoxypyrrolidine Chemical compound C=1C=CC=CC=1COC1CCNC1 CWBMYKUPMLRKQK-UHFFFAOYSA-N 0.000 claims description 3
- NZYBILDYPCVNMU-UHFFFAOYSA-N 3-phenylpiperidine Chemical compound C1CCNCC1C1=CC=CC=C1 NZYBILDYPCVNMU-UHFFFAOYSA-N 0.000 claims description 3
- PRRFFTYUBPGHLE-UHFFFAOYSA-N 3-phenylpyrrolidine Chemical compound C1NCCC1C1=CC=CC=C1 PRRFFTYUBPGHLE-UHFFFAOYSA-N 0.000 claims description 3
- AFYALJSDFPSAAZ-UHFFFAOYSA-N 4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1CCNCC1 AFYALJSDFPSAAZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 claims description 2
- KJZBZOFESQSBCV-UHFFFAOYSA-N 4-benzylpiperidin-4-ol Chemical compound C=1C=CC=CC=1CC1(O)CCNCC1 KJZBZOFESQSBCV-UHFFFAOYSA-N 0.000 claims description 2
- KQKFQBTWXOGINC-UHFFFAOYSA-N 4-phenylpiperidin-4-ol Chemical compound C=1C=CC=CC=1C1(O)CCNCC1 KQKFQBTWXOGINC-UHFFFAOYSA-N 0.000 claims description 2
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims description 2
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- FYUVLZRRIRGSTE-UHFFFAOYSA-N tert-butyl 2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1NCC2CN(C(=O)OC(C)(C)C)CC21 FYUVLZRRIRGSTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 150
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- 239000000203 mixture Substances 0.000 description 54
- 239000000460 chlorine Substances 0.000 description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 51
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 35
- 201000010099 disease Diseases 0.000 description 34
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- 235000002639 sodium chloride Nutrition 0.000 description 29
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- 238000003818 flash chromatography Methods 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 210000002569 neuron Anatomy 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 21
- 229940124597 therapeutic agent Drugs 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000000543 intermediate Substances 0.000 description 19
- 239000002904 solvent Substances 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 125000005842 heteroatom Chemical group 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 206010015037 epilepsy Diseases 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 12
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 238000004293 19F NMR spectroscopy Methods 0.000 description 11
- 125000004404 heteroalkyl group Chemical group 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 238000012746 preparative thin layer chromatography Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 8
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000003915 cell function Effects 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000012317 TBTU Substances 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 208000011117 substance-related disease Diseases 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102100026376 Artemin Human genes 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 208000023105 Huntington disease Diseases 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 239000003900 neurotrophic factor Substances 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 238000005897 peptide coupling reaction Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 5
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical group CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100033423 GDNF family receptor alpha-1 Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 208000008234 Tics Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- GVWISOJSERXQBM-UHFFFAOYSA-N n-methylpropan-1-amine Chemical compound CCCNC GVWISOJSERXQBM-UHFFFAOYSA-N 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 description 4
- 201000009032 substance abuse Diseases 0.000 description 4
- 231100000736 substance abuse Toxicity 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical compound C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- LTVLATJRJIBHDR-UHFFFAOYSA-N 3-bromo-4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1Br LTVLATJRJIBHDR-UHFFFAOYSA-N 0.000 description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 3
- 206010010539 Congenital megacolon Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710105157 GDNF family receptor alpha-1 Proteins 0.000 description 3
- 108091072531 GDNFR family Proteins 0.000 description 3
- 102000038719 GDNFR family Human genes 0.000 description 3
- 208000004592 Hirschsprung disease Diseases 0.000 description 3
- 101000997961 Homo sapiens GDNF family receptor alpha-1 Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 102100036660 Persephin Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000000323 Tourette Syndrome Diseases 0.000 description 3
- 208000016620 Tourette disease Diseases 0.000 description 3
- 208000003554 absence epilepsy Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 239000012615 aggregate Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001499 aryl bromides Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 102000045740 human GFRA1 Human genes 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 108010070453 persephin Proteins 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- GYINHXUIFCYFJX-UHFFFAOYSA-N 1-(3-bromo-4-methoxyphenyl)sulfonylpyrrolidine Chemical compound C1=C(Br)C(OC)=CC=C1S(=O)(=O)N1CCCC1 GYINHXUIFCYFJX-UHFFFAOYSA-N 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- ANXJGYLWCDSEJR-UHFFFAOYSA-N 1-bromo-2-(methoxymethoxy)-3-methylbenzene Chemical compound COCOC1=C(C)C=CC=C1Br ANXJGYLWCDSEJR-UHFFFAOYSA-N 0.000 description 2
- JRHNUZCXXOTJCA-UHFFFAOYSA-N 1-fluoropropane Chemical group CCCF JRHNUZCXXOTJCA-UHFFFAOYSA-N 0.000 description 2
- GRPWQLDSGNZEQE-UHFFFAOYSA-N 2-chloro-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1Cl GRPWQLDSGNZEQE-UHFFFAOYSA-N 0.000 description 2
- MXJFWCPNLKFFAA-UHFFFAOYSA-N 3-bromo-n,n-diethyl-4-methoxybenzenesulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(OC)C(Br)=C1 MXJFWCPNLKFFAA-UHFFFAOYSA-N 0.000 description 2
- CDDGNGVFPQRJJM-UHFFFAOYSA-N 3-fluoropyrrolidine Chemical compound FC1CCNC1 CDDGNGVFPQRJJM-UHFFFAOYSA-N 0.000 description 2
- QIKSNOSDJNOUAE-UHFFFAOYSA-N 3-phenylmethoxy-1h-pyrrole Chemical compound C=1C=CC=CC=1COC=1C=CNC=1 QIKSNOSDJNOUAE-UHFFFAOYSA-N 0.000 description 2
- ZHTZWMMTJWZNCT-UHFFFAOYSA-N 4-benzyl-1-(3-bromo-4-methoxyphenyl)sulfonylpiperidine Chemical compound C1=C(Br)C(OC)=CC=C1S(=O)(=O)N1CCC(CC=2C=CC=CC=2)CC1 ZHTZWMMTJWZNCT-UHFFFAOYSA-N 0.000 description 2
- QMQNIKYRPSFQKB-UHFFFAOYSA-N 4-benzylidenepiperidine Chemical compound C1CNCCC1=CC1=CC=CC=C1 QMQNIKYRPSFQKB-UHFFFAOYSA-N 0.000 description 2
- ZBWGQYVGZZZQJO-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)pyrimidine Chemical compound C1CN(C)CCN1C1=CN=CN=C1 ZBWGQYVGZZZQJO-UHFFFAOYSA-N 0.000 description 2
- OVBHASVDQJKCSZ-UHFFFAOYSA-N 5-bromo-6-chloro-n,n-diethylpyridine-3-sulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CN=C(Cl)C(Br)=C1 OVBHASVDQJKCSZ-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 101710205806 Artemin Proteins 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 201000001913 Childhood absence epilepsy Diseases 0.000 description 2
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000003449 Classical Lissencephalies and Subcortical Band Heterotopias Diseases 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 101150033452 Elk1 gene Proteins 0.000 description 2
- 208000002091 Febrile Seizures Diseases 0.000 description 2
- 208000001914 Fragile X syndrome Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 108090000722 Glial cell line-derived neurotrophic factor receptors Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010021750 Infantile Spasms Diseases 0.000 description 2
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 2
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000019430 Motor disease Diseases 0.000 description 2
- 208000013716 Motor tics Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000037158 Partial Epilepsies Diseases 0.000 description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 description 2
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 2
- 101100287693 Rattus norvegicus Kcnh4 gene Proteins 0.000 description 2
- 101100287705 Rattus norvegicus Kcnh8 gene Proteins 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 2
- 201000006791 West syndrome Diseases 0.000 description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 2
- IELIBVHWBDASBD-UHFFFAOYSA-N [4-fluoro-2-(trifluoromethyl)phenyl]-piperazin-1-ylmethanone Chemical compound FC(F)(F)C1=CC(F)=CC=C1C(=O)N1CCNCC1 IELIBVHWBDASBD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000004060 excitotoxin Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 206010069732 neurotrophic keratopathy Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 201000006366 primary open angle glaucoma Diseases 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 208000022074 proximal spinal muscular atrophy Diseases 0.000 description 2
- 201000005070 reflex epilepsy Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000011894 semi-preparative HPLC Methods 0.000 description 2
- TWEGKFXBDXYJIU-UHFFFAOYSA-M sodium;2-methylpropanoate Chemical group [Na+].CC(C)C([O-])=O TWEGKFXBDXYJIU-UHFFFAOYSA-M 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 208000016686 tic disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- CYQYBRMAYUBANC-UHFFFAOYSA-N 1,1-dichloroethane;n,n-dimethylformamide Chemical compound CC(Cl)Cl.CN(C)C=O CYQYBRMAYUBANC-UHFFFAOYSA-N 0.000 description 1
- QFCMBRXRVQRSSF-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole Chemical compound C1NCC2CNCC21 QFCMBRXRVQRSSF-UHFFFAOYSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHSOOAWURRKYMM-UHFFFAOYSA-N 2,3-dihydro-1,4-benzoxathiine Chemical compound C1=CC=C2OCCSC2=C1 NHSOOAWURRKYMM-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
- LUECOFFMVWPWDR-UHFFFAOYSA-N 2-bromo-6-chlorophenol Chemical compound OC1=C(Cl)C=CC=C1Br LUECOFFMVWPWDR-UHFFFAOYSA-N 0.000 description 1
- YXZPTVOCJLCMRO-UHFFFAOYSA-N 2-bromo-6-methylphenol Chemical compound CC1=CC=CC(Br)=C1O YXZPTVOCJLCMRO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YBBLSBDJIKMXNQ-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-benzothiazine Chemical compound C1=CC=C2NCCSC2=C1 YBBLSBDJIKMXNQ-UHFFFAOYSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- YUBXINNQKJTNES-UHFFFAOYSA-N 3-(methoxymethyl)azetidine Chemical compound COCC1CNC1 YUBXINNQKJTNES-UHFFFAOYSA-N 0.000 description 1
- BEEHKBVVTWJSRH-UHFFFAOYSA-N 3-bromo-4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1Br BEEHKBVVTWJSRH-UHFFFAOYSA-N 0.000 description 1
- ZELYQSZTABGDLA-UHFFFAOYSA-N 3-bromo-n,n-diethylbenzenesulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=CC(Br)=C1 ZELYQSZTABGDLA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- AOBSJQWEYXEPBK-UHFFFAOYSA-N 5-benzyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrole Chemical compound C1C2CNCC2CN1CC1=CC=CC=C1 AOBSJQWEYXEPBK-UHFFFAOYSA-N 0.000 description 1
- TURGMVYIESHZBE-UHFFFAOYSA-N 5-bromo-6-chloropyridine-3-sulfonyl chloride Chemical compound ClC1=NC=C(S(Cl)(=O)=O)C=C1Br TURGMVYIESHZBE-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- VGOUXHRZQNPOPY-UHFFFAOYSA-N 7-bromo-2,3-dihydro-1-benzofuran Chemical compound BrC1=CC=CC2=C1OCC2 VGOUXHRZQNPOPY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 244000045410 Aegopodium podagraria Species 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 206010054895 Baltic myoclonic epilepsy Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 description 1
- 206010070530 Benign rolandic epilepsy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010066131 Congenital central hypoventilation syndrome Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010070666 Cortical dysplasia Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000000289 Esophageal Achalasia Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 201000009010 Frontal lobe epilepsy Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000003078 Generalized Epilepsy Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101150107722 Gfra1 gene Proteins 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000004216 Glial cell line-derived neurotrophic factor receptors Human genes 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 102100025210 Histone-arginine methyltransferase CARM1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 description 1
- 101000994667 Homo sapiens Potassium voltage-gated channel subfamily KQT member 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 206010073659 Intestinal neuronal dysplasia Diseases 0.000 description 1
- 201000008189 Juvenile absence epilepsy Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 201000004246 Miller-Dieker lissencephaly syndrome Diseases 0.000 description 1
- 208000035022 Miller-Dieker syndrome Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010073149 Multiple endocrine neoplasia Type 2 Diseases 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030136 Oesophageal achalasia Diseases 0.000 description 1
- 206010030184 Oesophageal spasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 206010036312 Post-traumatic epilepsy Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- 208000033255 Progressive myoclonic epilepsy type 1 Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710083778 Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 108091008551 RET receptors Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000004974 Rolandic Epilepsy Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006657 Unverricht-Lundborg syndrome Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000007960 WAGR syndrome Diseases 0.000 description 1
- 201000006793 Walker-Warburg syndrome Diseases 0.000 description 1
- 208000010206 X-Linked Mental Retardation Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- HBQDCKPPSIWZLY-UHFFFAOYSA-M [dimethylamino-(2-oxopyridin-1-yl)oxymethylidene]-dimethylazanium;trifluoroborane;fluoride Chemical compound [F-].FB(F)F.CN(C)C(=[N+](C)C)ON1C=CC=CC1=O HBQDCKPPSIWZLY-UHFFFAOYSA-M 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 201000000621 achalasia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000015150 agyria-pachygyria type 1 Diseases 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 108010011562 aspartic acid receptor Proteins 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 201000008916 benign epilepsy with centrotemporal spikes Diseases 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- SISAYUDTHCIGLM-UHFFFAOYSA-N bromine dioxide Inorganic materials O=Br=O SISAYUDTHCIGLM-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000033205 childhood epilepsy with centrotemporal spikes Diseases 0.000 description 1
- 238000005957 chlorosulfonylation reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 108010030886 coactivator-associated arginine methyltransferase 1 Proteins 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 208000036970 congenital 1 with or without Hirschsprung disease central hypoventilation syndrome Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000004113 cyclononanyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 125000000597 dioxinyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 102000007656 ets-Domain Protein Elk-1 Human genes 0.000 description 1
- 108010032461 ets-Domain Protein Elk-1 Proteins 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 201000008186 generalized epilepsy with febrile seizures plus Diseases 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 102000050427 human RET Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- QOTKGSVSGMIHGN-UHFFFAOYSA-N hydron;4,4,4-trifluorobutan-1-amine;chloride Chemical compound Cl.NCCCC(F)(F)F QOTKGSVSGMIHGN-UHFFFAOYSA-N 0.000 description 1
- VLECDMDGMKPUSK-UHFFFAOYSA-N hydron;piperidin-3-ol;chloride Chemical compound Cl.OC1CCCNC1 VLECDMDGMKPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000027819 intestinal motility disease Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 208000017376 neurovascular disease Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 201000008654 non-syndromic X-linked intellectual disability Diseases 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 201000003040 photosensitive epilepsy Diseases 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006295 polythiol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- LBOHISOWGKIIKX-UHFFFAOYSA-M potassium;2-methylpropanoate Chemical compound [K+].CC(C)C([O-])=O LBOHISOWGKIIKX-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 201000001204 progressive myoclonus epilepsy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000013005 self healing agent Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 201000001197 subcortical band heterotopia Diseases 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000031906 susceptibility to X-linked 2 autism Diseases 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000034373 type A muscular dystrophy-dystroglycanopathy Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to novel polycyclic sulfonamides comprising at least one unsubstituted and unbridged piperazine.
- the compounds of the invention are useful as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological disorders.
- BACKGROUND OF INVENTION [0002] Neurological disorders (NDs) are heterogeneous diseases affecting the autonomic, peripheral and central nervous system of the body.
- CNS Central Nervous System
- AD Alzheimer’s disease
- PD Parkinson’s disease
- HD Huntington’s disease
- ALS Amyotrophic Lateral Sclerosis
- dementia stroke
- head trauma brain tumor
- pain and epilepsy are always the most challenging diseases to be addressed.
- Compounds actives for treating CNS might also be relevant to other diseases, for example diseases of the peripheral nervous system, eyes, spinal cord and enteric system.
- NDs diseases of the peripheral nervous system, eyes, spinal cord and enteric system.
- Neurons are postmitotic cells that must live for a lifetime.
- GDNF glial cell line-derived neurotrophic factor
- GDNF and other proteins of the GDNF family of neurotrophic factors such as neurturin, artemin and persephin acts as a powerful trophic factor favoring, not only the survival and plasticity, but also the proliferation, differentiation, and protection of dopaminergic neurons, as well as the synthesis of dopamine and dopaminergic transmission in the developing and adult brain.
- GDNF can promote neuroprotection through MAP kinase/ERK, Src kinase and PI3 kinase/AKT pathways by inducing several neuroprotective signaling cascade, including the activation of the transcription factor Elk1 through the activation of the GFR ⁇ 1-RET receptor complex.
- GDNF neurotrophic factor of the GDNF family
- Pre-clinical and clinical trials have been carried out to evaluate the effect of neurotrophic factors of the GDNF family for the prevention, treatment or management of Parkinson’s disease, chronic pain, Alzheimer’s disease, amyotrophic lateral sclerosis, neuropathy, depression, stroke, and these proteins were even suggested as male contraceptives.
- the clinical application of GDNF is hampered by its poor pharmacokinetic properties, the fact that it does not cross the blood-brain barrier and thus the necessity for intracranial delivery via stereotaxic surgery, varying biological activity, and high price.
- Blood-brain barrier penetrating small-molecule compounds that target the GDNF receptor complex and mimic GDNF biological effects in neurons may be an avenue to overcome these issues and translate to greater efficacy in the clinic.
- WO 2011/070177 A2 (BALTIC TECHNOLOGY DEV LTD) discloses polycyclic compounds for treating neurological disorders. Although these compounds represented a significant improvement at this time, they still have limitations in terms of activity on GFR ⁇ 1-RET target, solubility, membrane permeability (PAMPA and CaCO2), intrinsic clearance microsomes and hepatocytes, plasma protein binding, and pharmacokinetic profile. In particular, these compounds are limited in terms of activity on GFR ⁇ 1-RET target (as evidenced, for example, in luciferase assays). [0009] IVANOVA, L. et al. (ACS OMEGA, Vol. 3, No.
- WO 2011/070177 A2 discloses two compounds, also disclosed in WO 2011/070177 A2, and simulates the dynamic molecular modelling of the interactions between Gglial cell line-derived neurotrophic factor family receptor GFR ⁇ 1 and these two compounds.
- WO 2014/041179 A1 also disclose the same polycyclic compounds than WO 2011/070177 A2 for treating and/or preventing peripheral neuropathy (peripheric disease), therefore with the same limitations.
- An object of the present invention is a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof; wherein W, R A -R D , Z and R 5 -R 7 are as defined hereinafter and/or as defined in the claims.
- the compound of formula (I) is a compound of formula (I-i) or formula (I-ii) as defined hereinafter and/or as defined in the claims.
- the compound is selected from the compounds of Table 1 herein, and pharmaceutically acceptable salts and/or solvates thereof, provided that the compound is not N,N-diethyl-5-[4-[4-fluoro-2- (trifluoromethyl)benzoyl]piperazin-1-yl]-6-methoxy-pyridine-3-sulfonamide or a pharmaceutically acceptable salt and/or solvate thereof.
- Another object of the present invention is a pharmaceutical composition comprising a compound according to the invention and at least one pharmaceutically acceptable carrier.
- Another object of the present invention is a compound according to the invention or a pharmaceutical composition according to the invention for use as a medicament.
- the compound or the pharmaceutical composition is for use in the treatment of a neurological disorder.
- Another object of the present invention is a process for manufacturing a compound according to the invention.
- the following terms have the following meanings: Chemical definitions [0019] Where chemical substituents are combinations of chemical groups, the point of attachment of the substituent to the molecule is by the last chemical group recited on the right of the name of the substituent. For example, an arylalkyl substituent is linked to the rest of the molecule through the alkyl moiety and it may by represented as follows: “aryl-alkyl-”. [0020] Unless otherwise indicated, the compounds were named using BIOVIA Draw 2021 (Dassault, France).
- R x represents hydrogen, (C 1 -C 8 ) alkyl, (C 1 -C 8 ) alkyl-O- or cycloalkyl-(C 1 -C 8 ) alkyl-NH-; wherein the alkyl is optionally substituted by at least one F” means that any alkyl group present in the structure of R x may optionally substituted by at least one F, including said (C1-C8) alkyl as such (e.g., CF3), the alkyl comprised in said (C 1 -C 8 ) alkyl-O- (e.g., OCF 3 ) and the alkyl comprised in said cycloalkyl-(C1-C8) alkyl-NH- (e.g., cycloalkyl-(C1-C8) alkyl-NH- (e.g., cycloalkyl-(C1-C8) alkyl-NH- (e.g., cycloalkyl-(C1-C
- Alkoxy refers to an alkyl-O- group.
- Alkyl refers to a saturated linear or branched hydrocarbon chain, typically comprising from 1 to 16 carbon atoms, preferably from 1 to 12 carbon atoms, more preferably from 1 to 8 carbon atoms, furthermore preferably from 1 to 6 carbon atoms.
- Alkyl groups may be monovalent or polyvalent (i.e., “alkylene” groups, which are divalent alkyl groups, are encompassed in “alkyl” definition).
- Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl, pentyl and its isomers (e.g., n-pentyl, iso-pentyl), and hexyl and its isomers (e.g., n-hexyl, iso-hexyl).
- alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl (including methylene, ethylene, n-propylene, n-butylene and n-butylene).
- “Amine” refers to derivatives of ammonia (NH 3 ), wherein one or more hydrogen atoms have been replaced by a substituent such as, for example, alkyl or aryl.
- Ammonia refers to the -NH2 group.
- Aryl refers to a cyclic, polyunsaturated, aromatic hydrocarbyl group comprising at least one aromatic ring and comprising from 5 to 12 carbon atoms, preferably from 6 to 10 carbon atoms.
- Aryl groups may be monovalent or polyvalent (e.g., divalent).
- Aryl groups may have a single ring (e.g., phenyl) or multiple aromatic rings fused together (e.g., naphthyl) or linked covalently.
- the aromatic ring may optionally include one to two additional rings (either cycloalkyl, heterocycloalkyl or heteroaryl) fused thereto.
- aryl encompasses the partially hydrogenated derivatives of the carbocyclic systems enumerated herein, as long as at least one ring is aromatic.
- Aryls may optionally be substituted by at least one group such as, for example, halogen (e.g., F or Cl), (C1-C8) alkyl (e.g., methyl) or nitrile (CN).
- Non-limiting examples of aryl groups include phenyl, biphenyl, biphenylenyl, 5- or 6- tetralinyl, naphthalen-1- or -2-yl, 4-, 5-, 6 or 7-indenyl, 1- 2-, 3-, 4- or 5-acenaphthylenyl, 3-, 4- or 5-acenaphthenyl, 1- or 2-pentalenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8- tetrahydronaphthyl, 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, and 1-, 2-, 3-, 4- or 5-pyrenyl.
- aryl group is phenyl.
- the moiety is typically cyclic such as, for example, an heterocycloalkyl.
- “Cycloalkyl” refers to a cyclic alkyl group, typically comprising from 3 to 15 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably from 3 to 8 carbon atoms, further more preferably from 3 to 6 carbon atoms. Cycloalkyl groups may be monovalent or polyvalent (e.g., divalent).
- cycloalkyl encompasses polycyclic cycloalkyls (e.g., bicycles) and bridged cycloalkyl structures, including cycles bound together through one atom (“spiro”) or through two atoms.
- This definition of “cycloalkyl” encompasses cycloalkyls including a cyclic alkyl group substituted by at least one non-cyclic alkyl, such as, for example, a (C1-C8) alkyl (preferably, (C1-C4) alkyl, e.g., methyl).
- Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycoheptyl, cyclooctanyl, cyclononanyl, cyclodecanyl, norbornyl, adamantyl, bicyclo[2.2.2]octanyl, bicyclo[4.4.0]decanyl, bicyclo[3.2.1]octanyl, bicyclo[3.3.1]nonanyl, bicyclo[2.1.1]hexane, 2,3-dihydro-1H- indenyl, 1,2,3,4-tetrahydronaphthalenyl, decahydronaphthalenyl, 1,2,3,4- tetrahydronaphthalenyl, and octahydropentalenyl.
- Cx-Cy or “(Cx-Cy)” preceding the name of a group means that the group comprises from x to y carbon atoms, in accordance to common terminology in the chemistry field.
- Halogen refers to a fluorine, chlorine, bromine or iodine atom.
- Heteroalkyl refers to an alkyl group as defined herein, wherein one or more carbon atoms are replaced by a heteroatom selected from oxygen, nitrogen and sulfur, and wherein the resulting heteroalkyl group comprises at least one carbon atom.
- heteroalkyl groups the heteroatoms are bound along the alkyl chain only to carbon atoms, i.e., each heteroatom is separated from any other heteroatom by at least one carbon atom, typically by at least two carbon atoms.
- Heteroalkyl groups may be monovalent or polyvalent (e.g., divalent).
- the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized (e.g., sulfur may be oxidized as SO or SO2).
- the heteroalkyl is bound to another group or molecule through a carbon atom, i.e., the binding atom is not selected among the heteroatoms included therein. In one embodiment, the heteroalkyl is bound to another group or molecule through one of the heteroatoms included therein. When substituted by one or more other group(s), an heteroalkyl may be substituted either through a carbon atom or through a heteroatom (e.g., nitrogen), unless otherwise specified.
- Non-limiting examples of heteroalkyl include alkoxy, ethers and polyethers (e.g., polyethylene glycol), secondary and tertiary amines and polyamines, thioethers and polythioethers, and combinations thereof.
- Heteroaryl refers to aromatic rings or aromatic ring systems comprising from 5 to 15 carbon atoms, preferably from 4 to 12 carbon atoms, more preferably from 3 to 10 carbon atoms, having one or two rings that are fused together or linked covalently, wherein at least one ring is aromatic, and wherein one or more carbon atoms in one or more of these rings is replaced by oxygen, nitrogen and/or sulfur atoms.
- Heteroaryl groups may be monovalent or polyvalent (e.g., divalent).
- This definition of “heteroaryl” encompasses the partially hydrogenated derivatives of the carbocyclic systems enumerated herein, as well as ring systems including one or more fused non-aromatic cycloalkyl and/or heterocycloalkyl ring(s), as long as at least one ring is aromatic.
- the heteroaryl is bound to another group or molecule through a carbon atom, i.e., the binding atom is not selected among the heteroatoms included therein.
- the heteroaryl is bound to another group or molecule through one of the heteroatoms included therein.
- an heteroaryl may be substituted either through a carbon atom or through a heteroatom (e.g., nitrogen), unless otherwise specified.
- Heteroaryls may optionally be substituted by at least one group such as, for example, halogen (e.g., F or Cl), (C 1 -C 8 ) alkyl (preferably, (C 1 -C 4 ) alkyl, e.g., methyl) or nitrile (CN).
- heteroaryl groups include pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, dioxinyl, thiazinyl, triazinyl, tetrazinyl, imidazo[2,1- b][1,3]thiazolyl, thieno[3,2-b]furanyl, thieno[3,2-b]thiophenyl, thieno[2,3- d][l,3]thiazolyl, thieno[2,3-d]imi
- Non-limiting examples of heteroaryl groups comprising at least one fused non-aromatic ring include 2,3-dihydrobenzofuranyl, benzo[d][1,3]dioxolyl, indolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, 1,2,3,4-tetrahydroquinoxaline, 3,4-dihydro-2H-benzo[b][1,4]thiazine and 2,3-dihydrobenzo[b][1,4]oxathiine.
- the moiety is typically cyclic such as, for example, an heterocycloalkyl.
- “Heterocycloalkyl” refers to a cyclic heteroalkyl group, typically comprising from 2 to 15 carbon atoms, preferably from 2 to 11 carbon atoms, more preferably from 2 to 7 carbon atoms, furthermore preferably from 2 to 6 carbon atoms.
- Heterocycloalkyl groups may be monovalent or polyvalent (e.g., divalent).
- Heterocycloalkyl groups are typically 3- to 7-membered, preferably 5- or 6-membered.
- Heterocycloalkyl are typically monocyclic or bicyclic, preferably monocyclic.
- This definition encompasses polycyclic heterocycloalkyls (e.g., bicycles) and bridged heterocycloalkyl structures, including cycles bound together through one atom (“spiro”) or through two atoms.
- the heterocycloalkyl is bound to another group or molecule through a carbon atom, i.e., the binding atom is not selected among the heteroatoms included therein. In one embodiment, the heterocycloalkyl is bound to another group or molecule through one of the heteroatoms included therein. When substituted by one or more other group(s), an heterocycloalkyl may be substituted either through a carbon atom or through a heteroatom (e.g., nitrogen), unless otherwise specified.
- a heteroatom e.g., nitrogen
- halogen e.g., F or Cl
- C1-C8 alkyl preferably, (C1-C4) alkyl, e.g., methyl
- nitrile (CN) or O.
- heterocycloalkyl examples include aziridine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, azepane, azocane, octahydro-1H-isoindole, decahydroisoquinoline, tetrahydrofuran, tetrahydropyran, tetrahydroisoquinoline (e.g., 1,2,3,4-tetrahydroisoquiline), hexahydropyridazine, hexahydropyrazine, hexahydropyrimidine, decahydroquinoline, octahydropyrrolo[3,4- c]pyrrole, isoindoline, 1,2,3,4-tetrahydroquinoline and oxetane.
- heterocycloalkyl examples include aziridine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, a
- Prodrug refers to a pharmacologically acceptable derivative of a therapeutic agent (e.g., a compound according to the invention) whose in vivo biotransformation product is the therapeutic agent (active drug).
- Prodrugs are typically characterized by increased bioavailability and are readily metabolized in vivo into the active compounds.
- Non-limiting examples of prodrugs include amide prodrugs and carboxylic acid ester prodrugs.
- Solvate refers to molecular complex comprising a compound along with stoichiometric or sub-stoichiometric amounts of one or more molecules of one or more solvents, typically the solvent is a pharmaceutically acceptable solvent such as, for example, ethanol.
- hydrate refers to a solvate when the solvent is water (H2O).
- Ylidene refers to CH group involved in an exo carbon-carbon double bound with another moiety. The moiety is typically cyclic such as, for example, an heterocycloalkyl.
- General definitions [0037] “About” is used herein to mean approximately, roughly, around, or in the region of. The term “about” preceding a figure means plus or less 10 % of the value of the figure. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth by 10%.
- administering means providing a therapeutic agent alone or as part of a pharmaceutically acceptable composition, to the patient in whom/which the condition, symptom, or disease is to be treated.
- “Comprise” or a variant thereof e.g., “comprises”, “comprising” is used herein according to common patent application drafting terminology. Hence, “comprise” preceded by an object and followed by a constituent means that the presence of a constituent in the object is required (typically as a component of a composition), but without excluding the presence of any further constituent(s) in the object.
- any occurrence of “comprise” or a variant thereof herein also encompasses narrower expression “substantially consist of”, further narrower expression “consist of” and any variants thereof (e.g., “consists of”, “consisting of”), and may be replaced thereby, unless otherwise stated.
- “GDNF family receptor alpha-1”, “GFR ⁇ 1”, or “GDNFR ⁇ 1”, also named “RET ligand 1” or “TGF-beta-related neurotrophic factor receptor 1” is a protein from the GDNFR family that acts as a receptor for GDNF. It mediates the GDNF-induced autophosphorylation and activation of the RET receptor. In humans, GFR ⁇ 1 is encoded by the GFRA1 gene.
- Human refers to a male or female human subject at any stage of development, including neonate, infant, juvenile, adolescent and adult.
- Neuroprotective refers to the protection of a neuronal cell from insults, events, or conditions that would normally result in a loss of neuronal cell’s functions, and ultimately, neuronal cell death.
- Such insults, events, or conditions include, without limitation, neuronal stress, for instance, caused by hypoxia or ischemia; traumatic injuries; and exposure to toxic molecules, for instance, to abnormal misfolded proteins, protein aggregates, excitotoxins, reactive oxygen species, endoplasmic reticulum stressors, mitochondrial stressors, Golgi apparatus antagonists and the like.
- the term also characterizes the detectable biological activity of a compound in reducing the amount or level of neuronal cell’s loss of functions and/or neuronal cell death.
- Neuronal cell refers to the restoration or rescue of a neuronal cell and in particular of its functions, from the effect of an insult, event, or condition that would normally result in a loss of neuronal cell’s functions if not in neuronal cell death.
- “Patient” refers to a subject who/which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of the targeted disease or condition, such as, for example, a neurological disorder.
- “Pharmaceutically acceptable” means that the ingredients of a composition are compatible with each other and not deleterious to the subject to which/whom it is administered.
- “Pharmaceutically acceptable carrier” refers to an excipient that does not produce an adverse, allergic or other untoward reaction when administered to an animal, preferably a human. It includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by regulatory offices, such as, e.g., FDA Office or EMA.
- Examples of pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances (for example sodium carboxymethylcellulose), polyethylene glycol, polyacrylates, waxes, polyethylene- polyoxypropylene- block polymers, polyethylene glycol and wool fat.
- ion exchangers alumina, aluminium stearate, lecithin
- serum proteins such as human serum albumin
- buffer substances such as phosphates, glycine, sorbic acid, potassium
- “Pharmaceutical composition” refers to a composition comprising at least one therapeutic agent (e.g., a compound according to the present invention) and at least one pharmaceutically acceptable carrier.
- “Proto-oncogene tyrosine-protein kinase receptor Ret”, or in short “RET”, also named “cadherin family member 12”, is a receptor tyrosine kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation.
- RET is activated upon (i) binding of a neurotrophic factor of the GDNF family (e.g., GDNF, neurturin, artemin or persephin) to a receptor of the GDNFR family (e.g., GFR ⁇ 1, GFR ⁇ 2, GFR ⁇ 3 or GFR ⁇ 4), then (ii) complex formation between RET and the receptor of the GDNFR family, (iii) dimerization and (iv) trans-autophosphorylation.
- a neurotrophic factor of the GDNF family e.g., GDNF, neurturin, artemin or persephin
- GDNFR family e.g., GFR ⁇ 1, GFR ⁇ 2, GFR ⁇ 3 or GFR ⁇ 4
- An exemplary amino acid sequence of human RET is given in SEQ ID NO: 2, in which amino acid residues 1-28 correspond to the signal peptide.
- Subject refers to an animal, typically a warm-blooded animal, preferably a mammal, more preferably a primate, furthermore preferably a human.
- the subject is a “patient” as defined herein.
- the subject is affected, preferably is diagnosed, with a disease.
- the subject is at risk of developing a disease.
- risks factor examples include, but are not limited to, genetic predisposition, or familial history of the disease.
- “Therapeutic agent”, “active pharmaceutical ingredient” and “active ingredient” refer to a compound for therapeutic use and relating to health.
- a therapeutic agent e.g., a compound according to the present invention
- An active ingredient may also be indicated for improving the therapeutic activity of another therapeutic agent.
- “Therapeutically effective amount” refers to the amount of a therapeutic agent (e.g., a compound according to the present invention) that is sufficient to achieve the desired therapeutic, prophylactic or preventative effect in the patient to which/whom it is administered, without causing significant negative or adverse side effects to said patient.
- a therapeutically effective amount may be administered prior to the onset of the disease for a prophylactic or preventive action. Alternatively, or additionally, the therapeutically effective amount may be administered after initiation of the disease for a therapeutic action.
- Treating”, “treatment” or “alleviation” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder (herein a “disease”) (e.g., a neurological disorder).
- a disease e.g., a neurological disorder.
- Those in need of treatment include those already with the disease as well as those prone to have the disease or those in whom the condition or disease is to be prevented.
- a patient is successfully “treated” for a disease if, after receiving a therapeutic amount of a therapeutic agent (e.g., a compound according to the present invention), the patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of pathogens; reduction in the percent of total cells that are pathogenic; and/or relief to some extent, one or more of the symptoms associated with the specific disease; reduced morbidity and mortality, and improvement in quality of life issues.
- a therapeutic agent e.g., a compound according to the present invention
- An object of the present invention is a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof; wherein W represents CH or N; R A , R B , R C and R D each independently represents hydrogen, F, Cl, CH3, CF3, CHF2 or CH2F; R 7 represents hydrogen, OH, halogen, (C 1 -C 8 ) alkyl, cycloalkyl, (C 1 -C 8 ) alkyl- O-, cycloalkyl-O-, cycloalkyl-(C1-C8) alkyl-O-, heterocycloalkyl-O-, heterocycloalkyl-(C1-C8) alkyl-O-, aryl-(C1-C8) alkyl-O-, heteroaryl- (C 1 -C 8 ) alkyl-O-, R 11 O-(C 1 -C 8 ) alkyl-O-, R 11 R 12 N
- R D represents CF3
- R 7 represents OCH3
- Z represents C-H
- the remaining group among R A , R B and R C does not represent F.
- any alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, benzylidene or heteroarylidene may independently be optionally substituted as indicated under formula (I) herein, unless otherwise specified.
- R D represents hydrogen, F, Cl, CH 3 , CHF2 or CH2F.
- R 7 represents hydrogen, OH, halogen, (C 1 -C 8 ) alkyl, cycloalkyl, (C 2 -C 8 ) alkyl-O-, cycloalkyl-O-, cycloalkyl-(C 1 -C 8 ) alkyl-O-, heterocycloalkyl-O-, heterocycloalkyl-(C1-C8) alkyl-O-, aryl-(C1-C8) alkyl-O-, heteroaryl-(C1-C8) alkyl-O-, R 11 O-(C1-C8) alkyl-O-, R 11 R 12 N-(C1-C8) alkyl-O-, (R 11 O)(R 12 )N-(C 1 -C 8 ) alkyl-O-, R 11 R 12 N-(C 1 -C 8 )
- the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof; wherein W represents CH or N; R A , R B , R C and R D each independently represents hydrogen, F, Cl, CH3, CF3, CHF 2 or CH 2 F, R 7 represents hydrogen, OH, halogen, (C1-C8) alkyl, cycloalkyl, (C1-C8) alkyl- O-, cycloalkyl-O-, cycloalkyl-(C 1 -C 8 ) alkyl-O-, heterocycloalkyl-O-, R 11 O-(C1-C8) alkyl-O-, R 11 R 12 N-(C1-C8) alkyl-O- or (R 11 O)(R 12 )N- (C1-C8) alkyl-O-; wherein R 11 and
- W represents CH.
- at least one among R A , R B , R C and R D represents hydrogen. In one embodiment, exactly one among R A , R B , R C and R D represents hydrogen. In one embodiment, exactly two among R A , R B , R C and R D represents hydrogen. In one embodiment, exactly three among R A , R B , R C and R D represents hydrogen. [0062] In one embodiment, at least one among R A and R C represents hydrogen. In one particular embodiment, R A represents hydrogen. In one particular embodiment, R C represents hydrogen. [0063] According to one embodiment, at least one among R A , R B and R D represents F or Cl.
- R B and R D represents F or Cl.
- R B and R D each independently represents F or Cl.
- R B represents F.
- R B represents Cl.
- R D represents F.
- R D represents Cl.
- R B represents F.
- R D represents Cl.
- R B represents F and R D represents Cl.
- at least one among R A , R B and R D represents CHF 2 or CF 3 .
- at least one among R B and R D represents CHF 2 or CF 3 .
- R B and R D each independently represents H, F, CHF2 or CF3.
- R B represents H or F. In one further preferred embodiment, R B represents F. In one preferred embodiment, R D represents CHF 2 or CF 3 . In one further preferred embodiment, R B represents H or F and R D represents CHF2 or CF3.
- R 7 represents hydrogen, OH, halogen, (C 1 -C 8 ) alkyl, cycloalkyl, (C 1 -C 8 ) alkyl-O-, cycloalkyl-O-, cycloalkyl-(C 1 -C 8 ) alkyl-O-, heterocycloalkyl-O-, R 11 O-(C1-C8) alkyl-O-, R 11 R 12 N-(C1-C8) alkyl-O- or (R 11 O)(R 12 )N- (C1-C8) alkyl-O-; wherein R 11 and R 12 each independently represents hydrogen or (C 1 -C 8 ) alkyl; wherein the alkyl,
- R 7 represents hydrogen, OH or halogen. In one embodiment, R 7 represents hydrogen. In one preferred embodiment, R 7 represents hydroxyl (OH). In one embodiment, R 7 represents halogen. In one particular preferred embodiment, R 7 represents F or Cl. In one particular preferred embodiment, R 7 represents F. In one particular embodiment, R 7 represents Cl. [0067] In one preferred embodiment, R 7 does not represent hydrogen. [0068] According to one embodiment, R 7 represents (C1-C8) alkyl-O- (i.e., (C 1 -C 8 ) alkoxy) or cycloalkyl-O-.
- the alkyl or cycloalkyl is optionally substituted by at least one F, Cl, OH, (C 1 -C 8 ) alkoxy or aryl.
- R 7 represents OCH3 (methoxy), OCH2CH3, OCF3, cyclobutyl-O-, HO-CH2- CH2-O-, CH3O-CH2-CH2-O- or phenyl-CH2-O-.
- R 7 represents (C 1 -C 8 ) alkyl-O- (i.e., (C1-C8) alkoxy).
- the alkyl is optionally substituted by at least one F or Cl.
- the halogen is F.
- R 7 represents OCH 3 (methoxy), OCH 2 CH 3 or OCF 3 . In one preferred embodiment, R 7 represents OCH3 (methoxy). [0070] According to one embodiment, R 7 represents cycloalkyl-O-. In one embodiment, R 7 represents cyclobutyl-O-. [0071] According to one embodiment, R 7 represents (C 1 -C 8 ) alkyl-O- (i.e., (C1-C8) alkoxy), wherein the alkyl is optionally substituted by at least one OH or (C1-C8) alkoxy, i.e., RO-(C1-C8) alkyl-O- wherein R represents H or (C1-C8) alkyl.
- R 7 represents HO-CH 2 -CH 2 -O- or CH 3 O-CH 2 -CH 2 -O-.
- R 7 represents (C1-C8) alkyl-O- (i.e., (C1-C8) alkoxy), wherein the alkyl is optionally substituted by at least one aryl. In one embodiment, the aryl is not substituted. In one embodiment, R 7 represents phenyl- CH2-O-.
- R 7 represents (C1-C8) alkyl-O- (i.e., (C 1 -C 8 ) alkoxy), wherein the alkyl is optionally substituted by at least one heteroaryl.
- the heteroaryl is not substituted.
- R 7 represents heteroaryl-CH 2 -O-.
- R 7 represents (C1-C8) alkyl-O- (i.e., (C1-C8) alkoxy), wherein the alkyl is optionally substituted by at least one heterocycloalkyl.
- R 7 represents heterocycloalkyl-(C 1 -C 8 ) alkyl-O-, i.e., the alkyl is substituted by exactly one heterocycloalkyl.
- the heterocycloalkyl is not substituted.
- R 7 represents hydrogen, F, Cl, OH, OCH 3 (methoxy), HO-CH 2 -CH 2 -O-, CH 3 O-CH 2 -CH 2 -O- or phenyl-CH 2 -O-. [0076] In one further preferred embodiment, R 7 represents F, OH, OCH3 (methoxy) or phenyl-CH2-O-.
- Z represents C-H or N; or Z represents C-R 8 and R 7 and R 8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl; wherein the cycloalkyl or heterocycloalkyl is optionally substituted as defined under formula (I) hereinabove.
- R 8 represents hydrogen, except where R 7 and R 8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl.
- Z represents C-H or N. In one embodiment, Z represents C-H. In one embodiment, Z represents N.
- Z represents C-R 8 and R 7 and R 8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl; wherein the cycloalkyl or heterocycloalkyl is optionally substituted as defined under formula (I) herein.
- Z does not represent N.
- Z represents C-R 8 ; wherein R 8 represents (C1-C4) alkyl, F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH or (C1-C4) alkoxy.
- R 8 represents methyl, ethyl, F, Cl, CF3, CN or OH.
- R 8 represents methyl or Cl.
- Z represents C-R 8 and R 7 and R 8 form together with the carbon atoms to which they are bound an heterocycloalkyl; wherein the heterocycloalkyl is optionally substituted as defined under formula (I) herein.
- the heterocycloalkyl comprises at least one oxygen atom, i.e., the heterocycloalkyl is a cyclic ether.
- the heterocycloalkyl comprises exactly one oxygen atom.
- the heterocycloalkyl comprises at least one nitrogen atom, i.e., the heterocycloalkyl is a cyclic amine.
- the heterocycloalkyl is six-membered or five-membered. In one particular embodiment, the heterocycloalkyl is not substituted. In one preferred embodiment, the heterocycloalkyl is tetrahydrofuran (e.g., wherein -R 7 -R 8 - represents - O-CH2CH2-).
- R 5 represents hydrogen or (C1-C8) alkyl. In one embodiment, R 5 represents hydrogen. In one embodiment, R 5 represents (C 1 -C 8 ) alkyl. In one preferred embodiment, R 5 represents hydrogen, methyl or ethyl. In one particular embodiment, R 5 represents hydrogen. In one particular embodiment, R 5 represents methyl or ethyl.
- R 5 represents methyl. In one further particular embodiment, R 5 represents ethyl.
- R 6 represents (C1-C8) alkyl, cycloalkyl or cycloalkyl-(C1-C8) alkyl-. In one embodiment, the alkyl or cycloalkyl is optionally substituted by at least one F. In one embodiment, the alkyl or cycloalkyl is not substituted. In one embodiment, R 6 represents methyl, ethyl, n-propyl, 1-fluoro-n-propane, tert-butyl, cyclopropyl, cyclobutyl or cyclopropyl-CH2-.
- R 6 represents (C 1 -C 8 ) alkyl, cycloalkyl, heterocycloalkyl, cycloalkyl-(C1-C8) alkyl- or aryl-(C1-C8) alkyl-.
- the alkyl, cycloalkyl, heterocycloalkyl or aryl is optionally substituted by at least one methyl, Cl or F.
- R 6 represents ethyl, propyl (e.g., n-propyl), butyl (e.g., tert-butyl), cyclopentyl, cyclohexyl, 2-adamantyl, 3-methyloxetan-3-yl, cyclopropyl-CH2-, cyclobutyl-CH2-, cyclohexyl-CH2-, phenyl-CH2- (benzyl), 3-chlorophenyl-CH2- or 4-fluorophenyl-CH2-.
- R 6 represents propyl (e.g., n-propyl), butyl (e.g., tert-butyl), cyclohexyl, cyclopropyl-CH2- or 3-chlorophenyl-CH2-.
- R 6 represents (C1-C8) alkyl. In one embodiment, the alkyl is optionally substituted by at least one F. In one embodiment, the alkyl is not substituted.
- R 5 represents methyl, ethyl, n-propyl, 1-fluoro-n-propane or tert-butyl.
- R 6 represents cycloalkyl.
- R 6 represents cyclopropyl or cyclobutyl.
- R 6 represents cycloalkyl-(C1-C8) alkyl.
- R 6 represents cyclopropylmethyl (cyclopropyl-CH2-).
- R 5 and R 6 form together with the nitrogen atom to which they are bound an heterocycloalkyl.
- the heterocycloalkyl is optionally substituted by at least one F.
- R 5 and R 6 form together with the nitrogen atom to which they are bound a pyrrolidine, piperidine, 4-fluoropiperidine, 3-fluoropyrrolidine, 4-trifluoromethylpiperidine, 4-benzyl-piperidine, 3- benzylpyrrolidine, 3-benzyl-piperidine, 4-phenylpiperidine, 4-benzylidenepiperidine, octahydro-1H-isoindole, 2-benzyloctahydropyrrolo[3,4-c]pyrrole, 3-(benzyloxy)pyrrole, 3-(methoxymethyl)azetidine, 2-azabicyclo[2.2.1]heptane, 5-(4-methylpiperazin-1- yl)pyrimidine and 4-phenethylpiperidine.
- R 5 and R 6 form together with the nitrogen atom to which they are bound a pyrrolidine, 4-fluoropiperidine, 3-fluoropyrrolidine, 4-trifluoromethylpiperidine, 4-benzyl-piperidine, 3-benzylpyrrolidine, 3-benzyl-piperidine, 4-phenylpiperidine, 4-benzylidenepiperidine, octahydro-1H-isoindole, 3-(benzyloxy)pyrrole, 2-azabicyclo[2.2.1]heptane, 5-(4- methylpiperazin-1-yl)pyrimidine or 4-phenethylpiperidine.
- R 5 and R 6 form together with the nitrogen atom to which they are bound a pyrrolidine, 4-benzyl-piperidine, 4-phenyl-4-hydroxy-piperidine, 4-benzyl-4-hydroxy-piperidine, 4-benzyl-piperazine, tert-butyl 1,3,3a,4,6,6a- hexahydropyrrolo[3,4-c]pyrrole-2-carboxylate, 4-benzylidene-1-piperidine, 4-(2- phenylethyl)-piperidine, 4-phenylpiperidine, 3-phenylpiperidine, 3-benzyl-piperidine, 3- phenylpyrrolidin, 3-benzylpyrrolidine, 4-trifluoromethylpiperidine, 2- azabicyclo[2.2.1]heptane, 3-benzyloxypiperidine, 3-benzyloxypyrrolidine, 2-benzyl- 1,3,3a,4,6,6a-hexahydropyrrolo[
- R 5 and R 6 form together with the nitrogen atom to which they are bound a pyrrolidine, 4-benzyl-piperidine, 4-benzylidene-1-piperidine, 4- (2-phenylethyl)-piperidine, 4-phenylpiperidine, 3-phenylpiperidine, 3-benzyl-piperidine, 3-phenylpyrrolidin, 4-trifluoromethylpiperidine, 3-benzyloxypiperidine, 3- benzyloxypyrrolidine, 4-(4-fluorophenyl)piperidine, [2-(4- chlorophenyl)ethyl]piperazine, [2-(4-fluorophenyl)ethyl]piperazine, 2- (phenylpropyl)piperazine, [2-(4-fluorophenyl)propyl]piperazine, 4-fluoropiperidine or 2,2-dimethylpyrrolidine.
- At least one heterocycloalkyl present in the compound of formula (I) is a water-solubilizing group, the presence of this group in the molecule increases the solubility thereof in water, compared with the same molecule not comprising the heterocycloalkyl.
- the compound of formula (I) is a compound of formula (I-a) or a pharmaceutically acceptable salt and/or solvate thereof; wherein W, R B , R D , Z and R 5 -R 7 are as defined under formula (I) herein.
- W in formula (I-a) represents CH.
- R B and R D in formula (I-a) each independently represents F or Cl, and R 7 represents alkoxy. In one particular embodiment, R B represents F and R D represents Cl. [0098] In one embodiment, R 7 in formula (I-a) represents alkoxy. In one particular embodiment, R 7 represents methoxy (-OCH3). [0099] In one embodiment, R B and R D in formula (I-a) each independently represents F or CF 3 . In one particular embodiment, R B represents F and R D represents CF 3 . [0100] In one embodiment, Z in formula (I-a) represents N.
- the compound of formula (I) is selected from the compounds of Table 1 below, and pharmaceutically acceptable salts and/or solvates thereof.
- the compound is selected from the compounds of Table 1 herein, and pharmaceutically acceptable salts and/or solvates thereof, provided that the compound is not N,N-diethyl-5-[4-[4-fluoro-2- (trifluoromethyl)benzoyl]piperazin-1-yl]-6-methoxy-pyridine-3-sulfonamide (045) or a pharmaceutically acceptable salt and/or solvate thereof.
- R D when R D represents CF3, R 7 represents OCH3 and Z represents C-H, then R A , R B and R C do not represent F or Cl.
- R D when R D represents CF3 and R 7 represents OCH3, then R A , R B and R C do not represent F.
- R D when R D represents CF3, then R A , R B and R C do not represent F.
- R D when R D represents CF 3 , then R A , R B and R C do not represent F or Cl.
- R 7 when R 7 represents OCH 3 , then R A , R B and R C do not represent F. In one embodiment, in the compound of formula (I), when R 7 represents OCH 3 , then R A , R B and R C do not represent F or Cl. According to one embodiment, R D does not represent CF3. In one embodiment, R D does not represent CF 3 , CHF 2 or CH 2 F. According to one embodiment, R 7 does not represent methoxy (-OCH3). In one embodiment, R 7 does not represent alkoxy.
- references herein to a compound of the invention include references to salts, solvates, multi component complexes and liquid crystals thereof. All references herein to a compound of the invention include references to polymorphs and crystal habits thereof. All references herein to a compound of the invention include references to isotopically-labelled compounds thereof, including deuterated compounds thereof. All references herein to a compound of the invention include references to stereoisomers thereof. All references herein to a compound of the invention include references to pharmaceutically acceptable prodrugs thereof. [0105] In particular, the compounds of the invention may be in the form of pharmaceutically acceptable salts. According to one embodiment, the compound of the invention is a pharmaceutically acceptable salt.
- Pharmaceutically acceptable salts include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphat
- Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, 2-(diethylamino)ethanol, diolamine, ethanolamine, glycine, 4-(2-hydroxyethyl)- morpholine, lysine, magnesium, meglumine, morpholine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. When a compound contains an acidic group as well as a basic group the compound may also form internal salts, and such compounds are within the scope of the invention.
- salts and/or isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule may be prepared by one or more of these methods: (i) by reacting the compound with the desired acid; (ii) by reacting the compound with the desired base; (iii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound or by ring- opening a suitable cyclic precursor, e.g., a lactone or lactam, using the desired acid; and/or (iv) by converting one salt of the compound to another by reaction with an appropriate acid or by means of a suitable ion exchange column.
- the compounds of the invention may be in the form of pharmaceutically acceptable solvates.
- the compound of the invention is a pharmaceutically acceptable solvate.
- the compound of the invention is a pharmaceutically acceptable salt and solvate.
- the compounds of the invention may include at least one asymmetric center(s) and thus may exist as different stereoisomeric forms.
- references herein to a compound of the invention include all possible stereoisomers and include not only the racemic compounds, but the individual enantiomers and their non-racemic mixtures as well.
- Non-racemic mixtures may comprise any amounts of each distinct stereoisomer, for example one stereoisomer may be preponderant (e.g., a 90/10 or 80/20 mixture), or the enantiomeric ratio may be close to a racemic mixture (e.g., a 40/60 mixture).
- a compound is desired as a single enantiomer, such single enantiomer may be obtained by stereospecific synthesis, by resolution of the final product or any convenient intermediate, or by chiral chromatographic methods as each are known in the art.
- compositions comprising a compound according to the invention, as described herein.
- the composition further comprises at least one pharmaceutically acceptable carrier, so that the composition is a “pharmaceutical composition” as defined herein.
- the pharmaceutical composition comprises the compound according to the invention as sole therapeutic agent.
- the pharmaceutical composition further comprises at least another therapeutic agent such as, for example, a therapeutic agent suitable for treating a neurological disorder.
- Another object of the present invention is a medicament comprising a compound according to the invention, as described herein.
- Kit Another object of the present invention is a kit of parts (in short “kit”) comprising a compound or composition according to the invention, as described herein.
- the kit comprises a manufacture such as, for example, a package or a container.
- the kit comprises instructions for use.
- the kit may be promoted, distributed, or sold as a unit for performing the methods of the present invention.
- the kit comprises: a pharmaceutical composition comprising the compound according to the invention, and another separate pharmaceutical composition comprising at least another therapeutic agent such as, for example, a therapeutic agent suitable for treating a neurological disorder.
- Another object of the present invention is a compound or a composition according to the invention, as described herein, for use as a medicament.
- Another object of the present invention is a compound or a composition according to the invention, as described herein, for use in the treatment of a neurological disorder.
- Another object of the present invention is a method for treating a neurological disorder in a subject in need thereof.
- Another object of the present invention is the use of a compound or a composition according to the invention, as described herein, in the manufacture of a medicament for the treatment of a neurological disorder.
- Another object of the present invention is the use of a compound or a composition according to the invention, as described herein, for treating a neurological disorder.
- the method or the use comprises a step of administering to a subject a therapeutically effective amount of a compound, a composition or a medicament according to the invention, as described herein.
- the neurological disorder to be treated by the method or the use of the invention is: - a disease or a disorder associated with defective neurogenesis such as, for example, Hirschsprung disease, schizophrenia, Ataxia telangiectasia, age-related decline of nervous system performance, or a neurodevelopmental disorder; - a neurodegenerative disease or disorder, such as, for example, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis, Fronto- temporal dementia, retinal neurodegenerative diseases, neuro-ophthalmic diseases, neurotrophic keratitis, Charcot-Marie-Tooth disease, Spinal Muscular Atrophy, epilepsy (e.g., an epilepsy disorder, or a seizure disorder, or a chronic neurological disorder presenting with epilepsy
- the neurological disorder is epilepsy, such as, for example, Dravet syndrome, benign Rolandic epilepsy, frontal lobe epilepsy, infantile spasms, juvenile myoclonic epilepsy (JME), juvenile absence epilepsy, childhood absence epilepsy (e.g., pyknolepsy), febrile seizures, progressive myoclonus epilepsy of Lafora, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, Generalized Epilepsy with Febrile Seizures (GEFS+), Severe Myoclonic, Epilepsy of Infancy (SMEI), Benign Neonatal Familial Convulsions (BFNC), West Syndrome, Ohtahara Syndrome, early myoclonic encephalopathies, migrating partial epilepsy, infantile epileptic encephalopathies, Tuberous Sclerosis Complex (TSC), focal cortical dysplasia, Type I Lissencephaly, Miller-Dieker Syndrome, Angelman’s syndrome
- JME juvenile myoclo
- the composition or the medicament according to the invention is to be administered to a subject, and may be formulated using methods well-known in the art.
- forms adapted for administration include solutions (such as, for example, sterile aqueous solutions), gels, dispersions, emulsions, suspensions and solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to use (such as, for example, powder or liposomal forms).
- composition or the medicament according to the invention may be administered using administration route well-known in the art such as, for example, parenterally, orally, by inhalation, spray, rectally, nasally, or via an implanted reservoir.
- administration route well-known in the art such as, for example, parenterally, orally, by inhalation, spray, rectally, nasally, or via an implanted reservoir.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disease being treated and the severity of the disease; activity of the compound employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific therapeutic agent employed; the duration of the treatment; drugs used in combination or coincidental with the specific therapeutic agent employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- the total dose required for each treatment may be administered by multiple doses or in a single dose.
- the dosage of the compound is about 0.01 to 500 mg per kg patient body weight per day, which can be administered in single or multiple doses.
- the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day.
- a suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be about 0.05 to 0.5, about 0.5 to 5 or about 5 to 50 mg/kg per day.
- compositions are preferably provided in the form of tablets containing from about 1.0 to 1000 milligrams of the active ingredient, particularly about 1.0, about 5.0, about 10.0, about 15.0, about 20.0, about 25.0, about 50.0, about 75.0, about 100.0, about 150.0, about 200.0, about 250.0, about 300.0, about 400.0, about 500.0, about 600.0, about 750.0, about 800.0, about 900.0, and about 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
- composition or the medicament according to the invention is to be administered as sole therapeutic agent.
- composition or the medicament according to the invention is to be administered before at least another therapeutic agent, concomitantly with at least another therapeutic agent, and/or after at least another therapeutic agent.
- the other therapeutic agent is suitable for treating a neurological disorder.
- Another object of the present invention is a method of promoting neuronal cell’s survival and/or neuronal cell’s functions.
- Another object of the present invention is a compound or a composition according to the invention, as described herein, for use in promoting neuronal cell’s survival and/or neuronal cell’s functions.
- the method or the use comprises a step of contacting a neuronal cell with a therapeutically effective amount of a compound, a composition or a medicament according to the invention, as described herein.
- the method or the use may be in vitro, ex vivo or in vivo.
- Another object of the present invention is a method of rescuing neuronal cell’s functions after the neuronal cell has been subjected to insults, events, or conditions detrimental to neuronal cell’s functions.
- Another object of the present invention is a compound or a composition according to the invention, as described herein, for use in rescuing neuronal cell’s functions after the neuronal cell has been subjected to insults, events, or conditions detrimental to neuronal cell’s functions.
- Such insults, events, or conditions include, without limitation, neuronal stress, for instance, caused by hypoxia or ischemia; traumatic injuries; and exposure to toxic molecules, for instance, to abnormal misfolded proteins, protein aggregates, excitotoxins, reactive oxygen species, endoplasmic reticulum stressors, mitochondrial stressors, Golgi apparatus antagonists and the like.
- the method or the use comprises a step of contacting a neuronal cell with a therapeutically effective amount of a compound, a composition or a medicament according to the invention, as described herein.
- the method or the use may be in vitro, ex vivo or in vivo.
- Another object of the present invention is a method of binding or modulating GFR ⁇ 1 using a compound or a composition according to the invention, as described herein.
- Another object of the present invention is a compound or a composition according to the invention, as described herein, for binding or modulating GFR ⁇ 1.
- the compound or a composition is for activating GFR ⁇ 1.
- GFR ⁇ 1 is human GFR ⁇ 1, preferably with SEQ ID NO: 1.
- Another object of the present invention is a method of activating the GFR ⁇ 1/RET signaling pathway using a compound or a composition according to the invention, as described herein.
- Another object of the present invention is a compound or a composition according to the invention, as described herein, for activating the GFR ⁇ 1/RET signaling pathway.
- Another object of the present invention is a method of detecting GFR ⁇ 1 in a sample, using a compound or a composition according to the invention, as described herein.
- Another object of the present invention is a compound or a composition according to the invention, as described herein, for detecting GFR ⁇ 1 in a sample.
- GFR ⁇ 1 is human GFR ⁇ 1, preferably with SEQ ID NO: 1.
- the compound according to the invention may be fused to a detectable label, such as, e.g., a fluorophore or any other moiety that can re-emit light upon light excitation, a radiolabel, a contrast agent and the like.
- a detectable label such as, e.g., a fluorophore or any other moiety that can re-emit light upon light excitation, a radiolabel, a contrast agent and the like.
- Manufacturing process Synthesis of the compound [0130]
- the compound according to the invention, as described herein, may be manufactured by means of synthetic methods well-known in the art.
- Another object of the present invention is a process for manufacturing a compound of the invention, as described herein. According to one embodiment, the process is a Buchwald-Hartwig amination.
- the process comprises: (a-1) a step of reaction of a compound of formula (II) wherein Z, R 5 , R 6 and R 7 are as defined under formula (I) herein and X represents halide or -CF3SO3, with a compound of formula (III) wherein W and R A -R D are as defined under formula (I) herein, in presence of a base and a metal catalyst; thereby obtaining the compound of the invention.
- the base at step (a-1) is cesium carbonate (Cs 2 CO 3 ), sodium carbonate (Na 2 CO 3 ) or potassium carbonate (K 2 CO 3 ).
- the base is cesium carbonate (Cs2CO3).
- the base is sodium tert-butanoate (t-BuONa), potassium tert-butanoate (t-BuOK) or potassium phosphate.
- the base is sodium tert-butanoate (t-BuONa).
- the catalyst at step (a-1) is a palladium catalyst.
- the catalyst is a Pd(OAc) 2 and rac-BINAP (2,2’- bis(diphenylphosphino)-1,1’-binaphtyle) system.
- the catalyst is XPhos-Pd-G3.
- X represents halide.
- X represents Br.
- the reaction at step (a-1) is carried out in a solvent.
- the solvent is toluene.
- the reaction is carried out at reflux.
- the process comprises: (a’-1) a step of reaction of a compound of formula (II) wherein Z, R 5 , R 6 and R 7 are as defined under formula (I) herein and X represents halide or -CF 3 SO 3 , with a mono-protected piperazine (i.e., a piperazine wherein only one of the NH groups is protected by means of a protecting group R P ), in presence of a base and a metal catalyst; thereby obtaining a compound of formula (IV) wherein Z, R 5 , R 6 and R 7 are as defined under formula (II) above and R P is the protecting group; then (a’-2) a step of deprotection of the compound of formula (IV); thereby obtaining a compound of formula (V)
- the base and/or the catalyst at step (a’-1) are as described hereinabove under step (a-1).
- X represents halide.
- X represents Br.
- the protecting group may be any protecting group known in the art such as, for example, tert-butyloxycarbonyl (Boc).
- the protective group may be removed at step (a’-2) by any method known in the art appropriate to the nature of the protective group, such as, for example, addition of a strong Bronsted acid (e.g., hydrochloric acid [HCl]).
- a strong Bronsted acid e.g., hydrochloric acid [HCl]
- the peptide coupling agent at step (a’-3) may be any peptide coupling agent known in the art such as, for example, 2-(1H-benzotriazole-1-yl)-1,1,3,3- tetramethylaminium tetrafluoroborate (TBTU).
- the base at step (a’-3) may be any base known in the art such as, for example, an amine base.
- the amine is triethylamine (Et3N) or diisopropylethylamine (iPr 2 NEt).
- the reaction at step (a’-3) is carried out in a solvent.
- the solvent is dimethylformamide (DMF) and/or tetrahydrofuran (THF).
- the solvent is dichloroethane (DCE) and/or acetonitrile (MeCN).
- the reaction is carried out at room temperature (RT).
- the process comprises: (a’’-1) a step of reaction of: a compound of formula (III) wherein W and R A -R D are as defined under formula (I) herein, with a compound of formula (VII) wherein R 7 and Z are as defined under formula (I) herein, except that Z does not represent N, and X represents halide or -CF3SO3, in presence of a base and a metal catalyst; thereby obtaining a compound of formula (VIII) wherein W, R A -R D , R 7 and Z are as defined under formulae (III) and (VII) above; (a’’-2) a step of reaction of the compound of formula (VIII) with chlorosulfonic acid (HSO3Cl); thereby obtaining a compound of formula (IX); wherein W, R A -R D , R 7 and Z are as defined under formulae (III) and (VII) above; (a’’-3) a step of reaction of the compound
- the process comprises a step (a’’-1) of reaction of a compound of formula (III) with a compound of formula (VII) as described hereinabove, thereby obtaining a compound of formula (VIII); but no step (a’’-2) of reaction of the compound of formula (VIII) with chlorosulfonic acid (HSO3Cl); and Z may represent N.
- the base and/or the catalyst at step (a’’-1) are as described hereinabove under step (a-1).
- X represents halide. In one particular embodiment, X represents Br.
- the base at step (a’’-3) may be any base known in the art such as, for example, an amine base.
- the amine is triethylamine (Et 3 N) or diisopropylethylamine (iPr2NEt).
- the reaction at step (a’’-3) is carried out in a solvent.
- the solvent is dichloromethane (DCM).
- the process further comprises a work-up step (b).
- the work-up step (b) comprises a step of extraction by a solvent.
- the solvent is ethyl acetate (EtOAc).
- the solvent is water or a 1N HCl solution. In one particular embodiment, the solvent is dichloromethane (DCM).
- the work-up step (b) comprises a step of filtration. In one particular embodiment, the filtration is over Celite® In one embodiment, the work-up step (b) comprises a step of concentration under reduced pressure. [0149] In one embodiment, the process further comprises a purification step (c). In one embodiment, the purification step (c) comprises a purification by chromatography.
- the chromatography is flash chromatography (FC) (e.g., cHex/EtOAc gradient), preparative thin-layer chromatography (PTLC) or semi-preparative high-performance liquid chromatography (HPLC).
- FC flash chromatography
- PTLC preparative thin-layer chromatography
- HPLC semi-preparative high-performance liquid chromatography
- Another object of the present invention is a compound of formula (IV) wherein Z, R 5 , R 6 and R 7 are as defined under formula (I) herein and R P is a protecting group (e.g., Boc).
- R P is a protecting group (e.g., Boc).
- Another object of the present invention is a compound of formula (V) wherein Z, R 5 , R 6 and R 7 are as defined under formula (I) herein.
- Another object of the present invention is a compound of formula (VIII) wherein W, R A -R D , R 7 and Z are as defined under formula (I) herein.
- Z does not represent N.
- Another object of the present invention is a compound of formula (IX) wherein W, R A -R D , R 7 and Z are as defined under formula (I) herein. [0157] According to one preferred embodiment, in formula (IX) hereinabove, Z does not represent N. EXAMPLES [0158] The present invention is further illustrated by the following examples.
- Standard analytical parameters flow rate: 1 mL/min, Vinj.: 5 ⁇ L.
- Acidic conditions Waters XSelect CSH C18 column (3.5 ⁇ m, 2.1x 1550 mm). Gradient: (H2O + 0.04% v/v HCO 2 H (10mM))/ACN from 95/5 to 0/100 in 2.5 min.
- Alkaline conditions Waters Xbridge C18 column (3.5 ⁇ m, 2.1x 50 mm). Gradient: (H 2 O + 0.06% v/v NH 3 (aq.) (10mM))/ACN from 95/5 to 0/100 in 2.5 min.
- I-004 1-(3-bromo-4-methoxy-phenyl)sulfonylpyrrolidine (I-004) According to GP-4, I-004 was obtained as a white solid in 95% yield using 3-bromo-4- methoxy-benzenesulfonyl chloride (5.00g, 17.5mmol, 1 equiv.), pyrrolidine (2.16mL, 26.3mmol, 1.5 equiv.) and triethylamine (3.66mL, 26.3mmol, 1.5 equiv.) in DCM (70mL) for 1h at RT.
- 3-bromo-4- methoxy-benzenesulfonyl chloride 5.00g, 17.5mmol, 1 equiv.
- pyrrolidine (2.16mL, 26.3mmol, 1.5 equiv.
- triethylamine 3.66mL, 26.3mmol, 1.5 equiv.
- I-005 tert-butyl 4-(2-methoxy-5-pyrrolidin-1-ylsulfonyl-phenyl)piperazine-1- carboxylate (I-005)
- I-005 was obtained as a dark oil in 83% yield using I-004 (5.10g, 15.9mmol, 1 equiv.), tert-butyl piperazine-1-carboxylate (4.45g, 23.9mmol, 1.5 equiv.), Cs 2 CO 3 (15.6g, 47.8mmol, 3 equiv.), Pd(OAc) 2 (358mg, 1.59mmol, 0.1 equiv.) and rac-BINAP (1.49g, 2.39mmol, 0.15 equiv.) in toluene (80mL) at reflux for 28h.
- I-029 was obtained as an oil in 44% yield using I-028 (400mg, 1.73mmol, 1 equiv.), piperazine I-027 (504mg, 2.08mmol, 1.2 equiv.), Cs2CO3 (1.69g, 5.19mmol, 3 equiv.), Pd(OAc) 2 (38.9mg, 173 ⁇ mol, 0.1 equiv.) and rac-BINAP (162mg, 260 ⁇ mol, 0.15 equiv.) in toluene (8.7mL) at reflux for 2h.
- Results [0210] The results are presented on Table 4 below (* means “10 ⁇ M ⁇ EC50 ⁇ 50 ⁇ M”, ** means “5 ⁇ M ⁇ EC 50 ⁇ 10 ⁇ M”, *** means “1 ⁇ M ⁇ EC 50 ⁇ 5 ⁇ M”, and **** means “EC 50 ⁇ 1 ⁇ M”).
- Table 4 [0211] The above results clearly evidence that the tested compounds 001-060 have significant GFR ⁇ 1-RET activity. Thus, the compounds of the invention are useful as neuroprotective and neurorestorative agents.
- the tested compounds 001-060 are well-representing the class of the compounds of formula (I).
- Example 3 Biological activity of comparative compounds
- the purpose of this experiment was to compare the GFR ⁇ 1-RET activity of the compounds 001, 009 and 010 according to the invention to the GFR ⁇ 1-RET activity of comparative compounds C01 and C02.
- Materials and methods [0213] Comparatives compounds C01 and C02 were prepared by using the same synthetic pathways and methods as described hereinabove for the compounds according to the invention, using the general knowledge in the art to adapt the reactants and experimental conditions as needed. [0214] The structure of comparatives compounds C01 and C02 are presented on Table 5 below.
- Table 5 [0215] The compounds were tested for their activating activity of Elk1 signaling using the same materials and methods than for the compounds according to the invention (Example 2 herein, section “Materials and methods”). Results [0216] The results for comparative compounds C01 and C02 are presented on Table 6 below. For easier comparison, the corresponding values from Table 4 above for compounds 009, 010 and 001 according to the invention were also reported in Table 6 (AL means “EC50 > 50 ⁇ M”, * means “10 ⁇ M ⁇ EC50 ⁇ 50 ⁇ M”, ** means “5 ⁇ M ⁇ EC50 ⁇ 10 ⁇ M”, *** means “1 ⁇ M ⁇ EC 50 ⁇ 5 ⁇ M”, and **** means “EC 50 ⁇ 1 ⁇ M”).
- R D does not represent CF 3 in compounds 009 and 010, but rather CHF 2 (010) or Cl (009), whereas in compound C01 the substituent that would correspond to R D in formula (I) represents CF3.
- R D does not represent CF3 in compound 001, but rather Cl, whereas in compound C02 the substituent that would correspond to R D in formula (I) represents CF 3 .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological disorders.
Description
NOVEL PIPERAZINE-BASED SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS FIELD OF INVENTION [0001] The present invention relates to novel polycyclic sulfonamides comprising at least one unsubstituted and unbridged piperazine. The compounds of the invention are useful as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological disorders. BACKGROUND OF INVENTION [0002] Neurological disorders (NDs) are heterogeneous diseases affecting the autonomic, peripheral and central nervous system of the body. Amongst the Central Nervous System (CNS) diseases, Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS), dementia, stroke, head trauma, brain tumor, pain and epilepsy are always the most challenging diseases to be addressed. Compounds actives for treating CNS might also be relevant to other diseases, for example diseases of the peripheral nervous system, eyes, spinal cord and enteric system. [0003] The incidence of NDs is expected to increase dramatically in the 21st century, in particular due to increased life expectancy and demographic changes. Some of these diseases are characterized by age-related gradual decline in neurological functions. In medicine, neurological diseases are the world's important and common cause of disability-adjusted life years, or years of healthy life lost due to death or disability. CNS diseases represent the largest and fastest growing therapeutic domain of unmet medical need, and it is being recognized as a global public health challenge and become a major global health priority. Adequate neurological diagnosis represents an immense challenge, and patients are more concerned about the development of new effective treatments to treat pathophysiology or symptoms. Neurological disorders affect millions of people worldwide and cause permanent damage. They are progressive diseases with symptoms
that can degenerate overtime. Although there is generally no definitive cure, supporting treatments exist. The goal of these treatments is mainly to reduce symptoms and preserve the quality of life of the patient as long as possible. [0004] Neurons are postmitotic cells that must live for a lifetime. While young neurons have proper functioning of self-healing protective mechanisms, aging or external or internal insults disturb them, eventually leading to neurodegeneration. These external/internal hazards are traumatic injuries or excitotoxic compounds, reactive oxygen species (ROS), protein aggregates, and other toxic molecules. Fortunately, cells have an intrinsic machinery that blocks death by activating resilience mechanisms or promoting regeneration pathways. Dysfunctionality or insufficiency of these self-healing mechanisms has also been described in neurodegenerative diseases. [0005] Among natural self-healing agents, the glial cell line-derived neurotrophic factor (GDNF) acts as a potent neurotrophic factor, promoting survival in different neuronal populations such as spinal motor neurons, retinal cells, central noradrenergic neurons, or sympathetic neurons, among others. Likewise, GDNF (and other proteins of the GDNF family of neurotrophic factors such as neurturin, artemin and persephin) acts as a powerful trophic factor favoring, not only the survival and plasticity, but also the proliferation, differentiation, and protection of dopaminergic neurons, as well as the synthesis of dopamine and dopaminergic transmission in the developing and adult brain. GDNF can promote neuroprotection through MAP kinase/ERK, Src kinase and PI3 kinase/AKT pathways by inducing several neuroprotective signaling cascade, including the activation of the transcription factor Elk1 through the activation of the GFRα1-RET receptor complex. [0006] The field of applications for these proteins is vast. Pre-clinical and clinical trials have been carried out to evaluate the effect of neurotrophic factors of the GDNF family for the prevention, treatment or management of Parkinson’s disease, chronic pain, Alzheimer’s disease, amyotrophic lateral sclerosis, neuropathy, depression, stroke, and these proteins were even suggested as male contraceptives. However, the clinical application of GDNF is hampered by its poor pharmacokinetic properties, the fact that it
does not cross the blood-brain barrier and thus the necessity for intracranial delivery via stereotaxic surgery, varying biological activity, and high price. [0007] Blood-brain barrier penetrating small-molecule compounds that target the GDNF receptor complex and mimic GDNF biological effects in neurons may be an avenue to overcome these issues and translate to greater efficacy in the clinic. Superior tissue penetration of such compounds could promote survival in all affected neuronal pathways. [0008] WO 2011/070177 A2 (BALTIC TECHNOLOGY DEV LTD) discloses polycyclic compounds for treating neurological disorders. Although these compounds represented a significant improvement at this time, they still have limitations in terms of activity on GFRα1-RET target, solubility, membrane permeability (PAMPA and CaCO2), intrinsic clearance microsomes and hepatocytes, plasma protein binding, and pharmacokinetic profile. In particular, these compounds are limited in terms of activity on GFRα1-RET target (as evidenced, for example, in luciferase assays). [0009] IVANOVA, L. et al. (ACS OMEGA, Vol. 3, No. 3, 19 September 2018, pp. 11407-11414, ISSN: 2470-1343, DOI: 10.1021/acsomega.8b01524) discloses two compounds, also disclosed in WO 2011/070177 A2, and simulates the dynamic molecular modelling of the interactions between Gglial cell line-derived neurotrophic factor family receptor GFRα1 and these two compounds. [0010] WO 2014/041179 A1 (CHEMEDEST LTD) also disclose the same polycyclic compounds than WO 2011/070177 A2 for treating and/or preventing peripheral neuropathy (peripheric disease), therefore with the same limitations. [0011] It was surprisingly found out by the Applicants that novel polycyclic sulfonamides of formula (I) showed potent GFRα1-RET activity in a luciferase assay, thereby opening the way to overcoming the limitations of available therapeutic solutions.
SUMMARY [0012] An object of the present invention is a compound of formula (I)
or a pharmaceutically acceptable salt and/or solvate thereof; wherein W, RA-RD, Z and R5-R7 are as defined hereinafter and/or as defined in the claims. [0013] According to one preferred embodiment, the compound of formula (I) is a compound of formula (I-i) or formula (I-ii) as defined hereinafter and/or as defined in the claims. [0014] According to one embodiment, the compound is selected from the compounds of Table 1 herein, and pharmaceutically acceptable salts and/or solvates thereof, provided that the compound is not N,N-diethyl-5-[4-[4-fluoro-2- (trifluoromethyl)benzoyl]piperazin-1-yl]-6-methoxy-pyridine-3-sulfonamide or a pharmaceutically acceptable salt and/or solvate thereof. [0015] Another object of the present invention is a pharmaceutical composition comprising a compound according to the invention and at least one pharmaceutically acceptable carrier. [0016] Another object of the present invention is a compound according to the invention or a pharmaceutical composition according to the invention for use as a medicament. According to one embodiment, the compound or the pharmaceutical composition is for use in the treatment of a neurological disorder. [0017] Another object of the present invention is a process for manufacturing a compound according to the invention.
DEFINITIONS [0018] In the present invention, the following terms have the following meanings: Chemical definitions [0019] Where chemical substituents are combinations of chemical groups, the point of attachment of the substituent to the molecule is by the last chemical group recited on the right of the name of the substituent. For example, an arylalkyl substituent is linked to the rest of the molecule through the alkyl moiety and it may by represented as follows: “aryl-alkyl-”. [0020] Unless otherwise indicated, the compounds were named using BIOVIA Draw 2021 (Dassault, France). [0021] The definitions herein referring to the optional or mandatory substitution of a specified group apply both to the substituted group considered as such or to the same group comprised in another chemical moiety, which can both be substituted as set forth herein. For example, “Rx represents hydrogen, (C1-C8) alkyl, (C1-C8) alkyl-O- or cycloalkyl-(C1-C8) alkyl-NH-; wherein the alkyl is optionally substituted by at least one F” means that any alkyl group present in the structure of Rx may optionally substituted by at least one F, including said (C1-C8) alkyl as such (e.g., CF3), the alkyl comprised in said (C1-C8) alkyl-O- (e.g., OCF3) and the alkyl comprised in said cycloalkyl-(C1-C8) alkyl-NH- (e.g., cyclopropyl-CH2-CHF-CH2-NH-). [0022] “Alkoxy” refers to an alkyl-O- group. [0023] “Alkyl” refers to a saturated linear or branched hydrocarbon chain, typically comprising from 1 to 16 carbon atoms, preferably from 1 to 12 carbon atoms, more preferably from 1 to 8 carbon atoms, furthermore preferably from 1 to 6 carbon atoms. Alkyl groups may be monovalent or polyvalent (i.e., “alkylene” groups, which are divalent alkyl groups, are encompassed in “alkyl” definition). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl,
pentyl and its isomers (e.g., n-pentyl, iso-pentyl), and hexyl and its isomers (e.g., n-hexyl, iso-hexyl). Particular examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl (including methylene, ethylene, n-propylene, n-butylene and n-butylene). [0024] “Amine” refers to derivatives of ammonia (NH3), wherein one or more hydrogen atoms have been replaced by a substituent such as, for example, alkyl or aryl. “Amino” refers to the -NH2 group. [0025] “Aryl” refers to a cyclic, polyunsaturated, aromatic hydrocarbyl group comprising at least one aromatic ring and comprising from 5 to 12 carbon atoms, preferably from 6 to 10 carbon atoms. Aryl groups may be monovalent or polyvalent (e.g., divalent). Aryl groups may have a single ring (e.g., phenyl) or multiple aromatic rings fused together (e.g., naphthyl) or linked covalently. The aromatic ring may optionally include one to two additional rings (either cycloalkyl, heterocycloalkyl or heteroaryl) fused thereto. This definition of “aryl” encompasses the partially hydrogenated derivatives of the carbocyclic systems enumerated herein, as long as at least one ring is aromatic. Aryls may optionally be substituted by at least one group such as, for example, halogen (e.g., F or Cl), (C1-C8) alkyl (e.g., methyl) or nitrile (CN). Non-limiting examples of aryl groups include phenyl, biphenyl, biphenylenyl, 5- or 6- tetralinyl, naphthalen-1- or -2-yl, 4-, 5-, 6 or 7-indenyl, 1- 2-, 3-, 4- or 5-acenaphthylenyl, 3-, 4- or 5-acenaphthenyl, 1- or 2-pentalenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8- tetrahydronaphthyl, 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, and 1-, 2-, 3-, 4- or 5-pyrenyl. A particular example of aryl group is phenyl. [0026] “Benzylidene” refers to a phenyl group bond to a moiety through an exo carbon-carbon double bound, i.e., =CH-Ph bond to a carbon atom. The moiety is typically cyclic such as, for example, an heterocycloalkyl. [0027] “Cycloalkyl” refers to a cyclic alkyl group, typically comprising from 3 to 15 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably from 3 to 8 carbon atoms, further more preferably from 3 to 6 carbon atoms. Cycloalkyl groups may be monovalent or polyvalent (e.g., divalent). This definition of “cycloalkyl” encompasses
polycyclic cycloalkyls (e.g., bicycles) and bridged cycloalkyl structures, including cycles bound together through one atom (“spiro”) or through two atoms. This definition of “cycloalkyl” encompasses cycloalkyls including a cyclic alkyl group substituted by at least one non-cyclic alkyl, such as, for example, a (C1-C8) alkyl (preferably, (C1-C4) alkyl, e.g., methyl). Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycoheptyl, cyclooctanyl, cyclononanyl, cyclodecanyl, norbornyl, adamantyl, bicyclo[2.2.2]octanyl, bicyclo[4.4.0]decanyl, bicyclo[3.2.1]octanyl, bicyclo[3.3.1]nonanyl, bicyclo[2.1.1]hexane, 2,3-dihydro-1H- indenyl, 1,2,3,4-tetrahydronaphthalenyl, decahydronaphthalenyl, 1,2,3,4- tetrahydronaphthalenyl, and octahydropentalenyl. [0028] “Cx-Cy” or “(Cx-Cy)” preceding the name of a group means that the group comprises from x to y carbon atoms, in accordance to common terminology in the chemistry field. [0029] “Halogen” refers to a fluorine, chlorine, bromine or iodine atom. [0030] “Heteroalkyl” refers to an alkyl group as defined herein, wherein one or more carbon atoms are replaced by a heteroatom selected from oxygen, nitrogen and sulfur, and wherein the resulting heteroalkyl group comprises at least one carbon atom. In heteroalkyl groups, the heteroatoms are bound along the alkyl chain only to carbon atoms, i.e., each heteroatom is separated from any other heteroatom by at least one carbon atom, typically by at least two carbon atoms. Heteroalkyl groups may be monovalent or polyvalent (e.g., divalent). The nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized (e.g., sulfur may be oxidized as SO or SO2). Heteroalkyl groups may further include one or more =O and/or =S groups. In one embodiment, at least two carbon atoms are replaced by a heteroatom. In one embodiment, the heteroalkyl is bound to another group or molecule through a carbon atom, i.e., the binding atom is not selected among the heteroatoms included therein. In one embodiment, the heteroalkyl is bound to another group or molecule through one of the heteroatoms included therein. When substituted by one or more other group(s), an heteroalkyl may be substituted either through a carbon atom or through a heteroatom (e.g., nitrogen), unless otherwise specified. Non-limiting examples of
heteroalkyl include alkoxy, ethers and polyethers (e.g., polyethylene glycol), secondary and tertiary amines and polyamines, thioethers and polythioethers, and combinations thereof. [0031] “Heteroaryl” refers to aromatic rings or aromatic ring systems comprising from 5 to 15 carbon atoms, preferably from 4 to 12 carbon atoms, more preferably from 3 to 10 carbon atoms, having one or two rings that are fused together or linked covalently, wherein at least one ring is aromatic, and wherein one or more carbon atoms in one or more of these rings is replaced by oxygen, nitrogen and/or sulfur atoms. Heteroaryl groups may be monovalent or polyvalent (e.g., divalent). The nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized (e.g., the heteroatom is substituted by oxo (=O) for sulfur atom or (→O) for nitrogen atom). This definition of “heteroaryl” encompasses the partially hydrogenated derivatives of the carbocyclic systems enumerated herein, as well as ring systems including one or more fused non-aromatic cycloalkyl and/or heterocycloalkyl ring(s), as long as at least one ring is aromatic. In one embodiment, the heteroaryl is bound to another group or molecule through a carbon atom, i.e., the binding atom is not selected among the heteroatoms included therein. In one embodiment, the heteroaryl is bound to another group or molecule through one of the heteroatoms included therein. When substituted by one or more other group(s), an heteroaryl may be substituted either through a carbon atom or through a heteroatom (e.g., nitrogen), unless otherwise specified. Heteroaryls may optionally be substituted by at least one group such as, for example, halogen (e.g., F or Cl), (C1-C8) alkyl (preferably, (C1-C4) alkyl, e.g., methyl) or nitrile (CN). Non-limiting examples of heteroaryl groups include pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, dioxinyl, thiazinyl, triazinyl, tetrazinyl, imidazo[2,1- b][1,3]thiazolyl, thieno[3,2-b]furanyl, thieno[3,2-b]thiophenyl, thieno[2,3- d][l,3]thiazolyl, thieno[2,3-d]imidazolyl, tetrazolo[l,5-a]pyridinyl, indolyl, indolizinyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl, indazolyl, benzimidazolyl, 1,3-benzoxazolyl, 1,2-benzisoxazolyl, 2,1-benzisoxazolyl, 1,3-benzothiazolyl, 1,2-benzoisothiazolyl, 2,1-benzoisothiazolyl, benzotriazolyl, 1,2,3-
benzoxadiazolyl, 2,1,3-benzoxadiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-benzothiadiazolyl, thienopyridinyl, purinyl, imidazo[l,2-a]pyridinyl, 6-oxo- pyridazin-l(6H)-yl, 2-oxopyridin-l(2H)-yl, 6-oxo-pyridazin-l(6H)-yl, 2-oxopyridin- l(2H)-yl, 1,3-benzodioxolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl and quinoxalinyl. Non-limiting examples of heteroaryl groups comprising at least one fused non-aromatic ring include 2,3-dihydrobenzofuranyl, benzo[d][1,3]dioxolyl, indolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, 1,2,3,4-tetrahydroquinoxaline, 3,4-dihydro-2H-benzo[b][1,4]thiazine and 2,3-dihydrobenzo[b][1,4]oxathiine. [0032] “Heteroarylidene” refers to a heteroaryl group bond to a moiety through an exo carbon-carbon double bound, i.e., =CH-heteroaryl bond to a carbon atom. The moiety is typically cyclic such as, for example, an heterocycloalkyl. [0033] “Heterocycloalkyl” refers to a cyclic heteroalkyl group, typically comprising from 2 to 15 carbon atoms, preferably from 2 to 11 carbon atoms, more preferably from 2 to 7 carbon atoms, furthermore preferably from 2 to 6 carbon atoms. Heterocycloalkyl groups may be monovalent or polyvalent (e.g., divalent). Heterocycloalkyl groups are typically 3- to 7-membered, preferably 5- or 6-membered. Heterocycloalkyl are typically monocyclic or bicyclic, preferably monocyclic. This definition encompasses polycyclic heterocycloalkyls (e.g., bicycles) and bridged heterocycloalkyl structures, including cycles bound together through one atom (“spiro”) or through two atoms. The nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized (e.g., the heteroatom is substituted by oxo (=O) for sulfur atom or (→O) for nitrogen atom). In one embodiment, the heterocycloalkyl is bound to another group or molecule through a carbon atom, i.e., the binding atom is not selected among the heteroatoms included therein. In one embodiment, the heterocycloalkyl is bound to another group or molecule through one of the heteroatoms included therein. When substituted by one or more other group(s), an heterocycloalkyl may be substituted either through a carbon atom or through a heteroatom (e.g., nitrogen), unless otherwise specified. Heterocycloalkyls may optionally be substituted by at least one group such as, for example, halogen (e.g., F or Cl), (C1-C8) alkyl (preferably, (C1-C4) alkyl, e.g.,
methyl), nitrile (CN) or =O. Non-limiting examples of heterocycloalkyl include aziridine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, azepane, azocane, octahydro-1H-isoindole, decahydroisoquinoline, tetrahydrofuran, tetrahydropyran, tetrahydroisoquinoline (e.g., 1,2,3,4-tetrahydroisoquiline), hexahydropyridazine, hexahydropyrazine, hexahydropyrimidine, decahydroquinoline, octahydropyrrolo[3,4- c]pyrrole, isoindoline, 1,2,3,4-tetrahydroquinoline and oxetane. [0034] “Prodrug” refers to a pharmacologically acceptable derivative of a therapeutic agent (e.g., a compound according to the invention) whose in vivo biotransformation product is the therapeutic agent (active drug). Prodrugs are typically characterized by increased bioavailability and are readily metabolized in vivo into the active compounds. Non-limiting examples of prodrugs include amide prodrugs and carboxylic acid ester prodrugs. [0035] “Solvate” refers to molecular complex comprising a compound along with stoichiometric or sub-stoichiometric amounts of one or more molecules of one or more solvents, typically the solvent is a pharmaceutically acceptable solvent such as, for example, ethanol. The term “hydrate” refers to a solvate when the solvent is water (H2O). [0036] “Ylidene” refers to CH group involved in an exo carbon-carbon double bound with another moiety. The moiety is typically cyclic such as, for example, an heterocycloalkyl. General definitions [0037] “About” is used herein to mean approximately, roughly, around, or in the region of. The term “about” preceding a figure means plus or less 10 % of the value of the figure. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth by 10%. [0038] “Administration", or a variant thereof (e.g., “administering”), means providing a therapeutic agent alone or as part of a pharmaceutically acceptable composition, to the patient in whom/which the condition, symptom, or disease is to be treated.
[0039] “Comprise” or a variant thereof (e.g., “comprises”, “comprising”) is used herein according to common patent application drafting terminology. Hence, “comprise” preceded by an object and followed by a constituent means that the presence of a constituent in the object is required (typically as a component of a composition), but without excluding the presence of any further constituent(s) in the object. Moreover, any occurrence of “comprise” or a variant thereof herein also encompasses narrower expression “substantially consist of”, further narrower expression “consist of” and any variants thereof (e.g., “consists of”, “consisting of”), and may be replaced thereby, unless otherwise stated. [0040] “GDNF family receptor alpha-1”, “GFRα1”, or “GDNFRα1”, also named “RET ligand 1” or “TGF-beta-related neurotrophic factor receptor 1”, is a protein from the GDNFR family that acts as a receptor for GDNF. It mediates the GDNF-induced autophosphorylation and activation of the RET receptor. In humans, GFRα1 is encoded by the GFRA1 gene. An exemplary amino acid sequence of human GFRα1 is given in SEQ ID NO: 1, in which amino acid residues 1-24 correspond to the signal peptide and amino acid residues 430-465 correspond to the propeptide which is removed in mature form.
[0041] “Human” refers to a male or female human subject at any stage of development, including neonate, infant, juvenile, adolescent and adult.
[0042] “Neuroprotective” refers to the protection of a neuronal cell from insults, events, or conditions that would normally result in a loss of neuronal cell’s functions, and ultimately, neuronal cell death. Such insults, events, or conditions include, without limitation, neuronal stress, for instance, caused by hypoxia or ischemia; traumatic injuries; and exposure to toxic molecules, for instance, to abnormal misfolded proteins, protein aggregates, excitotoxins, reactive oxygen species, endoplasmic reticulum stressors, mitochondrial stressors, Golgi apparatus antagonists and the like. The term also characterizes the detectable biological activity of a compound in reducing the amount or level of neuronal cell’s loss of functions and/or neuronal cell death. [0043] “Neurorestorative” refers to the restoration or rescue of a neuronal cell and in particular of its functions, from the effect of an insult, event, or condition that would normally result in a loss of neuronal cell’s functions if not in neuronal cell death. [0044] “Patient” refers to a subject who/which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of the targeted disease or condition, such as, for example, a neurological disorder. [0045] “Pharmaceutically acceptable” means that the ingredients of a composition are compatible with each other and not deleterious to the subject to which/whom it is administered. [0046] “Pharmaceutically acceptable carrier” refers to an excipient that does not produce an adverse, allergic or other untoward reaction when administered to an animal, preferably a human. It includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by regulatory offices, such as, e.g., FDA Office or EMA. Examples of pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes,
such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances (for example sodium carboxymethylcellulose), polyethylene glycol, polyacrylates, waxes, polyethylene- polyoxypropylene- block polymers, polyethylene glycol and wool fat. [0047] “Pharmaceutical composition” refers to a composition comprising at least one therapeutic agent (e.g., a compound according to the present invention) and at least one pharmaceutically acceptable carrier. [0048] “Proto-oncogene tyrosine-protein kinase receptor Ret”, or in short “RET”, also named “cadherin family member 12”, is a receptor tyrosine kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation. RET is activated upon (i) binding of a neurotrophic factor of the GDNF family (e.g., GDNF, neurturin, artemin or persephin) to a receptor of the GDNFR family (e.g., GFRα1, GFRα2, GFRα3 or GFRα4), then (ii) complex formation between RET and the receptor of the GDNFR family, (iii) dimerization and (iv) trans-autophosphorylation. An exemplary amino acid sequence of human RET is given in SEQ ID NO: 2, in which amino acid residues 1-28 correspond to the signal peptide.
[0049] “Selected from” is used herein according to common patent application drafting terminology, to introduce a list of elements among which one or more item(s) is (are) selected. Any occurrence of “selected from” in the specification may be replaced by “selected from the group comprising or consisting of” and reciprocally without changing the meaning thereof. [0050] “Subject” refers to an animal, typically a warm-blooded animal, preferably a mammal, more preferably a primate, furthermore preferably a human. In one embodiment, the subject is a “patient” as defined herein. In one embodiment, the subject is affected, preferably is diagnosed, with a disease. In one embodiment, the subject is at risk of developing a disease. Examples of risks factor include, but are not limited to, genetic predisposition, or familial history of the disease. [0051] “Therapeutic agent”, “active pharmaceutical ingredient” and “active ingredient” refer to a compound for therapeutic use and relating to health. Especially, a therapeutic agent (e.g., a compound according to the present invention) may be indicated for treating a disease (e.g., a neurological disorder). An active ingredient may also be indicated for improving the therapeutic activity of another therapeutic agent. [0052] “Therapeutically effective amount” (in short “effective amount”) refers to the amount of a therapeutic agent (e.g., a compound according to the present invention) that is sufficient to achieve the desired therapeutic, prophylactic or preventative effect in the
patient to which/whom it is administered, without causing significant negative or adverse side effects to said patient. A therapeutically effective amount may be administered prior to the onset of the disease for a prophylactic or preventive action. Alternatively, or additionally, the therapeutically effective amount may be administered after initiation of the disease for a therapeutic action. [0053] “Treating”, “treatment” or “alleviation” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder (herein a “disease”) (e.g., a neurological disorder). Those in need of treatment include those already with the disease as well as those prone to have the disease or those in whom the condition or disease is to be prevented. A patient is successfully “treated” for a disease if, after receiving a therapeutic amount of a therapeutic agent (e.g., a compound according to the present invention), the patient shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of pathogens; reduction in the percent of total cells that are pathogenic; and/or relief to some extent, one or more of the symptoms associated with the specific disease; reduced morbidity and mortality, and improvement in quality of life issues. The above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician. DETAILED DESCRIPTION
[0054] An object of the present invention is a compound of formula (I)
or a pharmaceutically acceptable salt and/or solvate thereof;
wherein W represents CH or N; RA, RB, RC and RD each independently represents hydrogen, F, Cl, CH3, CF3, CHF2 or CH2F; R7 represents hydrogen, OH, halogen, (C1-C8) alkyl, cycloalkyl, (C1-C8) alkyl- O-, cycloalkyl-O-, cycloalkyl-(C1-C8) alkyl-O-, heterocycloalkyl-O-, heterocycloalkyl-(C1-C8) alkyl-O-, aryl-(C1-C8) alkyl-O-, heteroaryl- (C1-C8) alkyl-O-, R11O-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-O-, (R11O)(R12)N-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-, R11O-(C1-C8) alkyl-, NR11R12, CN, CO2H, CO2R11, CONH2, CON(R11)H, heterocycloalkyl, or heteroaryl; wherein R11 and R12 each independently represents hydrogen or (C1-C8) alkyl; wherein the alkyl or cycloalkyl in R7 is optionally substituted by at least one F, Cl, OH, =O, (C1-C8) alkyl, (C1-C8) alkyl-O-, heterocycloalkyl, aryl or heteroaryl; wherein the heterocycloalkyl, aryl or heteroaryl (i.e., any heterocycloalkyl, aryl or heteroaryl that is represented by R7 or that is part of any substituent thereof) is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, CHF2, CH2F, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR13R14, R13R14N- (C1-C8) alkyl-, R13O2C-(C1-C8) alkyl-, CO2H, R13R14N-C(O)-, R13O-NR14-, or (C1-C8) alkyl-CO2-; wherein R13 and R14 each independently represents hydrogen or (C1-C8) alkyl; Z represents C-H, C-R8 or N; wherein R8 represents (C1-C4) alkyl, F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH or (C1-C4) alkoxy; or Z represents C-R8 and R7 and R8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl,
wherein the cycloalkyl or heterocycloalkyl is optionally substituted by at least one F, OH, =O, →O, (C1-C8) alkyl, CF3, HO2C-CH2-, (C1-C4) alkyl-CO2- CH2-, R15R16N-CH2-, aryl, or aryl-(C1-C8) alkyl-, wherein R15 and R16 each independently represents hydrogen or (C1-C8) alkyl; R5 represents hydrogen, (C1-C8) alkyl, CH3 substituted by one to three (C1-C8) alkyl groups, cycloalkyl, heterocycloalkyl, aryl, or cycloalkyl- (C1-C8) alkyl; wherein the alkyl or cycloalkyl in R5 is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, OCF3, CN, OH, =O, (C1-C8) alkoxy, NR17R18, CO2H, R17R18N-C(O)-, R17O-NR18-, heterocycloalkyl, aryl or heteroaryl; wherein R17 and R18 each independently represents hydrogen or (C1-C8) alkyl; wherein the heterocycloalkyl, aryl or heteroaryl (i.e., any heterocycloalkyl, aryl or heteroaryl that is represented by R5 or that is part of any substituent thereof) is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, CHF2, CH2F, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR19R20, CO2H, R19R20N-C(O)-, R19O-NR20-, (C1-C8) alkyl-CO2-, R19R20N-(C1-C8) alkyl-, R19O2C-(C1-C8) alkyl-, heterocycloalkyl, heteroaryl, aryl, or aryl- (C1-C8) alkyl-; wherein R19 and R20 each independently represents hydrogen or (C1-C8) alkyl; R6 represents (C1-C8) alkyl, CH3 substituted by one to three (C1-C8) alkyl groups, cycloalkyl, heterocycloalkyl, aryl, or cycloalkyl-(C1-C8) alkyl; wherein the alkyl or cycloalkyl in R6 is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, OCF3, CN, OH, =O, (C1-C8) alkoxy, NR21R22, CO2H, R21R22N-C(O)-, R21O-NR22-, heterocycloalkyl, aryl or heteroaryl; wherein R21 and R22 each independently represents hydrogen or (C1-C8) alkyl; wherein the heterocycloalkyl, aryl or heteroaryl (i.e., any heterocycloalkyl, aryl or heteroaryl that is represented by R6 or that is part of any substituent thereof) is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3,
CHF2, CH2F, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR23R24, CO2H, R23R24N-C(O)-, R23O-NR24-, (C1-C8) alkyl-CO2-, R23R24N-(C1-C8) alkyl-, R23O2C-(C1-C8) alkyl-, heterocycloalkyl, heteroaryl, aryl, or aryl- (C1-C8) alkyl-; wherein R23 and R24 each independently represents hydrogen or (C1-C8) alkyl; or R5 and R6 form together with the nitrogen atom to which they are bound an heterocycloalkyl, wherein the heterocycloalkyl (i.e., the heterocycloalkyl that is formed by R5, R6 and the nitrogen atom to which they are bound) is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR25R26, CO2H, (C1-C8) alkyl-CO2-, R25R26N-C(O)- , R25O-NR26-, R25R26N-(C1-C8) alkyl-, R25O2C-(C1-C8) alkyl-, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyl-(C1-C8) alkyl-, heterocycloalkyl-(C1-C8) alkyl-, aryl-(C1-C8) alkyl-, heteroaryl- (C1-C8) alkyl-, aryl-cycloalkyl-, cycloalkyl-O-, heterocycloalkyl-O-, aryl- O-, heteroaryl-O-, cycloalkyl-(C1-C8) alkyl-O-, heterocycloalkyl- (C1-C8) alkyl-O-, aryl-(C1-C8) alkyl-O-, heteroaryl-(C1-C8) alkyl-O-, cycloalkyl-NR25-, heterocycloalkyl-NR25-, aryl-NR25-, heteroaryl-NR25-, cycloalkyl-(C1-C8) alkyl-NR25-, heterocycloalkyl-(C1-C8) alkyl-NR25-, aryl-(C1-C8) alkyl-NR25-, heteroaryl-(C1-C8) alkyl-NR25-, benzylidene, heteroarylidene, aryl-(C1-C8) alkyl-ylidene- or heteroaryl-(C1-C8) alkyl- ylidene-; wherein R25 and R26 each independently represents hydrogen or (C1-C8) alkyl; wherein the heterocycloalkyl, aryl, heteroaryl, benzylidene or heteroarylidene (i.e., any heterocycloalkyl, aryl, heteroaryl, benzylidene or heteroarylidene that is part of any substituent of the heterocycloalkyl formed by R5, R6 and the nitrogen atom to which they are bound) is optionally substituted at least one F, Cl, (C1-C8) alkyl, CF3, CHF2, CH2F, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR27R28,
CO2H, R27R28N-C(O)-, R27O-NR28-, (C1-C8) alkyl-CO2-, R27R28N-(C1- C8) alkyl-, R27O2C-(C1-C8) alkyl-, heterocycloalkyl, heteroaryl, aryl, or aryl-(C1-C8) alkyl-; wherein R27 and R28 each independently represents hydrogen or (C1-C8) alkyl. [0055] According to one preferred embodiment, when exactly two groups selected from RA, RB and RC represent hydrogen, RD represents CF3, R7 represents OCH3 and Z represents C-H, then the remaining group among RA, RB and RC does not represent F. [0056] In any one of the following embodiments directed to specific limitations to the structure of the compounds of formula (I), any alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, benzylidene or heteroarylidene may independently be optionally substituted as indicated under formula (I) herein, unless otherwise specified. [0057] According to one preferred embodiment, RD represents hydrogen, F, Cl, CH3, CHF2 or CH2F. In this embodiment, the formula (I) is noted “formula (I-i)”. [0058] According to one preferred embodiment, R7 represents hydrogen, OH, halogen, (C1-C8) alkyl, cycloalkyl, (C2-C8) alkyl-O-, cycloalkyl-O-, cycloalkyl-(C1-C8) alkyl-O-, heterocycloalkyl-O-, heterocycloalkyl-(C1-C8) alkyl-O-, aryl-(C1-C8) alkyl-O-, heteroaryl-(C1-C8) alkyl-O-, R11O-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-O-, (R11O)(R12)N-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-, R11O-(C1-C8) alkyl-, NR11R12, CN, CO2H, CO2R11, CONH2, CON(R11)H, heterocycloalkyl, or heteroaryl; wherein R11 and R12 each independently represents hydrogen or (C1-C8) alkyl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted as defined under formula (I) hereinabove. In this embodiment, the formula (I) is noted “formula (I-ii)”. [0059] According to one preferred embodiment, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof; wherein W represents CH or N; RA, RB, RC and RD each independently represents hydrogen, F, Cl, CH3, CF3, CHF2 or CH2F,
R7 represents hydrogen, OH, halogen, (C1-C8) alkyl, cycloalkyl, (C1-C8) alkyl- O-, cycloalkyl-O-, cycloalkyl-(C1-C8) alkyl-O-, heterocycloalkyl-O-, R11O-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-O- or (R11O)(R12)N- (C1-C8) alkyl-O-; wherein R11 and R12 each independently represents hydrogen or (C1-C8) alkyl; wherein the alkyl or cycloalkyl is optionally substituted by at least one F, Cl, heterocycloalkyl, aryl or heteroaryl; wherein the heterocycloalkyl, aryl or heteroaryl is optionally substituted by at least one F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH, (C1-C8) alkoxy, NR13R14, CO2H, R13R14N-C(O)-, or R13O-NR14-; wherein R13 and R14 each independently represents hydrogen or (C1-C8) alkyl; Z represents C-H or N; or Z represents C-R8 and R7 and R8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted by at least one F, OH, CF3, HO2C-CH2-, (C1-C4) alkyl-CO2-CH2-, or R15R16N-CH2-, wherein R15 and R16 each independently represents hydrogen or (C1-C8) alkyl; R5 represents hydrogen, (C1-C8) alkyl, CH3 substituted by one to three (C1-C8) alkyl groups, cycloalkyl or cycloalkyl-(C1-C8) alkyl; wherein the alkyl or cycloalkyl is optionally substituted by at least one F, Cl, CF3, OCF3, CN, OH, (C1-C8) alkoxy, NR17R18, CO2H, R17R18N-C(O)-, R17O-NR18-, heterocycloalkyl, aryl or heteroaryl; wherein R17 and R18 each independently represents hydrogen or (C1-C8) alkyl; wherein the heterocycloalkyl, aryl or heteroaryl is optionally substituted by at least one F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH, (C1-C8) alkoxy, NR19R20, CO2H, R19R20N-C(O)-, or R19O-NR20-; wherein R19 and R20 each independently represents hydrogen or (C1-C8) alkyl;
R6 represents (C1-C8) alkyl, CH3 substituted by one to three (C1-C8) alkyl groups, cycloalkyl or cycloalkyl-(C1-C8) alkyl; wherein the alkyl or cycloalkyl is optionally substituted by at least one F, Cl, CF3, OCF3, CN, OH, (C1-C8) alkoxy, NR21R22, CO2H, R21R22N-C(O)-, R21O-NR22-, heterocycloalkyl, aryl or heteroaryl; wherein R21 and R22 each independently represents hydrogen or (C1-C8) alkyl; wherein the heterocycloalkyl, aryl or heteroaryl is optionally substituted by at least one F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH, (C1-C8) alkoxy, NR23R24, CO2H, R23R24N-C(O)-, or R23O-NR24-; wherein R23 and R24 each independently represents hydrogen or (C1-C8) alkyl; or R5 and R6 form together with the nitrogen atom to which they are bound an heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted by at least one F, Cl, CF3, OCF3, CN, OH, (C1-C8) alkoxy, NR25R26, CO2H, R25R26N-C(O)-, R25O-NR26-, heterocycloalkyl, aryl, heteroaryl, heterocycloalkyl- (C1-C8) alkyl-, aryl-(C1-C8) alkyl-, heteroaryl-(C1-C8) alkyl-, cycloalkyl- (C1-C8) alkyl-O-, aryl-(C1-C8) alkyl-O-, heteroaryl-(C1-C8) alkyl-O-, cycloalkyl-(C1-C8) alkyl-NR25-, aryl-(C1-C8) alkyl-NR25-, heteroaryl- (C1-C8) alkyl-NR25-, benzylidene, heteroarylidene, aryl-(C1-C8) alkyl- ylidene- or heteroaryl-(C1-C8) alkyl-ylidene-; wherein R25 and R26 each independently represents hydrogen or (C1-C8) alkyl; wherein the heterocycloalkyl, aryl, heteroaryl, benzylidene or heteroarylidene is optionally substituted at least one F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH, (C1-C8) alkoxy, NR27R28, CO2H, R27R28N- C(O)-, or R27O-NR28-; wherein R27 and R28 each independently represents hydrogen or (C1-C8) alkyl; provided that, when exactly two groups selected from RA, RB and RC represent hydrogen, RD represents CF3, R7 represents OCH3 and Z represents C-H, then the remaining group among RA, RB and RC does not represent F.
[0060] According to one embodiment, W represents CH. [0061] According to one embodiment, at least one among RA, RB, RC and RD represents hydrogen. In one embodiment, exactly one among RA, RB, RC and RD represents hydrogen. In one embodiment, exactly two among RA, RB, RC and RD represents hydrogen. In one embodiment, exactly three among RA, RB, RC and RD represents hydrogen. [0062] In one embodiment, at least one among RA and RC represents hydrogen. In one particular embodiment, RA represents hydrogen. In one particular embodiment, RC represents hydrogen. [0063] According to one embodiment, at least one among RA, RB and RD represents F or Cl. In one embodiment, at least one among RB and RD represents F or Cl. In one particular embodiment, RB and RD each independently represents F or Cl. In one particular embodiment, RB represents F. In one particular embodiment, RB represents Cl. In one particular embodiment, RD represents F. In one particular embodiment, RD represents Cl. In one preferred embodiment, RB represents F. In one preferred embodiment, RD represents Cl. In one further preferred embodiment, RB represents F and RD represents Cl. [0064] According to one embodiment, at least one among RA, RB and RD represents CHF2 or CF3. In one embodiment, at least one among RB and RD represents CHF2 or CF3. In one particular embodiment, RB and RD each independently represents H, F, CHF2 or CF3. In one embodiment, RB represents H or F. In one further preferred embodiment, RB represents F. In one preferred embodiment, RD represents CHF2 or CF3. In one further preferred embodiment, RB represents H or F and RD represents CHF2 or CF3. [0065] According to one embodiment, R7 represents hydrogen, OH, halogen, (C1-C8) alkyl, cycloalkyl, (C1-C8) alkyl-O-, cycloalkyl-O-, cycloalkyl-(C1-C8) alkyl-O-, heterocycloalkyl-O-, R11O-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-O- or (R11O)(R12)N- (C1-C8) alkyl-O-; wherein R11 and R12 each independently represents hydrogen or (C1-C8) alkyl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted as defined under formula (I) hereinabove.
[0066] According to one embodiment, R7 represents hydrogen, OH or halogen. In one embodiment, R7 represents hydrogen. In one preferred embodiment, R7 represents hydroxyl (OH). In one embodiment, R7 represents halogen. In one particular preferred embodiment, R7 represents F or Cl. In one particular preferred embodiment, R7 represents F. In one particular embodiment, R7 represents Cl. [0067] In one preferred embodiment, R7 does not represent hydrogen. [0068] According to one embodiment, R7 represents (C1-C8) alkyl-O- (i.e., (C1-C8) alkoxy) or cycloalkyl-O-. In one embodiment, the alkyl or cycloalkyl is optionally substituted by at least one F, Cl, OH, (C1-C8) alkoxy or aryl. In one particular embodiment, R7 represents OCH3 (methoxy), OCH2CH3, OCF3, cyclobutyl-O-, HO-CH2- CH2-O-, CH3O-CH2-CH2-O- or phenyl-CH2-O-. [0069] According to one embodiment, R7 represents (C1-C8) alkyl-O- (i.e., (C1-C8) alkoxy). In one embodiment, the alkyl is optionally substituted by at least one F or Cl. In one particular embodiment, the halogen is F. In one embodiment, R7 represents OCH3 (methoxy), OCH2CH3 or OCF3. In one preferred embodiment, R7 represents OCH3 (methoxy). [0070] According to one embodiment, R7 represents cycloalkyl-O-. In one embodiment, R7 represents cyclobutyl-O-. [0071] According to one embodiment, R7 represents (C1-C8) alkyl-O- (i.e., (C1-C8) alkoxy), wherein the alkyl is optionally substituted by at least one OH or (C1-C8) alkoxy, i.e., RO-(C1-C8) alkyl-O- wherein R represents H or (C1-C8) alkyl. In one preferred embodiment, R7 represents HO-CH2-CH2-O- or CH3O-CH2-CH2-O-. [0072] According to one embodiment, R7 represents (C1-C8) alkyl-O- (i.e., (C1-C8) alkoxy), wherein the alkyl is optionally substituted by at least one aryl. In one embodiment, the aryl is not substituted. In one embodiment, R7 represents phenyl- CH2-O-. [0073] According to one embodiment, R7 represents (C1-C8) alkyl-O- (i.e., (C1-C8) alkoxy), wherein the alkyl is optionally substituted by at least one
heteroaryl. In one embodiment, the heteroaryl is not substituted. In one embodiment, R7 represents heteroaryl-CH2-O-. [0074] According to one embodiment, R7 represents (C1-C8) alkyl-O- (i.e., (C1-C8) alkoxy), wherein the alkyl is optionally substituted by at least one heterocycloalkyl. In one embodiment, R7 represents heterocycloalkyl-(C1-C8) alkyl-O-, i.e., the alkyl is substituted by exactly one heterocycloalkyl. In one embodiment, the heterocycloalkyl is not substituted. [0075] In one preferred embodiment, R7 represents hydrogen, F, Cl, OH, OCH3 (methoxy), HO-CH2-CH2-O-, CH3O-CH2-CH2-O- or phenyl-CH2-O-. [0076] In one further preferred embodiment, R7 represents F, OH, OCH3 (methoxy) or phenyl-CH2-O-. [0077] According to one embodiment, Z represents C-H or N; or Z represents C-R8 and R7 and R8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl; wherein the cycloalkyl or heterocycloalkyl is optionally substituted as defined under formula (I) hereinabove. In other words, in this embodiment, R8 represents hydrogen, except where R7 and R8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl. [0078] According to one embodiment, Z represents C-H or N. In one embodiment, Z represents C-H. In one embodiment, Z represents N. [0079] According to another embodiment, Z represents C-R8 and R7 and R8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl; wherein the cycloalkyl or heterocycloalkyl is optionally substituted as defined under formula (I) herein. [0080] According to one preferred embodiment, Z does not represent N. [0081] In one preferred embodiment, Z represents C-R8; wherein R8 represents (C1-C4) alkyl, F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH or (C1-C4) alkoxy. In one
particular embodiment, R8 represents methyl, ethyl, F, Cl, CF3, CN or OH. In one preferred embodiment, R8 represents methyl or Cl. [0082] In one preferred embodiment, Z represents C-R8 and R7 and R8 form together with the carbon atoms to which they are bound an heterocycloalkyl; wherein the heterocycloalkyl is optionally substituted as defined under formula (I) herein. In one particular embodiment, the heterocycloalkyl comprises at least one oxygen atom, i.e., the heterocycloalkyl is a cyclic ether. In one particular embodiment, the heterocycloalkyl comprises exactly one oxygen atom. In one particular embodiment, the heterocycloalkyl comprises at least one nitrogen atom, i.e., the heterocycloalkyl is a cyclic amine. In one particular embodiment, the heterocycloalkyl is six-membered or five-membered. In one particular embodiment, the heterocycloalkyl is not substituted. In one preferred embodiment, the heterocycloalkyl is tetrahydrofuran (e.g., wherein -R7-R8- represents - O-CH2CH2-). [0083] According to one embodiment, R5 represents hydrogen or (C1-C8) alkyl. In one embodiment, R5 represents hydrogen. In one embodiment, R5 represents (C1-C8) alkyl. In one preferred embodiment, R5 represents hydrogen, methyl or ethyl. In one particular embodiment, R5 represents hydrogen. In one particular embodiment, R5 represents methyl or ethyl. In one further particular embodiment, R5 represents methyl. In one further particular embodiment, R5 represents ethyl. [0084] According to one embodiment, R6 represents (C1-C8) alkyl, cycloalkyl or cycloalkyl-(C1-C8) alkyl-. In one embodiment, the alkyl or cycloalkyl is optionally substituted by at least one F. In one embodiment, the alkyl or cycloalkyl is not substituted. In one embodiment, R6 represents methyl, ethyl, n-propyl, 1-fluoro-n-propane, tert-butyl, cyclopropyl, cyclobutyl or cyclopropyl-CH2-. [0085] According to one embodiment, R6 represents (C1-C8) alkyl, cycloalkyl, heterocycloalkyl, cycloalkyl-(C1-C8) alkyl- or aryl-(C1-C8) alkyl-. In one embodiment, the alkyl, cycloalkyl, heterocycloalkyl or aryl is optionally substituted by at least one methyl, Cl or F.
[0086] In one embodiment, R6 represents ethyl, propyl (e.g., n-propyl), butyl (e.g., tert-butyl), cyclopentyl, cyclohexyl, 2-adamantyl, 3-methyloxetan-3-yl, cyclopropyl-CH2-, cyclobutyl-CH2-, cyclohexyl-CH2-, phenyl-CH2- (benzyl), 3-chlorophenyl-CH2- or 4-fluorophenyl-CH2-. [0087] In one further preferred embodiment, R6 represents propyl (e.g., n-propyl), butyl (e.g., tert-butyl), cyclohexyl, cyclopropyl-CH2- or 3-chlorophenyl-CH2-. [0088] According to one embodiment, R6 represents (C1-C8) alkyl. In one embodiment, the alkyl is optionally substituted by at least one F. In one embodiment, the alkyl is not substituted. In one particular embodiment, R5 represents methyl, ethyl, n-propyl, 1-fluoro-n-propane or tert-butyl. [0089] According to one embodiment, R6 represents cycloalkyl. In one embodiment, R6 represents cyclopropyl or cyclobutyl. [0090] According to one embodiment, R6 represents cycloalkyl-(C1-C8) alkyl. In one particular embodiment, R6 represents cyclopropylmethyl (cyclopropyl-CH2-). [0091] According to one embodiment, R5 and R6 form together with the nitrogen atom to which they are bound an heterocycloalkyl. In one embodiment, the heterocycloalkyl is optionally substituted by at least one F. In one embodiment, R5 and R6 form together with the nitrogen atom to which they are bound a pyrrolidine, piperidine, 4-fluoropiperidine, 3-fluoropyrrolidine, 4-trifluoromethylpiperidine, 4-benzyl-piperidine, 3- benzylpyrrolidine, 3-benzyl-piperidine, 4-phenylpiperidine, 4-benzylidenepiperidine, octahydro-1H-isoindole, 2-benzyloctahydropyrrolo[3,4-c]pyrrole, 3-(benzyloxy)pyrrole, 3-(methoxymethyl)azetidine, 2-azabicyclo[2.2.1]heptane, 5-(4-methylpiperazin-1- yl)pyrimidine and 4-phenethylpiperidine. In one particular embodiment, R5 and R6 form together with the nitrogen atom to which they are bound a pyrrolidine, 4-fluoropiperidine, 3-fluoropyrrolidine, 4-trifluoromethylpiperidine, 4-benzyl-piperidine, 3-benzylpyrrolidine, 3-benzyl-piperidine, 4-phenylpiperidine, 4-benzylidenepiperidine, octahydro-1H-isoindole, 3-(benzyloxy)pyrrole, 2-azabicyclo[2.2.1]heptane, 5-(4- methylpiperazin-1-yl)pyrimidine or 4-phenethylpiperidine.
[0092] In one preferred embodiment, R5 and R6 form together with the nitrogen atom to which they are bound a pyrrolidine, 4-benzyl-piperidine, 4-phenyl-4-hydroxy-piperidine, 4-benzyl-4-hydroxy-piperidine, 4-benzyl-piperazine, tert-butyl 1,3,3a,4,6,6a- hexahydropyrrolo[3,4-c]pyrrole-2-carboxylate, 4-benzylidene-1-piperidine, 4-(2- phenylethyl)-piperidine, 4-phenylpiperidine, 3-phenylpiperidine, 3-benzyl-piperidine, 3- phenylpyrrolidin, 3-benzylpyrrolidine, 4-trifluoromethylpiperidine, 2- azabicyclo[2.2.1]heptane, 3-benzyloxypiperidine, 3-benzyloxypyrrolidine, 2-benzyl- 1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolidine, 4-(4-fluorophenyl)piperidine, [2-(4- chlorophenyl)ethyl]piperazine, [2-(4-fluorophenyl)ethyl]piperazine, 2- (phenylpropyl)piperazine, [2-(4-fluorophenyl)propyl]piperazine, 4-fluoropiperidine or 2,2-dimethylpyrrolidine. [0093] In one preferred embodiment, R5 and R6 form together with the nitrogen atom to which they are bound a pyrrolidine, 4-benzyl-piperidine, 4-benzylidene-1-piperidine, 4- (2-phenylethyl)-piperidine, 4-phenylpiperidine, 3-phenylpiperidine, 3-benzyl-piperidine, 3-phenylpyrrolidin, 4-trifluoromethylpiperidine, 3-benzyloxypiperidine, 3- benzyloxypyrrolidine, 4-(4-fluorophenyl)piperidine, [2-(4- chlorophenyl)ethyl]piperazine, [2-(4-fluorophenyl)ethyl]piperazine, 2- (phenylpropyl)piperazine, [2-(4-fluorophenyl)propyl]piperazine, 4-fluoropiperidine or 2,2-dimethylpyrrolidine. [0094] According to one embodiment, at least one heterocycloalkyl present in the compound of formula (I) is a water-solubilizing group,
the presence of this group in the molecule increases the solubility thereof in water, compared with the same molecule not comprising the heterocycloalkyl.
[0095] According to one embodiment, the compound of formula (I) is a compound of formula (I-a)
or a pharmaceutically acceptable salt and/or solvate thereof; wherein W, RB, RD, Z and R5-R7 are as defined under formula (I) herein. [0096] In one embodiment, W in formula (I-a) represents CH. [0097] In one embodiment, RB and RD in formula (I-a) each independently represents F or Cl, and R7 represents alkoxy. In one particular embodiment, RB represents F and RD represents Cl. [0098] In one embodiment, R7 in formula (I-a) represents alkoxy. In one particular embodiment, R7 represents methoxy (-OCH3). [0099] In one embodiment, RB and RD in formula (I-a) each independently represents F or CF3. In one particular embodiment, RB represents F and RD represents CF3. [0100] In one embodiment, Z in formula (I-a) represents N. [0101] According to one embodiment, the compound of formula (I) is selected from the compounds of Table 1 below, and pharmaceutically acceptable salts and/or solvates thereof.
Table 1 001 002 003 004 005 006
[0102] According to one preferred embodiment, the compound is selected from the compounds of Table 1 herein, and pharmaceutically acceptable salts and/or solvates thereof, provided that the compound is not N,N-diethyl-5-[4-[4-fluoro-2- (trifluoromethyl)benzoyl]piperazin-1-yl]-6-methoxy-pyridine-3-sulfonamide (045) or a pharmaceutically acceptable salt and/or solvate thereof.
[0103] According to one embodiment, in the compound of formula (I), when RD represents CF3, R7 represents OCH3 and Z represents C-H, then RA, RB and RC do not represent F or Cl. According to one embodiment, in the compound of formula (I), when RD represents CF3 and R7 represents OCH3, then RA, RB and RC do not represent F. According to one embodiment, in the compound of formula (I), when RD represents CF3, then RA, RB and RC do not represent F. In one embodiment, in the compound of formula (I), when RD represents CF3, then RA, RB and RC do not represent F or Cl. According to one embodiment, in the compound of formula (I), when R7 represents OCH3, then RA, RB and RC do not represent F. In one embodiment, in the compound of formula (I), when R7 represents OCH3, then RA, RB and RC do not represent F or Cl.
According to one embodiment, RD does not represent CF3. In one embodiment, RD does not represent CF3, CHF2 or CH2F. According to one embodiment, R7 does not represent methoxy (-OCH3). In one embodiment, R7 does not represent alkoxy. [0104] All references herein to a compound of the invention (e.g., “compound of formula (I)”) include references to salts, solvates, multi component complexes and liquid crystals thereof. All references herein to a compound of the invention include references to polymorphs and crystal habits thereof. All references herein to a compound of the invention include references to isotopically-labelled compounds thereof, including deuterated compounds thereof. All references herein to a compound of the invention include references to stereoisomers thereof. All references herein to a compound of the invention include references to pharmaceutically acceptable prodrugs thereof. [0105] In particular, the compounds of the invention may be in the form of pharmaceutically acceptable salts. According to one embodiment, the compound of the invention is a pharmaceutically acceptable salt. Pharmaceutically acceptable salts include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinafoate salts. Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, 2-(diethylamino)ethanol, diolamine, ethanolamine, glycine, 4-(2-hydroxyethyl)- morpholine, lysine, magnesium, meglumine, morpholine, olamine, potassium, sodium, tromethamine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. When a compound contains an acidic group as well as a basic group the compound may also form internal salts, and such
compounds are within the scope of the invention. When a compound contains a hydrogen-donating heteroatom (e.g., NH), the invention also encompasses salts and/or isomers formed by transfer of said hydrogen atom to a basic group or atom within the molecule. [0106] Pharmaceutically acceptable salts of compounds of the invention may be prepared by one or more of these methods: (i) by reacting the compound with the desired acid; (ii) by reacting the compound with the desired base; (iii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound or by ring- opening a suitable cyclic precursor, e.g., a lactone or lactam, using the desired acid; and/or (iv) by converting one salt of the compound to another by reaction with an appropriate acid or by means of a suitable ion exchange column. All these reactions are typically carried out in solution. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionization in the salt may vary from completely ionized to almost non-ionized. [0107] In particular, the compounds of the invention may be in the form of pharmaceutically acceptable solvates. According to one embodiment, the compound of the invention is a pharmaceutically acceptable solvate. According to one embodiment, the compound of the invention is a pharmaceutically acceptable salt and solvate. [0108] In particular, the compounds of the invention may include at least one asymmetric center(s) and thus may exist as different stereoisomeric forms. Accordingly, all references herein to a compound of the invention include all possible stereoisomers and include not only the racemic compounds, but the individual enantiomers and their non-racemic mixtures as well. Non-racemic mixtures may comprise any amounts of each distinct stereoisomer, for example one stereoisomer may be preponderant (e.g., a 90/10 or 80/20 mixture), or the enantiomeric ratio may be close to a racemic mixture (e.g., a 40/60 mixture). When a compound is desired as a single enantiomer, such single enantiomer may be obtained by stereospecific synthesis, by resolution of the final product or any convenient intermediate, or by chiral chromatographic methods as each are known in the art. Resolution of the final product, an intermediate, or a starting material may be carried out by any suitable method known in the art.
Pharmaceutical composition [0109] Another object of the present invention is a composition comprising a compound according to the invention, as described herein. According to one embodiment, the composition further comprises at least one pharmaceutically acceptable carrier, so that the composition is a “pharmaceutical composition” as defined herein. [0110] In a first embodiment, the pharmaceutical composition comprises the compound according to the invention as sole therapeutic agent. In a second embodiment, the pharmaceutical composition further comprises at least another therapeutic agent such as, for example, a therapeutic agent suitable for treating a neurological disorder. [0111] Another object of the present invention is a medicament comprising a compound according to the invention, as described herein. Kit [0112] Another object of the present invention is a kit of parts (in short “kit”) comprising a compound or composition according to the invention, as described herein. According to one embodiment, the kit comprises a manufacture such as, for example, a package or a container. According to one embodiment, the kit comprises instructions for use. The kit may be promoted, distributed, or sold as a unit for performing the methods of the present invention. [0113] According to one embodiment, the kit comprises: a pharmaceutical composition comprising the compound according to the invention, and another separate pharmaceutical composition comprising at least another therapeutic agent such as, for example, a therapeutic agent suitable for treating a neurological disorder. Medical use of the compound [0114] Another object of the present invention is a compound or a composition according to the invention, as described herein, for use as a medicament.
[0115] Another object of the present invention is a compound or a composition according to the invention, as described herein, for use in the treatment of a neurological disorder. [0116] Another object of the present invention is a method for treating a neurological disorder in a subject in need thereof. Another object of the present invention is the use of a compound or a composition according to the invention, as described herein, in the manufacture of a medicament for the treatment of a neurological disorder. Another object of the present invention is the use of a compound or a composition according to the invention, as described herein, for treating a neurological disorder. [0117] According to one embodiment, the method or the use comprises a step of administering to a subject a therapeutically effective amount of a compound, a composition or a medicament according to the invention, as described herein. [0118] According to one embodiment, the neurological disorder to be treated by the method or the use of the invention is: - a disease or a disorder associated with defective neurogenesis such as, for example, Hirschsprung disease, schizophrenia, Ataxia telangiectasia, age-related decline of nervous system performance, or a neurodevelopmental disorder; - a neurodegenerative disease or disorder, such as, for example, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis, Fronto- temporal dementia, retinal neurodegenerative diseases, neuro-ophthalmic diseases, neurotrophic keratitis, Charcot-Marie-Tooth disease, Spinal Muscular Atrophy, epilepsy (e.g., an epilepsy disorder, or a seizure disorder, or a chronic neurological disorder presenting with epilepsy), dementia, age-related decline of nervous system performance, a prion disease, Creutzfeldt-Jacob disease, Multiple System Atrophy (Shy Drager Syndrome), Multiple sclerosis, or Guillain-Barre syndrome; - a disease or a disorder associated with nerve injury or neurotoxicity, such as, for example, head injury, brain damage, traumatic brain injury, peripheral nerve injury, traumatic peripheral nerve injury, peripheral neuropathy, nerve transplantation complications, spinal cord injury, traumatic spinal cord injury, severance of nerves
or nerve damage, severance of cerebrospinal nerve cord, a damage to brain or nerve cells, syringomyelia, optic neuropathy, trauma, stroke, ischemia, stroke, ischemic stroke, neurotoxicity caused by alcohol or substance abuse (e.g., ecstasy, methamphetamine etc.), or aphasia; - a neurodevelopmental disorder, such as, for example, Rett syndrome, X-linked mental retardation, fragile X syndrome, Down’s syndrome, Autism Spectrum Disorder, Hirschsprung’s disease, Tourette syndrome, childhood learning disorder, an attention deficit disorder, Attention Deficit Hyperactivity Disorder (ADHD), Angelman syndrome, micropreemie, schizophrenia, Language disorder, preterm birth, perinatal arterial ischemic stroke, spina bifida, mental retardation, nonsyndromic X-linked mental retardation, Ondine syndrome, or WAGR syndrome; - a neuropsychiatric disorder such as, for example, depression, Major Depressive Disorder, schizophrenia, schizophrenic form disorder, schizoaffective disorder, delusional disorder, anxiety, anxiety disorders, panic disorder, phobias, an obsessive-compulsive disorder, a post‑traumatic stress disorder, a bipolar disorder, anorexia nervosa, bulimia nervosa, anhedonia, apathy, dementia, substance- induced dementia, a motor and/or tic disorder characterized by motor and/or vocal tics (e.g., Tourette’s disorder), a substance use behavior, addiction, mood disorders, suicidality, cancer-related psychiatric symptoms, Alzheimer’s disease, Huntington’s disease, Fronto-temporal dementia, or a reward deficiency syndrome (RDS); - a movement disorder, such as, for example, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis, a motor and tic disorder characterized by motor and/or vocal tics (e.g., Tourette’s disorder), an ataxia, ataxias muscular rigidity (spasticity), Charcot-Marie-Tooth disease, Spinal Muscular Atrophy, Werdnig-Hoffmann disease, or chronic proximal spinal muscular atrophy; - a pain disorder, such as, for example, neuralgia, trigeminal neuralgia, chronic pain, inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer- associated pain, pain associated with digestive disease, pain associated with
Crohn’s disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with diabetic neuropathy, phantom limb pain, spontaneous pain, chronic post-surgical pain, chronic, temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain, complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal cord injury, pain associated with drug intake and recurrent acute pain, neuropathic pain, or inappropriate neuronal activity resulting in neurodystonia in a disease such as diabetes, an MS and a motor neuron disease; - an ophthalmic disease or an ocular disorder such as, for example, a retinal disorder, retinal neurodegenerative diseases, Retinitis Pigmentosa, Non-Arthritic Anterior Ischemic Optic Neuropathy (NAION), macular degeneration, age-related macular degeneration, glaucoma, diabetic retinopathy, optic neuropathy and retinal degeneration, neuro-ophthalmic diseases, age-related cataract, primary open-angle glaucoma (POAG), retinal ganglion cell damage, ocular hypertension, ischemic optic neuropathy, macular telangiectasia, cystoid macular edema, Macular Telangiectasia Type 2, neurotrophic keratitis, or strabismus; - a disorder of the enteric system or a gastro-intestinal disorder, such as, for example, a disorder of intestinal motility, constipation, Hirschsprung’s disease, Inflammatory Bowel Disease, Intestinal Neuronal Dysplasia, ulcerative colitis, Achalasia, Esophageal spasm, duodenal ulcer, Zollinger-Ellison Syndrome, hypersecretion of gastric acid, malabsorptive disorder or intestinal inflammation; - a progressive muscular dystrophy, such as, for example, Duchenne, Becker, Emery- Dreifuss, Landowy-Dejerine, scapulohumeral, limb-girdle, Von Graefe-Fuchs, oculopharyngeal, myotonic and congenital, a congenital or acquired myopathy, Charcot-Marie-Tooth disease, Werdnig-Hoffmann disease, or chronic proximal spinal muscular atrophy; - a disease or a disorder associated with defective long-term or short-term memory, such as, for example, memory loss, benign forgetfulness, or Alzheimer’s disease; - an autoimmune disorder such as, for example, multiple sclerosis, autoimmune encephalomyelitis, autoimmune encephalitis, autoimmune hemolytic anemia,
chronic lymphocytic leukemia, Churg-Strauss syndrome, anti-N-methyl-D- aspartate receptor (NMDAR) encephalitis, Thyroid-associated orbitopathy, autoimmune thyroiditis, Guillain-Barré syndrome, or autoimmune thrombocytopenic purpura; - a neuro-ontological disease or disorder such as, for example, cochlear sensory cell damage, defective auditory perception, hearing loss, or tinnitus; - a sleep disorder, such as, for example, narcolepsy, restless leg syndrome, Obstructive sleep apnea, chronic insomnia disorder, paradoxical sleep deprivation or REM sleep deprivation; - a cerebrovascular disease or a neurovascular disease, such as, for example, early brain injury (EBI) after subarachnoid hemorrhage (SAH), cerebral ischemia, stroke, hypoxic-ischemic brain injury, perinatal arterial ischemic stroke, or neovascular Age-related macular degeneration (nvAMD); - a substance abuse disorder, such as, for example, substance dependence, substance abuse and the sequalae of substance abuse dependence, substance-induced psychological disorder, substance withdrawal and substance-induced dementia or amnestic disorder; - a neuronal reaction to viral infection, Trypanosoma infection, a neurological deficit associated with AIDS, obesity, temporomandibular joint dysfunction, aphasia, Bell’s palsy, encephalitis, a kidney disease or renal dysfunction, phaeochromocytoma, a metabolic syndrome, cancer, eczema, thrombocytopenia; hypoplasia; disseminated intravascular coagulation (DIC); myelodysplasia; immune thrombocytopenic purpura (ITP), HIV induced ITP, a neuro-oncological disease or disorder, neuro-immunological disease or disorder, multiple endocrine neoplasia type 2, von Hippel-Lindau disease (VHL), type I neurofibromatosis, Scleroderma, an epidermal and stromal wound healing disorder and/or a scarring disorder; or - a disease or disorder associated with aging and/or senescence.
[0119] According to one embodiment, the neurological disorder is epilepsy, such as, for example, Dravet syndrome, benign Rolandic epilepsy, frontal lobe epilepsy, infantile spasms, juvenile myoclonic epilepsy (JME), juvenile absence epilepsy, childhood absence epilepsy (e.g., pyknolepsy), febrile seizures, progressive myoclonus epilepsy of Lafora, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, Generalized Epilepsy with Febrile Seizures (GEFS+), Severe Myoclonic, Epilepsy of Infancy (SMEI), Benign Neonatal Familial Convulsions (BFNC), West Syndrome, Ohtahara Syndrome, early myoclonic encephalopathies, migrating partial epilepsy, infantile epileptic encephalopathies, Tuberous Sclerosis Complex (TSC), focal cortical dysplasia, Type I Lissencephaly, Miller-Dieker Syndrome, Angelman’s syndrome, Fragile X syndrome, epilepsy in autism spectrum disorders, epilepsy in subcortical band heterotopia, epilepsy in Walker-Warburg syndrome, epilepsy in Alzheimer’s disease, post-traumatic epilepsy, progressive myoclonus epilepsies, reflex epilepsy, Rasmussen’s syndrome, temporal lobe epilepsy, limbic epilepsy, status epilepticus, abdominal epilepsy, massive bilateral myoclonus, catamenial epilepsy, Jacksonian seizure disorder, Unverricht-Lundborg disease, or photosensitive epilepsy. [0120] According to one embodiment, the composition or the medicament according to the invention, as described herein, is to be administered to a subject, and may be formulated using methods well-known in the art. Non-limiting examples of forms adapted for administration include solutions (such as, for example, sterile aqueous solutions), gels, dispersions, emulsions, suspensions and solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to use (such as, for example, powder or liposomal forms). [0121] The composition or the medicament according to the invention, as described herein, may be administered using administration route well-known in the art such as, for example, parenterally, orally, by inhalation, spray, rectally, nasally, or via an implanted reservoir. [0122] It will be however understood that the total daily usage of the compound, the composition or the medicament will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for
any particular patient will depend upon a variety of factors including the disease being treated and the severity of the disease; activity of the compound employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific therapeutic agent employed; the duration of the treatment; drugs used in combination or coincidental with the specific therapeutic agent employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. The total dose required for each treatment may be administered by multiple doses or in a single dose. [0123] In one embodiment, the dosage of the compound is about 0.01 to 500 mg per kg patient body weight per day, which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be about 0.05 to 0.5, about 0.5 to 5 or about 5 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing from about 1.0 to 1000 milligrams of the active ingredient, particularly about 1.0, about 5.0, about 10.0, about 15.0, about 20.0, about 25.0, about 50.0, about 75.0, about 100.0, about 150.0, about 200.0, about 250.0, about 300.0, about 400.0, about 500.0, about 600.0, about 750.0, about 800.0, about 900.0, and about 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
[0124] According to a first embodiment, the composition or the medicament according to the invention, as described herein, is to be administered as sole therapeutic agent. According to a second embodiment, the composition or the medicament according to the invention, as described herein, is to be administered before at least another therapeutic agent, concomitantly with at least another therapeutic agent, and/or after at least another therapeutic agent. In one embodiment, the other therapeutic agent is suitable for treating a neurological disorder. [0125] Another object of the present invention is a method of promoting neuronal cell’s survival and/or neuronal cell’s functions. Another object of the present invention is a compound or a composition according to the invention, as described herein, for use in promoting neuronal cell’s survival and/or neuronal cell’s functions. According to one embodiment, the method or the use comprises a step of contacting a neuronal cell with a therapeutically effective amount of a compound, a composition or a medicament according to the invention, as described herein. The method or the use may be in vitro, ex vivo or in vivo. [0126] Another object of the present invention is a method of rescuing neuronal cell’s functions after the neuronal cell has been subjected to insults, events, or conditions detrimental to neuronal cell’s functions. Another object of the present invention is a compound or a composition according to the invention, as described herein, for use in rescuing neuronal cell’s functions after the neuronal cell has been subjected to insults, events, or conditions detrimental to neuronal cell’s functions. Such insults, events, or conditions include, without limitation, neuronal stress, for instance, caused by hypoxia or ischemia; traumatic injuries; and exposure to toxic molecules, for instance, to abnormal misfolded proteins, protein aggregates, excitotoxins, reactive oxygen species, endoplasmic reticulum stressors, mitochondrial stressors, Golgi apparatus antagonists and the like. According to one embodiment, the method or the use comprises a step of contacting a neuronal cell with a therapeutically effective amount of a compound, a composition or a medicament according to the invention, as described herein. The method or the use may be in vitro, ex vivo or in vivo.
[0127] Another object of the present invention is a method of binding or modulating GFRα1 using a compound or a composition according to the invention, as described herein. Another object of the present invention is a compound or a composition according to the invention, as described herein, for binding or modulating GFRα1. According to one preferred embodiment, the compound or a composition is for activating GFRα1. In one embodiment, GFRα1 is human GFRα1, preferably with SEQ ID NO: 1. [0128] Another object of the present invention is a method of activating the GFRα1/RET signaling pathway using a compound or a composition according to the invention, as described herein. Another object of the present invention is a compound or a composition according to the invention, as described herein, for activating the GFRα1/RET signaling pathway. [0129] Another object of the present invention is a method of detecting GFRα1 in a sample, using a compound or a composition according to the invention, as described herein. Another object of the present invention is a compound or a composition according to the invention, as described herein, for detecting GFRα1 in a sample. In one embodiment, GFRα1 is human GFRα1, preferably with SEQ ID NO: 1. In one embodiment, the compound according to the invention may be fused to a detectable label, such as, e.g., a fluorophore or any other moiety that can re-emit light upon light excitation, a radiolabel, a contrast agent and the like. Manufacturing process Synthesis of the compound [0130] The compound according to the invention, as described herein, may be manufactured by means of synthetic methods well-known in the art. [0131] Another object of the present invention is a process for manufacturing a compound of the invention, as described herein. According to one embodiment, the process is a Buchwald-Hartwig amination.
[0132] According to one embodiment, the process comprises: (a-1) a step of reaction of a compound of formula (II)
wherein Z, R5, R6 and R7 are as defined under formula (I) herein and X represents halide or -CF3SO3, with a compound of formula (III)
wherein W and RA-RD are as defined under formula (I) herein, in presence of a base and a metal catalyst; thereby obtaining the compound of the invention. [0133] In one embodiment, the base at step (a-1) is cesium carbonate (Cs2CO3), sodium carbonate (Na2CO3) or potassium carbonate (K2CO3). In one particular embodiment, the base is cesium carbonate (Cs2CO3). In one embodiment, the base is sodium tert-butanoate (t-BuONa), potassium tert-butanoate (t-BuOK) or potassium phosphate. In one particular embodiment, the base is sodium tert-butanoate (t-BuONa). [0134] In one embodiment, the catalyst at step (a-1) is a palladium catalyst. In one particular embodiment, the catalyst is a Pd(OAc)2 and rac-BINAP (2,2’- bis(diphenylphosphino)-1,1’-binaphtyle) system. In one particular embodiment, the catalyst is XPhos-Pd-G3.
[0135] In one embodiment, X represents halide. In one particular embodiment, X represents Br. [0136] In one embodiment, the reaction at step (a-1) is carried out in a solvent. In one particular embodiment, the solvent is toluene. In one embodiment, the reaction is carried out at reflux. [0137] According to another embodiment, the process comprises: (a’-1) a step of reaction of a compound of formula (II)
wherein Z, R5, R6 and R7 are as defined under formula (I) herein and X represents halide or -CF3SO3, with a mono-protected piperazine (i.e., a piperazine wherein only one of the NH groups is protected by means of a protecting group RP), in presence of a base and a metal catalyst; thereby obtaining a compound of formula (IV)
wherein Z, R5, R6 and R7 are as defined under formula (II) above and RP is the protecting group; then (a’-2) a step of deprotection of the compound of formula (IV); thereby obtaining a compound of formula (V)
wherein Z, R5, R6 and R7 are as defined under formula (II) above; and (a’-3) a step of reaction of the compound of formula (V) with a compound of formula (VI)
wherein W and RA-RD are as defined under formula (I) herein, in presence of a peptide coupling agent and a base; thereby obtaining the compound of the invention. [0138] In one embodiment, the base and/or the catalyst at step (a’-1) are as described hereinabove under step (a-1). In one embodiment, X represents halide. In one particular embodiment, X represents Br. [0139] The protecting group may be any protecting group known in the art such as, for example, tert-butyloxycarbonyl (Boc). The protective group may be removed at step (a’-2) by any method known in the art appropriate to the nature of the protective group, such as, for example, addition of a strong Bronsted acid (e.g., hydrochloric acid [HCl]). [0140] The peptide coupling agent at step (a’-3) may be any peptide coupling agent known in the art such as, for example, 2-(1H-benzotriazole-1-yl)-1,1,3,3- tetramethylaminium tetrafluoroborate (TBTU). [0141] The base at step (a’-3) may be any base known in the art such as, for example, an amine base. According to one embodiment, the amine is triethylamine (Et3N) or diisopropylethylamine (iPr2NEt).
[0142] In one embodiment, the reaction at step (a’-3) is carried out in a solvent. In one particular embodiment, the solvent is dimethylformamide (DMF) and/or tetrahydrofuran (THF). In one particular embodiment, the solvent is dichloroethane (DCE) and/or acetonitrile (MeCN). In one embodiment, the reaction is carried out at room temperature (RT). [0143] According to another embodiment, the process comprises: (a’’-1) a step of reaction of: a compound of formula (III)
wherein W and RA-RD are as defined under formula (I) herein, with a compound of formula (VII)
wherein R7 and Z are as defined under formula (I) herein, except that Z does not represent N, and X represents halide or -CF3SO3, in presence of a base and a metal catalyst; thereby obtaining a compound of formula (VIII)
wherein W, RA-RD, R7 and Z are as defined under formulae (III) and (VII) above; (a’’-2) a step of reaction of the compound of formula (VIII) with chlorosulfonic acid (HSO3Cl); thereby obtaining a compound of formula (IX);
wherein W, RA-RD, R7 and Z are as defined under formulae (III) and (VII) above; (a’’-3) a step of reaction of the compound of formula (IX) with a secondary amine of formula (X) NHR5R6 (X) wherein R5 and R6 are as defined under formula (I) herein, in presence of a base; thereby obtaining the compound of the invention. [0144] According to an alternative embodiment, the process comprises a step (a’’-1) of reaction of a compound of formula (III) with a compound of formula (VII) as described hereinabove, thereby obtaining a compound of formula (VIII); but no step (a’’-2) of reaction of the compound of formula (VIII) with chlorosulfonic acid (HSO3Cl); and Z may represent N. [0145] In one embodiment, the base and/or the catalyst at step (a’’-1) are as described hereinabove under step (a-1). In one embodiment, X represents halide. In one particular embodiment, X represents Br.
[0146] The base at step (a’’-3) may be any base known in the art such as, for example, an amine base. According to one embodiment, the amine is triethylamine (Et3N) or diisopropylethylamine (iPr2NEt). [0147] In one embodiment, the reaction at step (a’’-3) is carried out in a solvent. In one particular embodiment, the solvent is dichloromethane (DCM). [0148] In one embodiment, the process further comprises a work-up step (b). In one embodiment, the work-up step (b) comprises a step of extraction by a solvent. In one particular embodiment, the solvent is ethyl acetate (EtOAc). In one particular embodiment, the solvent is water or a 1N HCl solution. In one particular embodiment, the solvent is dichloromethane (DCM). In one embodiment, the work-up step (b) comprises a step of filtration. In one particular embodiment, the filtration is over Celite® In one embodiment, the work-up step (b) comprises a step of concentration under reduced pressure. [0149] In one embodiment, the process further comprises a purification step (c). In one embodiment, the purification step (c) comprises a purification by chromatography. In one particular embodiment, the chromatography is flash chromatography (FC) (e.g., cHex/EtOAc gradient), preparative thin-layer chromatography (PTLC) or semi-preparative high-performance liquid chromatography (HPLC). Synthetic intermediates [0150] Another object of the present invention is a compound of formula (II)
wherein Z, R5, R6 and R7 are as defined under formula (I) herein and X represents halide or -CF3SO3.
[0151] Another object of the present invention is a compound of formula (III)
wherein W and RA-RD are as defined under formula (I) herein. [0152] Another object of the present invention is a compound of formula (IV)
wherein Z, R5, R6 and R7 are as defined under formula (I) herein and RP is a protecting group (e.g., Boc). [0153] Another object of the present invention is a compound of formula (V)
wherein Z, R5, R6 and R7 are as defined under formula (I) herein. [0154] Another object of the present invention is a compound of formula (VIII)
wherein W, RA-RD, R7 and Z are as defined under formula (I) herein.
[0155] According to one preferred embodiment, in formula (VIII) hereinabove, Z does not represent N. [0156] Another object of the present invention is a compound of formula (IX)
wherein W, RA-RD, R7 and Z are as defined under formula (I) herein. [0157] According to one preferred embodiment, in formula (IX) hereinabove, Z does not represent N. EXAMPLES [0158] The present invention is further illustrated by the following examples. Example 1: Synthesis of the compounds General material and methods Abbreviations [0159] List of abbreviations: Ac : acetyl Ar: argon BINAP: (2,2′-bis(diphenylphosphino)-1,1′-binaphthyl) t-Bu: tert-butyl cHex: cyclohexane dba: dibenzylideneacetone DCM: dichloromethane DCE: dichloroethane
DMF: dimethylformamide Et: ethyl FC: flash chromatography HPLC: high-performance liquid chromatography iPr: isopropyl PTLC: preparative thin-layer chromatography RT: room temperature TBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate THF: tetrahydrofuran TPTU: O-(2-Oxo-1(2H)pyridyl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate XPhos: dicyclohexyl[2′,4′,6′-tris(propan-2-yl)[1,1′-biphenyl]-2-yl]phosphane XantPhos: (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane) Analytical methods [0160] 1H NMR spectra (400 MHz) and 19F NMR spectra (376 MHz) were recorded with a Bruker ULTRASHIELD 400 spectrometer. Processing and analyses of the spectra were performed with MestReNova. Data appear in the following order: chemical shifts in ppm which were referenced to the internal solvent signal, multiplicity, coupling constant J in Hertz and number of protons. [0161] Reversed-phase HPLC/MS analyses were carried out with a Waters Alliance 2795 HPLC equipped with an autosampler, an inline membrane degasser, a column oven 10 (T° = 45 °C), a UV detector, and a ZQ quadrupole mass detector working in ionization electrospray mode. Analyzed compounds (0.1 to 0.3 mg) were solubilized in a minimum amount of DMSO completed with acetonitrile (total volume: 1 mL). Standard analytical parameters: flow rate: 1 mL/min, Vinj.: 5μL. Acidic conditions: Waters XSelect CSH C18 column (3.5μm, 2.1x 1550 mm). Gradient: (H2O + 0.04% v/v HCO2H (10mM))/ACN from 95/5 to 0/100 in 2.5 min. Alkaline conditions: Waters Xbridge C18 column (3.5μm, 2.1x 50 mm). Gradient: (H2O + 0.06% v/v NH3 (aq.) (10mM))/ACN from 95/5 to 0/100 in 2.5 min.
General synthetic methods General protocol 1 (GP-1): Peptide coupling using TBTU [0162] To a solution of the required carboxylic acid in DMF at RT, was added TBTU. The mixture was stirred for 15 min at RT and a solution of the required piperazine and Et3N in THF was added dropwise. The mixture was stirred at RT for the required time. The volatiles were removed under reduced pressure and the residue was partitioned between 1N HCl and EtOAc. The layers were separated and the aqueous phase was extracted with EtOAc. The combined organic extracts were washed (1N HCl, aq. sat. NaHCO3, brine), dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (cHex/EtOAc gradient) or PTLC to afford the required product. General protocol 2 (GP-2): Peptide coupling using TPTU (small scale) [0163] To a solution of the required carboxylic acid in DCE/MeCN (1/1) at RT, were added iPr2NEt and TPTU. After stirring for 5min at RT, the required piperazine was added and the mixture was stirred at RT for the required time.2 drops of ethylene diamine were added and the reaction mixture was concentrated under reduced pressure. The residue was purified by FC (cHex/EtOAc gradient), PTLC or semi-preparative HPLC to afford the required product. General protocol 3 (GP-3): Chlorosulfonylation [0164] To chlorosulfonic acid at 0°C, was added dropwise a solution of the required arene in DCM. The mixture was allowed to warm-up to RT and allowed to stir at RT for the required time. The reaction mixture was poured dropwise on crushed ice while stirring (very exothermic quench). At the end of the addition, the residual ice was allowed to melt, DCM was added and the layers were separated. The aqueous phase was extracted with DCM and the combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure to afford the desired sulfonyl chloride.
General protocol 4 (GP-4): Sulfonamide formation [0165] To a solution of the required sulfonyl chloride in DCM at RT, was added a solution of the required amine and either Et3N or iPr2NEt in DCM. The reaction mixture was stirred at RT for the required time. The reaction mixture was partitioned between EtOAc and aq. sat. NH4Cl. The layers were separated and the aqueous phase was extracted with EtOAc. The combined organic extracts were washed (aq. sat. NH4Cl, brine), dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (cHex/EtOAc gradient), PTLC or semi-preparative HPLC to afford the required product. General protocol 5 (GP-5): Buchwald coupling using Pd(OAc)2/rac-BINAP [0166] A microwave reaction vial was charged with the required arylbromide, the required piperazine, Cs2CO3, Pd(OAc)2 and rac-BINAP. The vial was flushed with argon and degassed toluene was added. The vial was sealed and the reaction was stirred at reflux in a preheated heating-block for the required time. After cooling down to RT, EtOAc was added and the suspension as filtered over Celite® (EtOAc rinses). The filtrate was concentrated under reduced pressure. The residue was purified by FC (cHex/EtOAc gradient) or PTLC to afford the required product. General protocol 6 (GP-6): Buchwald coupling using XantPhos-Pd-G3 [0167] A microwave reaction vial was charged with the required arylbromide, the required piperazine, t-BuONa and XantPhos-Pd-G3. The vial was flushed with argon and degassed toluene was added. The vial was sealed and the reaction was stirred at reflux in a preheated heating-block for the required time. After cooling down to RT, EtOAc was added and the suspension as filtered over Celite® (EtOAc rinses). The filtrate was concentrated under reduced pressure. The residue was purified by FC (cHex/EtOAc gradient) or PTLC to afford the required product. General protocol 7 (GP-7): Buchwald coupling using XPhos-Pd-G3 [0168] A microwave reaction vial was charged with the required arylbromide, the required piperazine, t-BuONa and XPhos-Pd-G3. The vial was flushed with argon and
degassed toluene was added. The vial was sealed and the reaction was stirred at reflux in a preheated heating-block for the required time. After cooling down to RT, EtOAc was added and the suspension as filtered over Celite® (EtOAc rinses). The filtrate was concentrated under reduced pressure. The residue was purified by FC (cHex/EtOAc gradient) or PTLC to afford the required product. Synthesis of intermediate compounds [0169] Intermediate compound [4-fluoro-2-(trifluoromethyl)phenyl]-piperazin-1-yl- methanone was prepared as described by JI, D. et al.: “Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors”, Bioorganic and medicinal chemistry, 05 February 2020, Vol. 28, No. 6, pp. 1-12. [0170] Intermediate compound 3-bromo-N,N-diethyl-benzenesulfonamide was prepared as described by SUTHERLAND, M. et al.: “Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics”, ChemMedChem, 29 January 2021, Vol. 16, No. 7, pp. 1116-1125. Synthesis of intermediates required for final products 001 and 002 [0171] 3-bromo-N,N-diethyl-4-methoxy-benzenesulfonamide (I-001)
According to GP-4, I-001 was obtained as a yellow oil in 93% yield using 3-bromo-4- methoxy-benzenesulfonyl chloride (5.00g, 17.5mmol, 1 equiv.), diethylamine (2.72mL, 26.3mmol, 1.5 equiv.) and triethylamine (3.66mL, 26.3mmol, 1.5 equiv.) in DCM (70mL) for 16h at RT. 1H NMR (400 MHz, Chloroform-d) δ 7.91 (d, J = 2.4 Hz, 1H), 7.67 (dd, J = 8.8, 2.4 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 3.89 (s, 3H), 3.15 (q, J = 7.2 Hz, 4H), 1.07 (t, J = 7.2 Hz, 6H). [0172] tert-butyl 4-[5-(diethylsulfamoyl)-2-methoxy-phenyl]piperazine-1- carboxylate (I-002)
To a solution of I-002 (6.48g, 15.2mmol, 1 equiv.) in dioxane (38mL) at 0°C, was added HCl (4M solution in dioxane, 38.0mL, 152mmol, 10 equiv.). The mixture was stirred at RT for 16h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water and DCM. Na2CO3(s) was added portionwise until pH>11. The layers were separated and the aqueous phase was extracted with DCM (2*). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (DCM/MeOH(7N NH3) = 99:1 to 90:10) to afford 4.87g (98%) of I-003 as a colorless oil.1H NMR (400 MHz, DMSO-d6) δ 7.39 (dd, J = 8.5, 2.3 Hz, 1H), 7.20 – 7.05 (m, 2H), 3.87 (s, 3H), 3.43 (m, 1H), 3.13 (q, J = 7.1 Hz, 4H), 3.05 – 2.56 (m, 8H), 1.03 (t, J = 7.1 Hz, 6H). MS (ESI+): [M+H]+ 328.
Synthesis of intermediates required for final products 003 and 004 [0174] 1-(3-bromo-4-methoxy-phenyl)sulfonylpyrrolidine (I-004)
According to GP-4, I-004 was obtained as a white solid in 95% yield using 3-bromo-4- methoxy-benzenesulfonyl chloride (5.00g, 17.5mmol, 1 equiv.), pyrrolidine (2.16mL, 26.3mmol, 1.5 equiv.) and triethylamine (3.66mL, 26.3mmol, 1.5 equiv.) in DCM (70mL) for 1h at RT. 1H NMR (400 MHz, DMSO-d6) δ 7.91 (d, J = 2.3 Hz, 1H), 7.81 (dd, J = 8.7, 2.2 Hz, 1H), 7.32 (d, J = 8.7 Hz, 1H), 3.95 (s, 3H), 3.13 (m, 4H), 1.66 (m, 4H). MS (ESI+): [M+H]+ 320/322. [0175] tert-butyl 4-(2-methoxy-5-pyrrolidin-1-ylsulfonyl-phenyl)piperazine-1- carboxylate (I-005)
According to GP-5, I-005 was obtained as a dark oil in 83% yield using I-004 (5.10g, 15.9mmol, 1 equiv.), tert-butyl piperazine-1-carboxylate (4.45g, 23.9mmol, 1.5 equiv.), Cs2CO3 (15.6g, 47.8mmol, 3 equiv.), Pd(OAc)2 (358mg, 1.59mmol, 0.1 equiv.) and rac-BINAP (1.49g, 2.39mmol, 0.15 equiv.) in toluene (80mL) at reflux for 28h. Purification by FC (cHex/EtOAc = 95/5 to 40/60).1H NMR (400 MHz, DMSO-d6) δ 7.44 (dd, J = 8.5, 2.2 Hz, 1H), 7.17 (s, 1H), 7.16 (d, J = 5.2 Hz, 1H), 3.89 (s, 3H), 3.47 (t, J = 4.9 Hz, 4H), 3.15 – 3.07 (m, 4H), 2.96 (t, J = 5.0 Hz, 4H), 1.71 – 1.59 (m, 4H), 1.43 (s, 9H). MS (ESI+): [M+H]+ 426. [0176] 1-(2-methoxy-5-pyrrolidin-1-ylsulfonyl-phenyl)piperazine (I-006)
To a solution of I-005 (5.90g, 13.9mmol, 1 equiv.) in dioxane (35mL) at 0°C, was added HCl (4M solution in dioxane, 39.0mL, 139mmol, 10 equiv.). The mixture was stirred at RT for 16h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water and DCM. Na2CO3(s) was added portionwise until pH>11. The layers were separated and the aqueous phase was extracted with DCM (2*). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (DCM/MeOH(7N NH3) = 99:1 to 90:10) to afford 4.37g (97%) of I-006 as a colorless oil.1H NMR (400 MHz, DMSO-d6) (m,
According to GP-4, I-007 was obtained as a yellow oil in 96% yield using 3-bromo-4- methoxy-benzenesulfonyl chloride (5.00g, 17.5mmol, 1 equiv.), N-methylpropylamine (2.69mL, 26.3mmol, 1.5 equiv.) and triethylamine (3.66mL, 26.3mmol, 1.5 equiv.) in DCM (70mL) for 16h at RT. 1H NMR (400 MHz, Chloroform-d) δ 7.98 (d, J = 2.2 Hz, 1H), 7.74 (dd, J = 8.6, 2.2 Hz, 1H), 6.99 (d, J = 8.6 Hz, 1H), 3.99 (s, 3H), 3.02 – 2.96 (m, 2H), 2.74 (s, 3H), 1.65 – 1.52 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). MS (ESI+): [M+H]+ 322/324.
[0178] tert-butyl 4-[2-methoxy-5-[methyl(propyl)sulfamoyl]phenyl]piperazine-1- carboxylate (I-008)
RT for 16h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water and DCM. Na2CO3(s) was added portionwise until pH>11. The layers were separated and the aqueous phase was extracted with DCM (2*). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (DCM/MeOH(7N NH3) = 99:1 to 90:10) to afford 2.70g (96%) of I-009 as an orange oil. 1H NMR (400 MHz, Chloroform-d) δ 7.44 (dd, J = 8.5, 2.2 Hz, 1H), 7.28 (d, J = 2.3 Hz, 1H), 6.93 (d, J = 8.6
Hz, 1H), 3.93 (s, 3H), 3.10 – 3.00 (m, 8H), 2.94 (t, J = 7.2 Hz, 2H), 2.70 (s, 3H), 1.93 (s, 1H), 1.54 (h, J = 7.4 Hz, 2H), 0.92 (t, J = 7.4 Hz, 3H).MS (ESI+): [M+H]+ 328. Synthesis of intermediates required for final products 007 to 010 [0180] 4-benzyl-1-(3-bromo-4-methoxy-phenyl)sulfonyl-piperidine (I-010)
7.43 (dd, J = 8.5, 2.2 Hz, 1H), 7.35 – 7.15 (m, 4H), 7.15 – 7.05 (m, 2H), 6.94 (d, J = 8.6
Hz, 1H), 3.95 (s, 3H), 3.76 (d, J = 11.5 Hz, 2H), 3.66 – 3.58 (m, 4H), 3.08 – 2.98 (m, 4H), 2.53 (d, J = 6.6 Hz, 2H), 2.19 (td, J = 11.7, 2.4 Hz, 2H), 1.81 – 1.62 (m, 2H), 1.51 (s, 9H), 1.45 – 1.30 (m, 3H). MS (ESI+): [M+H]+ 530. [0182] 1-[5-[(4-benzyl-1-piperidyl)sulfonyl]-2-methoxy-phenyl]piperazine (I-012)
To a solution of I-011 (2.40g, 3.35mmol, 1 equiv.) in DCM (16mL) at 0°C, was added HCl (4M solution in dioxane, 8.4mL, 34mmol, 10 equiv.). The mixture was stirred at RT for 16h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water and DCM. Na2CO3(s) was added portionwise until pH>11. The layers were separated and the aqueous phase was extracted with DCM (2*). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (DCM/MeOH(7N NH3) = 99:1 to 90:10) to afford 1.45g (100%) of I-012 as a white solid.1H NMR (400 MHz, Chloroform-d) δ 7.41 (dd, J = 8.5, 2.2 Hz, 1H), 7.32 – 7.23 (m, 3H), 7.23 – 7.16 (m, 1H), 7.15 – 7.05 (m, 2H),
According to GP-1, I-013 was obtained in 85% yield as a colorless oil using 2-chloro-4- fluoro-benzoic acid (5.99g, 34.3mmol, 1.2 equiv.), Et3N (8.0mL, 57mmol, 2 equiv.), TBTU (11.0g, 34.3mol, 1.2 equiv.) and 1-(2-methoxyphenyl)piperazine (5.50g, 28.6mmol, 1 equiv.) in THF (140mL) at RT for 16h. The residue was purified by FC
According to GP-4, I-015 was obtained in 64% yield using sulfonyl chloride I-014 (120mg, 0.268mmol, 1 equiv.), 4,4,4-Trifluorobutylamine hydrochloride (66mg, 0.40mmol, 1.5 equiv.) and iPr2NEt (140µL, 0.804mmol, 3 equiv.) in DCM (2mL) at RT for 2h. Purification by FC (cHex/EtOAc = 20/80).1H NMR (400 MHz, DMSO-d6) δ 7.58 (dt, J = 9.1, 2.2 Hz, 1H), 7.55 – 7.48 (m, 2H), 7.44 (dt, J = 8.6, 2.0 Hz, 1H), 7.34 (tt, J = 8.5, 2.1 Hz, 1H), 7.25 (t, J = 2.0 Hz, 1H), 7.14 (dd, J = 8.7, 1.8 Hz, 1H), 3.88 (s, 3H), 3.84 – 3.73 (m, 2H), 3.31 – 3.27 (m, 2H), 3.15 – 2.91 (m, 4H), 2.78 (q, J = 6.7 Hz, 2H), 2.30 – 2.15 (m, 2H), 1.61 – 1.50 (m, 2H).19F NMR (376 MHz, Chloroform-d) δ -64.8, - 110.1. MS (ESI+): [M+H]+ 538/540. Synthesis of intermediate required for final product 038 [0186] Rac-(2-chloro-4-fluoro-phenyl)-[4-[5-[(3-hydroxy-1-piperidyl)sulfonyl]-2- methoxy-phenyl]piperazin-1-yl]methanone (I-016)
According to GP-4, I-016 was obtained in 79% yield using sulfonyl chloride I-014 (150mg, 0.335mmol, 1 equiv.), rac-piperidin-3-ol hydrochloride (69mg, 0.50mmol, 1.5 equiv.) and iPr2NEt (175µL, 1.00mmol, 3 equiv.) in DCM (2mL) at RT for 16h. Purification by FC (DCM/MeOH = 98/2 to 90/10).1H NMR (400 MHz, Chloroform-d) δ 7.46 (dd, J = 8.5, 2.2 Hz, 1H), 7.36 – 7.30 (m, 1H), 7.22 (d, J = 2.2 Hz, 1H), 7.18 (dd, J = 8.4, 2.4 Hz, 1H), 7.07 (td, J = 8.2, 2.5 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H), 4.02 – 3.96 (m, 2H), 3.94 (s, 3H), 3.91 – 3.83 (m, 1H), 3.52 – 3.44 (m, 1H), 3.43 – 3.35 (m, 1H), 3.31
(d, J = 11.2 Hz, 1H), 3.24 – 3.07 (m, 4H), 3.02 – 2.94 (m, 1H), 2.83 – 2.75 (m, 1H), 2.73 – 2.66 (m, 1H), 1.90 – 1.80 (m, 2H), 1.79 – 1.70 (m, 1H), 1.68 – 1.56 (m, 1H), 1.40 (dtd, J = 12.6, 8.4, 3.9 Hz, 1H). 19F NMR (376 MHz, Chloroform-d) δ -109.2. MS (ESI+): [M+H]+ 512/514. Synthesis of intermediate required for final product 039 [0187] (2-chloro-4-fluoro-phenyl)-[4-[5-(3-hydroxypyrrolidin-1-yl)sulfonyl-2- methoxy-phenyl]piperazin-1-yl]methanone (I-017)
According to GP-4, I-017 was obtained in 90% yield using sulfonyl chloride I-014 (150mg, 0.335mmol, 1 equiv.), rac-pyrrolidin-3-ol (44mg, 0.50mmol, 1.5 equiv.) and iPr2NEt (175µL, 1.00mmol, 3 equiv.) in DCM (2mL) at RT for 16h. Purification by FC (DCM/MeOH = 98/2 to 90/10).1H NMR (400 MHz, Chloroform-d) δ 7.54 (dd, J = 8.6, 2.1 Hz, 1H), 7.36 – 7.29 (m, 2H), 7.18 (dd, J = 8.5, 2.4 Hz, 1H), 7.07 (td, J = 8.3, 2.5 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H), 4.42 – 4.35 (m, 1H), 3.99 (t, J = 5.2 Hz, 2H), 3.94 (s, 3H), 3.52 – 3.28 (m, 5H), 3.25 – 3.07 (m, 4H), 2.99 (dd, J = 11.2, 6.6 Hz, 1H), 1.97 (dtd, J = 13.7, 8.8, 4.9 Hz, 1H), 1.88 – 1.79 (m, 1H), 1.51 (d, J = 4.7 Hz, 1H).19F NMR (376 MHz, Chloroform-d) δ -109.2. MS (ESI+): [M+H]+ 498/500. Synthesis of intermediate required for final product 040 [0188] [4-[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-ylsulfonyl)-2- methoxy-phenyl]piperazin-1-yl]-(2-chloro-4-fluoro-phenyl)methanone (I-018)
To a solution of 022 (300mg, 0.481mmol, 1 equiv.) in DCM (2.4mL) at 0°C, was added HCl (4M solution in dioxane, 1.2mL, 4.8mmol, 10 equiv.). The mixture was stirred at RT for 2h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water and DCM. K2CO3(s) was added portionwise until pH>11. The layers were separated and the aqueous phase was extracted with DCM (2*). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure to afford 250mg (99%) of I-018 as a white foam. 1H NMR (400 MHz, DMSO-d6) δ 7.58 (dd, J = 9.0, 2.4 Hz, 1H), 7.52 (dd, J = 8.5, 6.1 Hz, 1H), 7.41 (dd, J = 8.6, 2.1 Hz, 1H), 7.34 (td, J = 8.5, 2.5 Hz, 1H), 7.18 (d, J = 8.6 Hz, 1H), 7.13 (d, J = 2.2 Hz, 1H), 3.89 (s, 3H), 3.86 – 3.69 (m, 2H), 3.30 – 3.26 (m, 3H), 3.17 (d, J = 3.9 Hz, 2H), 3.14 – 3.06 (m, 4H), 2.98 (t, J = 5.0 Hz, 2H), 2.81 – 2.71 (m, 4H), 2.42 (dd, J = 10.8, 2.9 Hz, 2H). 19F NMR (376 MHz, Chloroform-d) δ -109.2. MS (ESI+): [M+H]+ 523/525. Synthesis of intermediate required for final product 042 [0189] 3-bromo-4-fluoro-N-methyl-N-propyl-benzenesulfonamide (I-019)
According to GP-4, I-019 was obtained as a yellow oil in 95% yield using 3-bromo-4- fluoro-benzenesulfonyl chloride (200µL, 1.35mmol, 1 equiv.), N-methylpropylamine
(145µL, 1.41mmol, 1.05 equiv.) and triethylamine (281µL, 2.02mmol, 1.5 equiv.) in DCM (7mL) for 1h at RT. 1H NMR (400 MHz, Chloroform-d) δ 8.01 (dd, J = 6.3, 2.3 Hz, 1H), 7.73 (ddd, J = 8.6, 4.5, 2.2 Hz, 1H), 7.33 – 7.15 (m, 1H), 3.08 – 2.90 (m, 2H), 2.75 (s, 3H), 1.67 – 1.55 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 19F NMR (376 MHz, Chloroform-d) δ -99.9. MS (ESI+): [M+H]+ 310/312. Synthesis of intermediate required for final product 043 [0190] [4-(2,3-dihydrobenzofuran-7-yl)piperazin-1-yl]-[4-fluoro-2- (trifluoromethyl)phenyl]methanone (I-020)
A microwave reaction vial was charged with 7-bromo-2,3-dihydrobenzofuran (300mg, 1.51mmol, 1 equiv.), [4-fluoro-2-(trifluoromethyl)phenyl]-piperazin-1-yl-methanone (614mg, 2.22mmol, 1.5 equiv.), Pd2dba3 (94mg, 0.10mmol, 0.07 equiv.), tri(2- tolyl)phosphine (55mg, 0.18mmol, 0.12 equiv.) and sodium tert-butylate (212mg, 2.21mmol, 1.5 equiv.). The vial was flushed with argon and degassed toluene (10 mL) was added. The vial was sealed and the mixture was stirred at 110 °C for 22h. The suspension was cooled down to RT, filtered over Celite (EtOAc rinses) and concentrated. The residue was purified by FC (cHex/EtOAc = 95/5 to 0/100) to afford 136mg (23%) of I-020 as a brown foam. 1H NMR (400 MHz, Chloroform-d) δ 7.42 (dd, J = 8.8, 2.5 Hz, 1H), 7.37 (dd, J = 8.5, 5.3 Hz, 1H), 7.31 (td, J = 8.1, 2.6 Hz, 1H), 6.90 (dd, J = 7.4, 1.2 Hz, 1H), 6.81 (t, J = 7.6 Hz, 1H), 6.67 (dd, J = 7.9, 1.2 Hz, 1H), 4.59 (t, J = 8.8 Hz, 2H), 3.97 (qt, J = 13.2, 5.1 Hz, 2H), 3.34 (dd, J = 5.9, 4.4 Hz, 2H), 3.27 – 3.11 (m, 4H), 3.10 – 2.94 (m, 2H).19F NMR (376 MHz, Chloroform-d) δ -60.2, -109.4. MS (ESI+): [M+H]+ 395.
[0191] 7-[4-[4-fluoro-2-(trifluoromethyl)benzoyl]piperazin-1-yl]-2,3- dihydrobenzofuran-5-sulfonyl chloride (I-021)
According to GP-3, I-021 was obtained as a white solid in 83% yield using I-020 (135mg, 0.342mmol, 1 equiv.) and HSO3Cl (0.50mL, 7.5mmol, 22 equiv.) in DCM (2mL) for 2h. 1H NMR (400 MHz, Chloroform-d) δ 7.58 – 7.55 (m, 1H), 7.45 (dd, J = 8.8, 2.4 Hz, 1H), 7.41 – 7.32 (m, 2H), 7.32 – 7.28 (m, 1H), 4.78 (t, J = 8.9 Hz, 2H), 3.98 (t, J = 5.2 Hz, 2H), 3.43 – 3.20 (m, 6H), 3.18 – 2.99 (m, 2H). 19F NMR (376 MHz, Chloroform-d) δ - 60.2, -109.0. Synthesis of intermediates required for final products 044 and 045 [0192] 5-bromo-6-chloro-N,N-diethyl-pyridine-3-sulfonamide (I-022)
According to GP-4, I-022 was obtained as a yellow solid in 100% yield using 5-bromo- 6-chloro-pyridine-3-sulfonyl chloride (438mg, 1.50mmol, 1.1 equiv.), diethylamine (100mg, 1.37mmol, 1 equiv.) and triethylamine (229µL, 1.64mmol, 1.2 equiv.) in DCM (6.8mL) for 1h at RT.1H NMR (400 MHz, Chloroform-d) δ 8.74 (d, J = 2.2 Hz, 1H), 8.32 (d, J = 2.2 Hz, 1H), 3.31 (q, J = 7.2 Hz, 4H), 1.21 (t, J = 7.1 Hz, 6H).
[0193] 5-bromo-6-methoxy-N,N-diethyl-pyridine-3-sulfonamide (I-023)
To a solution of I-022 (150mg, 0.458mmol, 1 equiv.) in dry MeOH (1.8mL) at RT, was added MeONa (124mg, 2.29mol, 5 equiv.). The mixture was stirred at RT for 60h. The RM was partitioned between aq. sat. NH4Cl and EtOAc. The layers were separated and the aqueous phase was extracted with EtOAc. The combined organic extracts were washed (brine), dried (Na2SO4), filtered and concentrated under reduced pressure to afford 138mg (93%) of I-023 as light yellow solid. 1H NMR (400 MHz, Chloroform-d) δ 8.55 (d, J = 2.2 Hz, 1H), 8.18 (d, J = 2.2 Hz, 1H), 4.10 (s, 3H), 3.28 (q, J = 7.2 Hz, 4H), 1.20 (t, J = 7.1 Hz, 6H). Synthesis of intermediates required for final products 046 and 047 [0194] 3-bromo-4-hydroxy-N-methyl-N-propyl-benzenesulfonamide (I-024)
To a solution of I-007 (200mg, 0.620mmol, 1 equiv.) in DCM (7.7mL) at 0°C, was added BBr3 (1M solution in DCM, 1.86mL, 1.86mmol, 2 equiv.). The mixture was stirred at RT for 48h. After cooling down to 0°C, water was added dropwise (exotherm). The layers were separated and the aqueous phase was extracted with DCM (2*). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure to afford 214mg (quantitative) of I-024 as an orange oil. 1H NMR (400 MHz, Chloroform-d) δ (ppm) 7.95 (d, J = 2.2 Hz, 1H), 7.74 (dd, J = 8.6 and 2.2 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.05 (br s, 1H), 3.02 – 2.95 (m, 2H), 2.75 (s, 3H), 1.65 – 1.52 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H). MS (ESI+): [M+H]+ 308/310.
[0195] 3-bromo-4-(2-methoxyethoxy)-N-methyl-N-propyl-benzenesulfonamide (I-025)
To a solution of I-024 (191mg, 0.620mmol, 1 equiv.) in DMF (2.5mL) at RT, were added K2CO3 (257mg, 1.86mmol, 3 equiv.) and 2-bromomethyl methyl ether (129mg, 0.930mmol, 1.5 equiv.). The mixture was stirred at 50°C for 16h. The reaction mixture was partitioned between aq. sat. NH4Cl and EtOAc. The layers were separated and the aqueous phase was extracted with EtOAc (2*). The combined organic extracts were washed (sat. aq. NH4Cl, sat. aq. NaHCO3, brine), dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (cHex/EtOAc =
with EtOAc (2*). The combined organic extracts were washed (sat. aq. NH4Cl, sat. aq. NaHCO3, brine), dried (Na2SO4), filtered and concentrated under reduced pressure. The
residue was purified by FC (cHex/EtOAc = 100/0 to 50/50) to afford 330mg (86%) of I- 026 as a yellow oil. 1H NMR (400 MHz, Chloroform-d) δ 7.99 (d, J = 2.3 Hz, 1H), 7.67 (dd, J = 8.6, 2.2 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.44 – 7.38 (m, 2H), 7.38 – 7.31 (m, 1H), 7.01 (d, J = 8.7 Hz, 1H), 5.23 (s, 2H), 3.05 – 2.91 (m, 2H), 2.72 (s, 3H), 1.67 – 1.49 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H). MS (ESI+): [M+H]+ 398/400. Synthesis of intermediates required for piperazine I-027 [0197] tert-butyl 4-(2-chloro-4-fluoro-benzoyl)piperazine-1-carboxylate (Boc-I-027)
Formula Weight: 342,79 Molecular Formula: C16H20ClFN2O3 To a solution of 2-chloro-4-fluorobenzoic acid (5.00g, 28.6mmol, 1 equiv.) in THF (89mL) at RT, was added TBTU (9.20g, 28.6mmol, 1 equiv.). The mixture was stirred 15min at RT, and a solution of tert-butyl piperazine-1-carboxylate (6.40g, 34.4mmol, 1.2 equiv.) and Et3N (6.0mL, 43mmol, 1.5 equiv.) in THF (30mL) was added dropwise. The mixture was stirred at RT for 60h. The reaction mixture was concentrated under reduced pressure. The reaction mixture was partitioned between 1N HCl and EtOAc. The layers were separated and the aqueous phase was extracted with EtOAc(2*). The combined organic extracts were washed (aq. 1N HCl, aq. sat. NaHCO3, brine), dried (Na2SO4), filtered and concentrated under reduced pressure to afford 10.2g (100%) of tert-butyl 4- (2-chloro-4-fluoro-benzoyl)piperazine-1-carboxylate (Boc-I-027) as an orange oil. 1H NMR (400 MHz, Chloroform-d) δ 7.32-7.29 (m, 1H), 7.18 (dd, J = 8.5, 2.5 Hz, 1H), 7.07 (td, J = 8.3, 2.5 Hz, 1H), 3.92-3.79 (m, 1H), 3.73 (dt, J = 13.2, 5.7 Hz, 1H), 3.63-3.50 (m, 2H), 3.48-3.34 (m, 2H), 3.34-3.10 (m, 2H), 1.48 (s, 9H). MS (ESI+): [M+H]+ 343.1/345.1.
[0198] (2-chloro-4-fluoro-phenyl)-piperazin-1-yl-methanone (I-027)
Formula Weight: 242,68 Molecular Formula: C11H12ClFN2O To a solution of crude tert-butyl 4-(2-chloro-4-fluoro-benzoyl)piperazine-1-carboxylate Boc-I-027 (10.2g, 28.6mmol, 1 equiv.) in dioxane (37 mL) at RT, was added HCl (4M solution in dioxane, 37mL, 148 mmol, 5 equiv.). The mixture was stirred at RT for 16h. The reaction mixture was concentrated under reduced pressure and the residue was partitioned between water and DCM. K2CO3(s) was added portionwise until pH >11. The layers were separated and the aqueous phase was extracted with DCM (2*). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (80g column, dry load, DCM/MeOH = 98/2 to 80/20) to afford 5.24g (72%) of (2-chloro-4-fluoro-phenyl)-piperazin-1-yl-methanone I-027 as an orange solid.1H NMR (400 MHz, Chloroform-d) δ 7.41 (dd, J = 8.8, 2.4 Hz, 1H), 7.32 (qd, J = 8.4, 5.6 Hz, 2H), 3.87-3.69 (m, 2H), 3.15 (t, J = 5.1 Hz, 2H), 2.94 (t, J = 5.2 Hz, 2H), 2.80 – 2.70 (m, 2H). MS (ESI+): [M+H]+ 243.1/245.1. Synthesis of intermediates required for final products 054 & 55 [0199] 1-bromo-2-(methoxymethoxy)-3-methyl-benzene (I-028)
Formula Weight: 231,09 Molecular Formula: C9H11BrO2 To a solution of 2-bromo-6-methyl-phenol (1.00g, 5.35mmol, 1 equiv.) and iPr2NEt (1.4mL, 8.1mmol, 1.5 equiv.) in DCM (21mL) at RT, was added chloromethyl methyl ether (0.49mL, 6.4mmol, 1.2 equiv.). The mixture was stirred at RT for 60h. 1N HCl was added. The layers were separated and the aqueous phase was extracted with DCM. The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced
pressure to afford 1.22g of I-028 (99%) as a colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 7.42 (ddd, J = 8.0, 1.6, 0.7 Hz, 1H), 7.15 (ddd, J = 7.6, 1.6, 0.8 Hz, 1H), 6.92 (t, J = 7.8 Hz, 1H), 5.11 (s, 2H), 3.68 (s, 3H), 2.39 (s, 3H). [0200] (2-chloro-4-fluoro-phenyl)-[4-[2-(methoxymethoxy)-3-methyl- phenyl]piperazin-1-yl]methanone (I-029)
Formula Weight: 392,85 Molecular Formula: C20H22ClFN2O3 According to GP-5, I-029 was obtained as an oil in 44% yield using I-028 (400mg, 1.73mmol, 1 equiv.), piperazine I-027 (504mg, 2.08mmol, 1.2 equiv.), Cs2CO3 (1.69g, 5.19mmol, 3 equiv.), Pd(OAc)2 (38.9mg, 173µmol, 0.1 equiv.) and rac-BINAP (162mg, 260µmol, 0.15 equiv.) in toluene (8.7mL) at reflux for 2h. Purification by FC (cHex/EtOAc = 95/5 to 50/50). 1H NMR (400 MHz, Chloroform-d) δ 7.32 (dd, J = 8.5, 5.9 Hz, 1H), 7.18 (dd, J = 8.4, 2.4 Hz, 1H), 7.07 (td, J = 8.2, 2.5 Hz, 1H), 6.98 (t, J = 7.7 Hz, 1H), 6.94 – 6.86 (m, 1H), 6.79 (dd, J = 8.0, 1.7 Hz, 1H), 5.17 (s, 2H), 3.96 (t, J = 5.1 Hz, 2H), 3.60 (s, 3H), 3.50 – 3.28 (m, 2H), 3.28 – 3.02 (m, 3H), 3.02 – 2.88 (m, 1H), 2.32 (s, 3H). 19F NMR (376 MHz, Chloroform-d) δ -109.4. MS (ESI+): [M+H]+ 393.1/395.1. [0201] 3-[4-(2-chloro-4-fluoro-benzoyl)piperazin-1-yl]-4-hydroxy-5-methyl- benzenesulfonyl chloride (I-030)
Formula Weight: 447,31 Molecular Formula: C18H17Cl2FN2O4S
According to GP-3, I-030 was obtained as a yellow solid in 50% yield using I-029 (300mg, 0.748mmol, 1 equiv.) and HSO3Cl (1.2mL, 19mmol, 25 equiv.) in DCM (3mL) at RT for 1h. The material was directly engaged in the next step Synthesis of intermediates required for final products 057 to 59 (I-031)
Formula Weight: 251,5 Molecular Formula: C8H8BrClO2 To a solution of 2-bromo-6-chlorophenol (3.17g, 10.5mmol, 1 equiv.) and iPr2NEt (3.73mL, 15.7mmol, 1.5 equiv.) in DCM (21mL) at RT, was added chloromethyl methyl ether (0.95mL, 13mmol, 1.2 equiv.). The mixture was stirred at RT for 16h. The volatiles were removed under reduced pressure. EtOAc was added and the organic solution was washed (1N HCl, brine), dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by FC (cHex/EtOAc = 95/5) to afford 2.59g of I-031 (98%) as a colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 7.50 (dd, J = 8.0, 1.6 Hz, 1H), 7.37 (dd, J = 8.1, 1.5 Hz, 1H), 6.97 (t, J = 8.0 Hz, 1H), 5.21 (s, 2H), 3.74 (s, 3H). [0203] (2-chloro-4-fluoro-phenyl)-[4-[3-chloro-2-(methoxymethoxy)phenyl]piperazin- 1-yl]methanone (I-032)
rac-BINAP (365mg, 587µmol, 0.12 equiv.) in toluene (24.5mL) at reflux for 16h.
Purification by FC (cHex/EtOAc = 95/5 to 50/50). 1H NMR (400 MHz, Chloroform-d) δ 7.30 (dd, J = 8.5, 5.9 Hz, 1H), 7.18 (dd, J = 8.4, 2.4 Hz, 1H), 7.12 – 7.03 (m, 2H), 7.00 (t, J = 8.1 Hz, 1H), 6.83 (dd, J = 8.1, 1.5 Hz, 1H), 5.22 (s, 2H), 4.01 – 3.86 (m, 2H), 3.66 (s, 3H), 3.50 – 3.29 (m, 2H), 3.25 – 2.91 (m, 4H). 19F NMR (376 MHz, Chloroform-d) δ -109.2. MS (ESI+): [M+H]+ 413.0/415.0/417.0. [0204] (2-chloro-4-fluoro-phenyl)-[4-(3-chloro-2-hydroxy-phenyl)piperazin-1- yl]methanone (I-033)
To a solution of I-032 (1.26g, 3.05mmol, 1 equiv.) in DCM (15mL) at RT, was added CF3CO2H (4.7mL, 61mmol, 20 equiv.). The mixture was stirred at RT for 1h. It was concentrated under reduced pressure and the residue was azeotroped with toluene. The residue was purified by FC (cHex/EtOAc = 95/5 to 20/80) to afford 1.12g of I-033 (97%) as a white foam. 1H NMR (400 MHz, Chloroform-d) δ 7.35 (dd, J = 8.5, 5.8 Hz, 1H), 7.24 – 7.16 (m, 2H), 7.14 – 7.02 (m, 2H), 6.86 (t, J = 8.1 Hz, 1H), 6.26 (s, 1H), 4.22 – 4.06 (m, 1H), 4.06 – 3.93 (m, 1H), 3.59 – 3.38 (m, 2H), 3.28 – 2.86 (m, 4H). 19F NMR (376 MHz, Chloroform-d) δ -108.1. MS (ESI+): [M+H]+ 369.0/371.0/373.0. [0205] 3-chloro-5-[4-(2-chloro-4-fluoro-benzoyl)piperazin-1-yl]-4-hydroxy- benzenesulfonyl chloride (I-034)
467,73 Molecular Formula: C17H14Cl3FN2O4S
According to GP-3, I-034 was obtained as a beige solid in 80% yield using I-033 (500mg, 1.35mmol, 1 equiv.) and HSO3Cl (2.3mL, 34mmol, 25 equiv.) in DCM (7mL) at reflux for 4h. 1H NMR (400 MHz, Chloroform-d) δ 7.88 (d, J = 2.2 Hz, 1H), 7.62 (d, J = 2.2 Hz, 1H), 7.34 (dd, J = 8.5, 5.8 Hz, 1H), 7.19 (dd, J = 8.4, 2.4 Hz, 1H), 7.09 (td, J = 8.2, 2.5 Hz, 1H), 5.75 (br s, 1H), 4.03 (t, J = 5.1 Hz, 2H), 3.61 – 3.34 (m, 2H), 3.19 – 2.85 (m, 4H).19F NMR (376 MHz, Chloroform-d) δ -108.5. Synthesis of final compounds Synthetic methods for final compounds [0206] The synthetic protocols for the final compounds are presented on the following Table 2. Table 2
Analytical data for the final compounds [0207] The analytical data for the final compounds are presented on the following Table 3. Table 3
Example 2: Biological activity of the compounds [0208] The purpose of this experiment was to evaluate the GFRα1-RET activity of the compounds 001-060 according to the invention. Materials and methods [0209] The compounds were tested for their activating activity of Elk1 signaling using the previously developed reporter-gene-based system in cells expressing GFRα1-RET (MG87 murine fibroblast stably transfected with PathDetect Elk-1, GFRα1, and RET) disclosed in Sidorova, Y. A. et al.: “Persephin signaling through GFRα1: The potential for the treatment of Parkinson’s disease.” Molecular and Cellular Neuroscience, July 2010, Vol. 44, pp. 223-232. DOI: 10.1016/j.mcn.2010.03.009. For EC50 determination, a dose-response test was performed using 6 concentrations of each tested compound. Dose-response curves were fitted using the sigmoidal dose-response (variable slope) analysis in GraphPad Prism program (Graph Pad Inc) and EC50 of agonist / activator activity was calculated. Dose-response experiments were all performed in duplicate, two times independently. Results [0210] The results are presented on Table 4 below (* means “10 µM < EC50 < 50 µM”, ** means “5 µM < EC50 < 10 µM”, *** means “1 µM < EC50 < 5 µM”, and **** means “EC50 < 1 µM”). Table 4
[0211] The above results clearly evidence that the tested compounds 001-060 have significant GFRα1-RET activity. Thus, the compounds of the invention are useful as neuroprotective and neurorestorative agents. The tested compounds 001-060 are well-representing the class of the compounds of formula (I). Example 3: Biological activity of comparative compounds [0212] The purpose of this experiment was to compare the GFRα1-RET activity of the compounds 001, 009 and 010 according to the invention to the GFRα1-RET activity of comparative compounds C01 and C02. Materials and methods [0213] Comparatives compounds C01 and C02 were prepared by using the same synthetic pathways and methods as described hereinabove for the compounds according to the invention, using the general knowledge in the art to adapt the reactants and experimental conditions as needed.
[0214] The structure of comparatives compounds C01 and C02 are presented on Table 5 below. Table 5
[0215] The compounds were tested for their activating activity of Elk1 signaling using the same materials and methods than for the compounds according to the invention (Example 2 herein, section “Materials and methods”). Results [0216] The results for comparative compounds C01 and C02 are presented on Table 6 below. For easier comparison, the corresponding values from Table 4 above for compounds 009, 010 and 001 according to the invention were also reported in Table 6 (AL means “EC50 > 50 µM”, * means “10 µM < EC50 < 50 µM”, ** means “5 µM < EC50 < 10 µM”, *** means “1 µM < EC50 < 5 µM”, and **** means “EC50 < 1 µM”). Table 6
[0217] The above results clearly evidence that the compounds according to the invention have significantly higher GFRα1-RET activity than comparative compounds C01 and C02. Indeed, compounds C01 and C02 have an EC50 higher than 50 µM, whereas compounds 001, 009 and 010 have an EC50 lower than 10 µM, or even further lower. In the context of the medical uses according to the present invention, an EC50 higher than 50 µM is actually quite high and might possibly be considered by a person skilled in the art “inactive” or “not active enough to be of therapeutical interest”. [0218] It is noteworthy that the only structural difference between the compounds C01 and C02 and, respectively, compounds 009 and 010 or compound 001, is the substitution
the definitions of RA-RD substituents in formula (I). In particular, RD does not represent CF3 in compounds 009 and 010, but rather CHF2 (010) or Cl (009), whereas in compound C01 the substituent that would correspond to RD in formula (I) represents CF3. Similarly, RD does not represent CF3 in compound 001, but rather Cl, whereas in compound C02 the substituent that would correspond to RD in formula (I) represents CF3. [0219] Therefore, these results unambiguously evidence that the compounds of the invention are better activators of GFRa1-RET and thus better neuroprotective and neurorestorative candidates than the comparative compounds. Moreover, this surprising technical effect is directly associated with the specific structural feature of the compounds according to the invention.
Claims
CLAIMS 1. Compound of formula (I-i)
or a pharmaceutically acceptable salt and/or solvate thereof; wherein W represents CH or N; RA, RB and RC each independently represents hydrogen, F, Cl, CH3, CF3, CHF2 or CH2F; RD represents hydrogen, F, Cl, CH3, CHF2 or CH2F; R7 represents hydrogen, OH, halogen, (C1-C8) alkyl, cycloalkyl, (C1-C8) alkyl- O-, cycloalkyl-O-, cycloalkyl-(C1-C8) alkyl-O-, heterocycloalkyl-O-, heterocycloalkyl-(C1-C8) alkyl-O-, aryl-(C1-C8) alkyl-O-, heteroaryl- (C1-C8) alkyl-O-, R11O-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-O-, (R11O)(R12)N-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-, R11O-(C1-C8) alkyl-, NR11R12, CN, CO2H, CO2R11, CONH2, CON(R11)H, heterocycloalkyl, or heteroaryl; wherein R11 and R12 each independently represents hydrogen or (C1-C8) alkyl; wherein the alkyl or cycloalkyl in R7 is optionally substituted by at least one F, Cl, OH, =O, (C1-C8) alkyl, (C1-C8) alkyl-O-, heterocycloalkyl, aryl or heteroaryl;
wherein the heterocycloalkyl, aryl or heteroaryl is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, CHF2, CH2F, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR13R14, R13R14N-(C1-C8) alkyl-, R13O2C(C1-C8) alkyl-, CO2H, R13R14N-C(O)-, R13O-NR14-, or (C1-C8) alkyl-CO2-; wherein R13 and R14 each independently represents hydrogen or (C1-C8) alkyl; Z represents C-H, C-R8 or N; wherein R8 represents (C1-C4) alkyl, F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH or (C1-C4) alkoxy; or Z represents C-R8 and R7 and R8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted by at least one F, OH, =O, →O, (C1-C8) alkyl, CF3, HO2C-CH2-, (C1-C4) alkyl-CO2- CH2-, R15R16N-CH2-, aryl, or aryl-(C1-C8) alkyl-, wherein R15 and R16 each independently represents hydrogen or (C1-C8) alkyl; R5 represents hydrogen, (C1-C8) alkyl, CH3 substituted by one to three (C1-C8) alkyl groups, cycloalkyl, heterocycloalkyl, aryl, or cycloalkyl- (C1-C8) alkyl; wherein the alkyl or cycloalkyl in R5 is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, OCF3, CN, OH, =O, (C1-C8) alkoxy, NR17R18, CO2H, R17R18N-C(O)-, R17O-NR18-, heterocycloalkyl, aryl or heteroaryl; wherein R17 and R18 each independently represents hydrogen or (C1-C8) alkyl; wherein the heterocycloalkyl, aryl or heteroaryl is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, CHF2, CH2F, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR19R20, CO2H, R19R20N-C(O)-, R19O-NR20-, (C1-C8) alkyl- CO2-, R19R20N-(C1-C8) alkyl-, R19O2C-(C1-C8) alkyl-, heterocycloalkyl, heteroaryl, aryl, or aryl-(C1-C8) alkyl-; wherein R19 and R20 each independently represents hydrogen or (C1-C8) alkyl;
R6 represents (C1-C8) alkyl, CH3 substituted by one to three (C1-C8) alkyl groups, cycloalkyl, heterocycloalkyl, aryl, or cycloalkyl-(C1-C8) alkyl; wherein the alkyl or cycloalkyl in R6 is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, OCF3, CN, OH, =O, (C1-C8) alkoxy, NR21R22, CO2H, R21R22N-C(O)-, R21O-NR22-, heterocycloalkyl, aryl or heteroaryl; wherein R21 and R22 each independently represents hydrogen or (C1-C8) alkyl; wherein the heterocycloalkyl, aryl or heteroaryl is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, CHF2, CH2F, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR23R24, CO2H, R23R24N-C(O)-, R23O-NR24-, (C1-C8) alkyl- CO2-, R23R24N-(C1-C8) alkyl-, R23O2C-(C1-C8) alkyl-, heterocycloalkyl, heteroaryl, aryl, or aryl-(C1-C8) alkyl-; wherein R23 and R24 each independently represents hydrogen or (C1-C8) alkyl; or R5 and R6 form together with the nitrogen atom to which they are bound an heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR25R26, CO2H, (C1-C8) alkyl-CO2-, R25R26N-C(O)-, R25O-NR26-, R25R26N- (C1-C8) alkyl-, R25O2C-(C1-C8) alkyl-, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyl-(C1-C8) alkyl-, heterocycloalkyl-(C1-C8) alkyl-, aryl-(C1-C8) alkyl-, heteroaryl-(C1-C8) alkyl-, aryl-cycloalkyl-, cycloalkyl-O-, heterocycloalkyl-O-, aryl-O-, heteroaryl-O-, cycloalkyl- (C1-C8) alkyl-O-, heterocycloalkyl-(C1-C8) alkyl-O-, aryl-(C1-C8) alkyl- O-, heteroaryl-(C1-C8) alkyl-O-, cycloalkyl-NR25-, heterocycloalkyl- NR25-, aryl-NR25-, heteroaryl-NR25-, cycloalkyl-(C1-C8) alkyl-NR25-, heterocycloalkyl-(C1-C8) alkyl-NR25-, aryl-(C1-C8) alkyl-NR25-, heteroaryl-(C1-C8) alkyl-NR25-, benzylidene, heteroarylidene, aryl- (C1-C8) alkyl-ylidene- or heteroaryl-(C1-C8) alkyl-ylidene-; wherein R25 and R26 each independently represents hydrogen or (C1-C8) alkyl;
wherein the heterocycloalkyl, aryl, heteroaryl, benzylidene or heteroarylidene is optionally substituted at least one F, Cl,
heterocycloalkyl, heteroaryl, aryl, or aryl-(C1-C8) alkyl-; wherein R27 and R28 each independently represents hydrogen or (C1-C8) alkyl. 2. Compound of formula (I-ii)
or a pharmaceutically acceptable salt and/or solvate thereof; wherein W represents CH or N; RA, RB, RC and RD each independently represents hydrogen, F, Cl, CH3, CF3, CHF2 or CH2F; R7 represents hydrogen, OH, halogen, (C1-C8) alkyl, cycloalkyl, (C2-C8) alkyl- O-, cycloalkyl-O-, cycloalkyl-(C1-C8) alkyl-O-, heterocycloalkyl-O-, heterocycloalkyl-(C1-C8) alkyl-O-, aryl-(C1-C8) alkyl-O-, heteroaryl- (C1-C8) alkyl-O-, R11O-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-O-, (R11O)(R12)N-(C1-C8) alkyl-O-, R11R12N-(C1-C8) alkyl-, R11O-(C1-C8) alkyl-, NR11R12, CN, CO2H, CO2R11, CONH2, CON(R11)H, heterocycloalkyl, or heteroaryl; wherein R11 and R12 each independently represents hydrogen or (C1-C8) alkyl;
wherein the alkyl or cycloalkyl in R7 is optionally substituted by at least one F, Cl, OH, =O, (C1-C8) alkyl, (C1-C8) alkyl-O-, heterocycloalkyl, aryl or heteroaryl; wherein the heterocycloalkyl, aryl or heteroaryl is optionally substituted by at least one F, Cl, (C1-C8) alkyl, CF3, CHF2, CH2F, OCF3, CN, OH, =O, →O, (C1-C8) alkoxy, NR13R14, R13R14N-(C1-C8) alkyl-, R13O2C(C1-C8) alkyl-, CO2H, R13R14N-C(O)-, R13O-NR14-, or (C1-C8) alkyl-CO2-; wherein R13 and R14 each independently represents hydrogen or (C1-C8) alkyl; Z represents C-H, C-R8 or N; wherein R8 represents (C1-C4) alkyl, F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH or (C1-C4) alkoxy; or Z represents C-R8 and R7 and R8 form together with the carbon atoms to which they are bound a cycloalkyl or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl is optionally substituted by at least one F, OH, =O, →O, (C1-C8) alkyl, CF3, HO2C-CH2-, (C1-C4) alkyl-CO2- CH2-, R15R16N-CH2-, aryl, or aryl-(C1-C8) alkyl-, wherein R15 and R16 each independently represents hydrogen or (C1-C8) alkyl; and R5 and R6 are each independently as defined in claim 1. 3. The compound according to claim 1 or claim 2, wherein W represents CH. 4. The compound according to any one of claims 1 to 3, wherein: at least one among RA, RB, RC and RD represents hydrogen, preferably at least one among RA and RC represents hydrogen, more preferably RC represents hydrogen; and/or at least one among RA, RB and RD represents F or Cl, preferably at least one among RB and RD represents F or Cl; more preferably RB and RD each independently represents F or Cl. 5. The compound according to any one of claims 1 to 4, wherein R7 represents hydrogen, OH or halogen; preferably R7 represents OH or F.
6. The compound according to any one of claims 1 or 3 to 5, wherein R7 represents (C1-C8) alkyl-O- or cycloalkyl-O-, wherein the alkyl or cycloalkyl is optionally substituted by at least one F, Cl, OH, (C1-C8) alkoxy or aryl; preferably R7 represents OCH3, HO-CH2-CH2-O-, CH3O-CH2-CH2-O- or phenyl-CH2-O-. 7. The compound according to any one of claims 1 to 6, wherein Z represents C-R8, wherein R8 represents (C1-C4) alkyl, F, Cl, CF3, CHF2, CH2F, OCF3, CN, OH or (C1-C4) alkoxy; preferably wherein R8 represents methyl or Cl. 8. The compound according to any one of claims 1 to 6, wherein Z represents C-R8 and R7 and R8 form together with the carbon atoms to which they are bound a heterocycloalkyl; wherein the heterocycloalkyl is optionally substituted by at least one F, OH, =O, (C1-C8) alkyl, CF3, HO2C-CH2-, (C1-C4) alkyl-CO2-CH2-, or R15R16N-CH2-, wherein R15 and R16 each independently represents hydrogen or (C1-C8) alkyl-. 9. The compound according to any one of claims 1 to 8, wherein R5 represents hydrogen or (C1-C8) alkyl; preferably R5 represents hydrogen, methyl or ethyl; and/or R6 represents (C1-C8) alkyl, cycloalkyl, heterocycloalkyl, cycloalkyl- (C1-C8) alkyl- or aryl-(C1-C8) alkyl-, wherein the alkyl, cycloalkyl, heterocycloalkyl or aryl is optionally substituted by at least one methyl, Cl or F; preferably R6 represents ethyl, propyl, butyl, cyclopentyl, cyclohexyl, 2-adamantyl, 3-methyloxetan-3-yl, cyclopropyl-CH2-, cyclobutyl-CH2-, cyclohexyl-CH2-, phenyl-CH2- (benzyl), 3-chlorophenyl-CH2- or 4-fluorophenyl-CH2-. 10. The compound according to any one of claims 1 to 9, wherein R5 and R6 form together with the nitrogen atom to which they are bound an heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted by at least one F; preferably R5 and R6 form together with the nitrogen atom to which they are bound a pyrrolidine, 4-benzyl-piperidine, 4-phenyl-4-hydroxy-piperidine, 4-benzyl-4- hydroxy-piperidine, 4-benzyl-piperazine, tert-butyl 1,3,3a,4,6,6a- hexahydropyrrolo[3,4-c]pyrrole-2-carboxylate, 4-benzylidene-1-piperidine, 4-(2- phenylethyl)-piperidine, 4-phenylpiperidine, 3-phenylpiperidine, 3-benzyl-
piperidine, 3-phenylpyrrolidin, 3-benzylpyrrolidine, 4-trifluoromethylpiperidine, 2-azabicyclo[2.2.1]heptane, 3-benzyloxypiperidine, 3-benzyloxypyrrolidine, 2- benzyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolidine, 4-(4- fluorophenyl)piperidine, [2-(4-chlorophenyl)ethyl]piperazine, [2-(4- fluorophenyl)ethyl]piperazine, 2-(phenylpropyl)piperazine, [2-(4- fluorophenyl)propyl]piperazine, 4-fluoropiperidine or 2,2-dimethylpyrrolidine. 11. The compound according to claim 1 or claim 2, wherein said compound is selected from:
and pharmaceutically acceptable salts and/or solvates thereof. 12. Pharmaceutical composition comprising a compound according to any one of claims 1 to 11 and at least one pharmaceutically acceptable carrier. 13. The compound according to any one of claims 1 to 11 or the pharmaceutical composition according to claim 12 for use as a medicament. 14. The compound or the pharmaceutical composition according to claim 13 for use in the treatment of a neurological disorder. 15. Process for manufacturing a compound according to any one of claims 1 to 11, wherein said process comprises a step of reaction of: a compound of formula (II)
wherein Z, R5, R6 and R7 are either as defined in claim 1 or as defined in claim 2, and X represents halide or -CF3SO3, with a compound of formula (III)
wherein W and RA-RD are either as defined in claim 1 or as defined in claim 2, in presence of a base and a metal catalyst; thereby obtaining either the compound of formula (I-i) or the pharmaceutically acceptable salt and/or solvate thereof, or the compound of formula (I-ii) or the pharmaceutically acceptable salt and/or solvate thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22201683 | 2022-10-14 | ||
EP22201683.4 | 2022-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024079351A1 true WO2024079351A1 (en) | 2024-04-18 |
Family
ID=83898070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/078567 WO2024079351A1 (en) | 2022-10-14 | 2023-10-13 | Novel piperazine-based sulfonamides and their use as neuroprotective and/or neurorestorative agents |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024079351A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011070177A2 (en) | 2009-12-11 | 2011-06-16 | Baltic Technology Development, Ltd. | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
WO2014041179A1 (en) | 2012-09-17 | 2014-03-20 | Chemedest Ltd. | Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists |
-
2023
- 2023-10-13 WO PCT/EP2023/078567 patent/WO2024079351A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011070177A2 (en) | 2009-12-11 | 2011-06-16 | Baltic Technology Development, Ltd. | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
WO2014041179A1 (en) | 2012-09-17 | 2014-03-20 | Chemedest Ltd. | Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists |
Non-Patent Citations (5)
Title |
---|
IVANOVA LARISA ET AL: "Molecular Dynamics Simulations of the Interactions between Glial Cell Line-Derived Neurotrophic Factor Family Receptor GFR[alpha]1 and Small-Molecule Ligands", vol. 3, no. 9, 19 September 2018 (2018-09-19), US, pages 11407 - 11414, XP093007310, ISSN: 2470-1343, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/acsomega.8b01524> DOI: 10.1021/acsomega.8b01524 * |
IVANOVA, L. ET AL., ACS OMEGA, vol. 3, no. 3, 19 September 2018 (2018-09-19), pages 11407 - 11414, ISSN: 2470-1343 |
JI, D. ET AL.: "Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 28, no. 6, 5 February 2020 (2020-02-05), pages 1 - 12, XP086052065, DOI: 10.1016/j.bmc.2020.115354 |
SIDOROVA, Y. A. ET AL.: "Persephin signaling through GFRal: The potential for the treatment of Parkinson's disease", MOLECULAR AND CELLULAR NEUROSCIENCE, vol. 44, July 2010 (2010-07-01), pages 223 - 232 |
SUTHERLAND, M. ET AL.: "Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics", CHEMMEDCHEM, vol. 16, no. 7, 29 January 2021 (2021-01-29), pages 1116 - 1125 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2895129C (en) | Quinazoline neurotensin receptor 1 agonists and uses thereof | |
AU2023202086A1 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
US10968210B2 (en) | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
US11261164B2 (en) | Small molecule agonists of neurotensin receptor 1 | |
WO2017016669A1 (en) | Substituted amide derivatives having multimodal activity against pain | |
WO2015185207A1 (en) | Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
WO2021076572A1 (en) | Ergoline-like compounds for promoting neural plasticity | |
CA2878006C (en) | Carbamate/urea derivatives | |
JP2009537542A (en) | N-benzoylpyrrolidin-3-ylamine and N-benzylpyrrolidin-3-ylamine as histamine-3 antagonists | |
CA3180803A1 (en) | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 | |
AU2016356488B2 (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
CA3022492A1 (en) | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | |
WO2024079351A1 (en) | Novel piperazine-based sulfonamides and their use as neuroprotective and/or neurorestorative agents | |
KR20180002717A (en) | Selective Modulators of GPR55 Receptor Activity: Chromenopyrazole derivatives | |
US11104670B2 (en) | 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | |
WO2024023287A1 (en) | [4-[5-(methylsulfonyl)-phenyl]piperazin-1-yl]-(phenyl)methanone derivatives and similar compounds with gfr alpha 1-ret activity as neuroprotective agents for the treatment of neurological disorders | |
WO2024023284A1 (en) | Novel sulfonamides and their use as neuroprotective and/or neurorestorative agents | |
CN113121398B (en) | Arylalkylamine compound, preparation method and medical application thereof | |
EP3328847A1 (en) | Amide derivatives having multimodal activity against pain | |
JP2023544037A (en) | Methods for preparing biheteroaryl compounds and their crystalline forms | |
CN114980891A (en) | Sigma-1 receptor ligands and therapeutic uses thereof | |
CN113527172A (en) | M2 acetylcholine receptor antagonists and uses thereof | |
WO2018153546A1 (en) | Tetrahydropyran and tetrahydrothiopyran methanone derivatives having multimodal activity against pain | |
MX2007012242A (en) | Piperazinyl substituted cyclohexane 1,4-diamines. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23792907 Country of ref document: EP Kind code of ref document: A1 |